



(19)

Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 443 568 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
12.06.1996 Bulletin 1996/24

(51) Int. Cl.⁶: **C07D 495/04, A61K 31/435**
// (C07D495/04, 333:00,
221:00), (C07D495/04, 333:00,
239:00)

(21) Application number: **91102513.8**(22) Date of filing: **21.02.1991****(54) Fused thiophene derivatives, their production and use**

Annelierte Thiophen-Derivate, ihre Herstellung und Verwendung

Dérivés fusés de thiophène, leur préparation et leur application

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(56) References cited:
EP-A- 0 323 841 EP-A- 0 400 835
US-A- 4 670 560 US-A- 4 835 157
US-A- 4 880 804

(30) Priority: **22.02.1990 JP 42125/90**
17.01.1991 JP 3958/91

- **JOURNAL OF MEDICINAL CHEMISTRY**, vol. 31, 1988, pages 1786 - 1793; R.K. RUSSELL et al.: "Thiophene Systems. 9. Thienopyrimidinedione Derivatives as Potential Antihypertensive Agents."
- **CHEMICAL ABSTRACTS**, vol. 99, no. 3, 18 July 1983 Columbus, Ohio, USA R. BOEHM et al.: "Thieno compounds. Part 1. Phase transfer-catalyzed alkylation of thieno[2,3-d]pyrimidin-4[3H]-ones or -2,4-diones" page 616;
- **HYPERTENSION**, vol. 13, 1989, Dallas, Tex., US, pages 489 - 497; P.C. WONG et al.: "Nonpeptide Angiotensin II Receptor Antagonists. IV. EXP6155 and EXP6803"
- **JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS**, vol. 247, no. 1, October 1988, pages 1 - 7; P.C. WONG et al.: "Nonpeptide Angiotensin II Receptor Antagonists. I. Pharmacological Characterization of 2-n-Butyl-4-chloro-1-[2-chlorobenzyl]..."

(43) Date of publication of application:
28.08.1991 Bulletin 1991/35

(73) Proprietor: **Takeda Chemical Industries, Ltd.**
Chuo-ku, Osaka (JP)

(72) Inventors:

- **Morimoto, Akira**
Ikeda, Osaka 563 (JP)
- **Nishikawa, Kohei**
Nishikyo-ku, Kyoto 610-11 (JP)
- **Naka, Takehiko**
Higashinada-ku, Kobe, Hyogo 658 (JP)

(74) Representative: **Keller, Günter, Dr. et al**
Lederer, Keller & Riederer
Patentanwälte
Prinzregentenstrasse 16
80538 München (DE)

USSN: 10/619,662 FILED: 07/15/2003
PC25132A

EP 0 443 568 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description**FIELD OF THE INVENTION**

5 The present invention relates to novel fused thiophene derivatives having potent pharmacological activity and intermediates for the preparation thereof. More particularly, the present invention relates to compounds having potent angiotensin II antagonist activity and antihypertensive activity, which are useful as therapeutic agents for treating circulatory diseases such as hypertensive diseases, heart diseases, strokes, etc.

10 BACKGROUND OF THE INVENTION

The renin-angiotensin system is involved in the homeostatic function to control systemic blood pressure, the volume of body fluid, balance among the electrolytes, etc., associated with the aldosterone system. Development of angiotensin II converting enzyme inhibitors (ACE inhibitor) (this converting enzyme produces angiotensin II which possesses strong vasoconstrictive activity) has clarified the relation between the renin-angiotensin system and hypertension. Since angiotensin II elevates blood pressure via the angiotensin II receptors on cell membranes, angiotensin II antagonists as well as the ACE inhibitor would be useful in treating hypertension.

It has been reported that various angiotensin II analogues such as saralasin, [Sar¹,Ile⁸]A II, and the like, possess potent angiotensin II antagonist activity.

20 It has, however, been reported that, when peptide antagonists are administered parenterally, their actions are not prolonged and, when administered orally, they are ineffective (M. A. Ondetti and D. W. Cushman, Annual Reports in Medicinal Chemistry, 13, 82-91 (1978)).

Non-peptide angiotensin II antagonists are disclosed in Japanese Patent Laid Open No. 71073/1981; No. 71074/1981; No. 92270/1982; No. 157768/1983; No. 240683/1987; No. 23868/1988; and No. 117876/1989, and European Patent Laid Open No. 0323841, etc.

25 Imidazole derivatives having angiotensin II antagonist activity are disclosed in A. T. Chiu et al., Eur. J. Pharm., 157, 13 (1981), P. C. Wong et al., J. Pharmcol. Exp. Ther., 247, 1 (1988), P. C. Wong et al., Hypertension, 13, 489 (1989), etc.


US 4,670,560 discloses thienopyrimidine-2,4-dione derivatives as vasodilating agents and anti-hypertensive agents. US 4,835,157 discloses thienopyrimidine-2,4-dione piperidine derivatives as selective serotonin antagonists and alpha adrenergic blocking agents. Substituted benzimidazoles as angiotensin II antagonists are disclosed in EP-A-0 400 835.

30 It has not yet been known that fused thiophene derivatives possess potent angiotensin II antagonist activity.

SUMMARY OF THE INVENTION


35 The present inventors made extensive investigations to prepare useful compounds which have angiotensin II antagonist activity. As a result of these researches, the present inventors have succeeded in synthesizing fused thiophene derivatives possessing excellently potent angiotensin II antagonist activity and developed their work to accomplish the present invention.

40 The present invention provides fused thiophene derivatives having the formula I:



wherein W is

5



R¹ and R² which may be the same or different, are each independently

- 10 (1) hydrogen,
- (2) halogen,
- (3) cyano,
- (4) nitro,
- (5) a group having the formula: R⁸CONH- wherein R⁸ is hydrogen or (C₁₋₈)alkyl group which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, (C₁₋₄)alkanoyloxy, benzoyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or naphthyl, or (6) a hydrocarbon residue selected from the group consisting of (i) (C₁₋₈)alkyl, (ii) (C₂₋₈)alkenyl, (iii) (C₂₋₈)alkynyl, (iv) (C₃₋₉)cycloalkyl, (v) an aromatic hydrocarbon selected from the group consisting of phenyl and naphthyl, wherein said hydrocarbon residue may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, (C₁₋₄)alkanoyloxy, benzoyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy, (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;

R³ is

- 30 (1) hydrogen,
- (2) (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino, or
- (3) -COD where D is hydrogen, C₁₋₄-alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino, wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro or lower (C₁₋₄) alkoxy;

R⁴ is hydrogen, halogen or nitro;

R⁵ is carboxyl, lower (C₁₋₄)alkoxycarbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide, phosphoric acid or sulfonic acid;

R⁶ is hydrogen or (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;

R⁷ is a hydrocarbon residue which may be substituted like R¹ and R²; A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group selected from the group consisting of (C₁₋₄)alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, or -CH=CH-; and n is an integer of 1 or 2; and a pharmaceutically acceptable salt thereof.

These compounds are potent angiotensin II antagonists which are of value in the treatment of circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.

Another aspect of the present invention relates to pharmaceutical compositions comprising an effective amount of the fused thiophene derivative having the formula I and a pharmaceutically acceptable carrier useful in treating circulatory

system diseases such as hypertensive diseases, heart diseases, strokes, etc., and processes for preparing such compounds and compositions.

Still another aspect of the present invention relates to a use of the fused thiophene derivative having the formula I or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for antagonizing angiotensin II.


5

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides fused thiophene derivatives having the formula I and the pharmaceutically acceptable salts thereof, which possess potent angiotensin II antagonist activity and are of value in the treatment of circulatory 10 diseases such as hypertensive diseases, heart diseases, strokes, etc., pharmaceutical compositions comprising an effective amount of the fused thiophene derivative having the formula I and a pharmaceutically acceptable carrier useful in treating said circulatory diseases and processes for preparing such compounds and compositions.

The present invention further provides a method for treating said circulatory system diseases of hosts, which comprises administering an effective amount of the fused thiophene derivative having the formula I or the pharmaceutical 15 composition thereof to said host.

An important group of compounds according to the present invention are the compounds of the formula Ia:



30

wherein R¹ and R² are as defined above;

R³ is hydrogen, formyl, optionally substituted alkyl or alkenyl as defined in claim 1, or -COD wherein D is alkoxy, hydroxy, halogen, or optionally substituted amino as defined above;

R⁴ is hydrogen, halogen or nitro;


35 R⁵ is as defined above;

R⁶, A and n are as defined above

and a pharmaceutically acceptable salt thereof.

Another important group of compounds according to the present invention are the compounds of the formula Ib:

40



wherein R¹ and R² are as defined above;

R⁴ is hydrogen, halogen or nitro;

55 R⁵ is as defined above;

R⁷, A and n are as defined above;

and a pharmaceutically acceptable salt thereof.

With regard to the foregoing formula (I), halogen for R¹ and R² include fluorine, chlorine, bromine, and iodine.

R¹ and R² include a group having the formula: R⁸CONH- wherein R⁸ is hydrogen or lower alkyl of 1 to 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, and the like), which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, (C₁₋₄)alkanoyloxy, benzoyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or naphthyl.

Examples of hydrocarbon residues for R¹, R² and R⁷ include acyclic hydrocarbon residues such as lower alkyl of 1 to 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, and the like), lower alkenyl of 2 to 8 carbon atoms (e.g. vinyl, allyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-octenyl, and the like), and lower alkynyl of 2 to 8 carbon atoms (e.g. ethynyl, 2-butynyl, 2-pentynyl, 2-octynyl, and the like); cyclic hydrocarbon residues such as alicyclic hydrocarbon residues of 3 to 8 carbon atoms (e.g. cyclopropyl, cyclopentyl, cyclohexyl, 2-cyclohexen-1-yl, cyclooctyl and the like), and aromatic hydrocarbon residues selected from the group consisting of phenyl and naphthyl.

Said hydrocarbon residues for R¹, R² and R⁷ may be optionally substituted with hydroxyl, lower (C₁₋₄) alkoxy (e.g. methoxy, ethoxy, and the like), lower (C₁₋₄) alkyl (e.g. methyl, ethyl, and the like), halogen (e.g. F, Cl, Br and the like), nitro, amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, diethylamino, etc.), phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxyphenyl)piperazino, lower (C₁₋₄) alkanoyloxy, benzoyloxy, phenyl which may be optionally substituted with halogen, nitro, lower (C₁₋₄) alkoxy or lower (C₁₋₄) alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy, lower (C₁₋₄) alkoxy (e.g. methoxy, ethoxy, and the like), amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, diethylamino, etc.), phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino or N-phenylpiperazino.

Alkyl or alkenyl groups for R³ and R⁶ are lower alkyl of 1 to 8 carbon atoms and lower alkenyl of 2 to 8 carbon atoms which may be straight or branched. Examples of such alkyl and alkenyl groups for R³ and R⁶ include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, vinyl, allyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-octenyl, and the like. Said alkyl or alkenyl groups for R³ may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, diethylamino, etc.), halogen, lower (C₁₋₄) alkoxy (e.g. methoxyl, ethoxyl, and the like) and -COD" wherein D" is lower (C₁₋₄) alkoxy (e.g. methoxy, ethoxy, and the like), hydroxy, halogen, amino, N-lower (C₁₋₄) alkyl amino such as methylamino and ethylamino, N,N-dilower (C₁₋₄) alkyl amino such as dimethylamino and diethylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino and N-phenylpiperazino.

Said alkyl or alkenyl groups for R⁶ may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, diethylamino, etc.), halogen, lower (C₁₋₄) alkoxy (e.g. methoxyl, ethoxyl, and the like) and -COD" wherein D" is lower (C₁₋₄) alkoxy (e.g. methoxy, ethoxy, and the like), hydroxy, halogen, N-lower (C₁₋₄) alkyl amino such as methylamino and ethylamino, N,N-dilower (C₁₋₄) alkyl amino such as dimethylamino and diethylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino and N-phenylpiperazino. Where R³ is a group having the formula: -COD, alkoxy groups for D include lower (C₁₋₄) alkoxy (e.g. methoxy, ethoxy, and the like). For D, examples of halogen include Cl, Br and the like. D may further represent amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, and the like), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, and the like), phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-phenylpiperazino or N-(p-fluorophenyl)piperazino, wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, hydroxyl, amino, N-lower (C₁₋₄) alkyl amino (e.g. methylamino, ethylamino, and the like), N,N-dilower (C₁₋₄) alkyl amino (e.g. dimethylamino, and the like), morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro, or lower (C₁₋₄) alkoxy (e.g. methoxyl, ethoxyl).

The compounds wherein D is halogen are useful as synthetic intermediates for the preparation of those wherein D is alkoxy.


R⁴ represents hydrogen, halogen (e.g. chlorine, bromine, and the like) or nitro, which may be in the ortho or meta position to the -A- group.

The residues capable of forming an anion and residues convertible into the anion for R⁵ are carboxyl, lower (C₁₋₄) alkoxy carbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide (-NHSO₂CF₃), phosphoric acid or sulfonic acid. Such residues include those which are capable of forming anions either chemically or under biological and/or physiological conditions. R⁵ is preferable in the ortho position. The compounds wherein R⁵ is a residue capable of forming an anion or convertible thereinto chemically (e.g. by oxidation, reduction or hydrolysis) (e.g. cyano and the like), are useful as synthetic intermediates.

A shows that the adjacent phenylene group is bonded to the phenyl group directly or through a spacer whose atomic chain is 2 or less.

Such spacers are lower (C₁₋₄) alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, -CH=CH-.


A preferred embodiment of the invention is a compound of the formula (Ia'):



15 wherein R¹ is (C₁₋₈)alkyl; R³ is hydrogen, (C₁₋₈)alkyl which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, halogen, (C₁₋₄)alkoxy or -COD' wherein D' is (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino (e.g. lower (C₁₋₄) alkoxymethyl, and the like) or -COD where D is hydrogen, (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethyamino, morpholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl (*inter alia* tetrazolyl); and the pharmaceutically acceptable salts thereof.

20

A further preferred embodiment of the invention is a compound of the formula (Ib').





wherein R¹ is (C₁₋₈)alkyl; R⁷ is (C₁₋₈)alkyl which may be optionally substituted with phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, or -COD' wherein D' is (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino or N-phenylpiperazino, (C₃₋₈)cycloalkyl, or phenyl or naphthyl which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, (C₁₋₄)alkanoyloxy, benzyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: - COD' wherein D' is hydroxy, (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl (*inter alia* tetrazolyl); and the pharmaceutically acceptable salts thereof.

50 The compounds (I) of the present invention may be prepared by several reaction schemes, as illustrated below for a preferred compound.

Scheme A


5

10




III

15



20




25

wherein R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, and X is halogen.

Scheme B


30

35



IV

40



V

45


50

55

wherein each group is of the same meaning as defined above.

Scheme C

5




wherein R₁, R₂, R₄, R₅, R₆, A and n have the above-defined meanings, and R⁹ is lower (C_{1-4}) alkyl.

20

Scheme D


25



wherein R₁, R₂, R₄, R₅, R₆, R₉, A and n have the above-defined meanings, and R¹⁰ and R¹¹ are each independently hydrogen or a hydrocarbon residue.

10

Scheme E




55

wherein R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, and X is halogen.

Scheme F

5




15

wherein R¹, R², R⁴, R⁵, R⁶, R¹⁰, R¹¹, X, A and n have the above-defined meanings.

20

Scheme G

25



30

35

wherein R¹, R², R⁴, A, W and n have the above-defined meanings and R¹² is a protective group.

The reaction as illustrated in Scheme A is an alkylation using an alkylating agent in the presence of a base. One molar portion of the compound (II) is employed with 1 to 3 moles of the base and about 1 to about 3 moles of the alkylating agent. The reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethylmethylketone, and the like. Examples of such bases include sodium hydride, potassium t-butoxide, cesium carbonate, potassium carbonate, sodium carbonate, and the like. Examples of such alkylating agents include substituted halides (e.g. chlorides, bromides, iodides, and the like), substituted sulfonate esters (e.g. methyl p-toluenesulfonate esters, and the like), etc.

The reaction conditions may vary depending on the combination of the base and the alkylating agent. A temperature in the range of ice-cooling - 100°C is preferred and a reaction period of 1-about 10 hours is preferably employed.

The cyano substituent on the benzene of the compounds (IV) is reacted with various azides to form the tetrazole compounds (V) as illustrated in Scheme B. One molar portion of the compound (IV) is employed with 1-10 moles of the azide. The reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, toluene, benzene, and the like.

Examples of such azides include trialkyl-tin azide, triphenyl-tin azide, hydrogen azide, and the like. In the case where the organo-tin azide compound is employed, the reaction is carried out in toluene or benzene by heating under reflux for a period of 10 - 30 hours. When the hydrogen azide is used, 5 moles of sodium azide and ammonium chloride per compound (IV) are employed and the reaction is conducted in dimethylformamide at a temperature ranging from 100°C - 130°C for 1-10 days. During this reaction, it is preferable to facilitate working by adding an appropriate amount of sodium azide and ammonium chloride.

The reaction as illustrated in Scheme C is hydrolysis of the ester (VI) into the carboxylic acid (VII) in the presence of an alkali. One molar portion of the compound (VI) is employed with 1 to 3 moles of the alkali. The reaction is conven-

tionally conducted in solvents such as alcohols containing water (e.g. methanol, ethanol, methylcellosolve, and the like). Examples of such alkalis include sodium hydroxide, potassium hydroxide, and the like. The reaction is preferably conducted at a temperature in the range of room temperature - 100°C for 1-10 hours.

The compounds (VI) are reacted with various amines to form the amide compounds (VIII) as illustrated in Scheme

5 D. One molar portion of the compound (VI) is employed with about 2 to 50 moles of the amine. The reaction is conventionally conducted in solvents such as alcohols (e.g. methanol, ethanol, and the like) or without a solvent. The reaction is preferably conducted at a temperature in the range of room temperature - 200°C. Examples of such amines include ammonia, alkylamines (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, butylamine, hydroxyethylamine, etc.), aralkylamines (e.g. benzylamine, o-methoxybenzylamine, etc.), arylamines (e.g. aniline, etc.), heteroaralkylamines (e.g. 2-, 3- or 4-pyridylmethylamine, etc.), alicyclic amines (e.g. morpholine, piperidine, piperazine, N-phenylpiperazine, 2-piperidylmethylamine, etc.), and the like.

The compounds (VII) are treated with various halogenating agents to form the acid halides (IX) as illustrated in Scheme E. One molar portion of the compound (VII) is employed with about 1 to 5 moles of the halogenating agent. The reaction is conventionally conducted in solvents such as halogenated hydrocarbons (e.g. CHCl₃, CH₂Cl₂, 15 CICH₂CH₂Cl, and the like), ethers (e.g. tetrahydrofuran, dioxane, and the like) and aromatic hydrocarbons (e.g. benzene, toluene, and the like). Examples of such halogenating agents include oxalyl chloride, thionyl chloride, phosphorous oxychloride, phosphorous trichloride, phosphorous pentachloride, etc. The reaction is preferably conducted at room temperature - 100°C for 1-10 hours.

The acid halides (IX) are reacted with various amines to form the amide compounds (VIII) as illustrated in Scheme

20 F. One molar portion of the compound (IX) is employed with about 2 to 50 moles of the amine. The reaction is conventionally conducted in solvents such as alcohols (e.g. methanol, ethanol, and the like) and ethers (e.g. ethyl ether, tetrahydrofuran, dioxane, and the like). Examples of such amines include ammonia, alkylamines (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, butylamine, hydroxyethylamine, etc.), aralkylamines (e.g. benzylamine, o-methoxybenzylamine, etc.), arylamines (e.g. aniline, etc.), heteroaralkylamines (e.g. 2-, 3- or 4-pyridylmeth-25 ylamine, etc.), alicyclic amines (e.g. morpholine, piperidine, piperazine, N-phenylpiperazine, 2-piperidylmethylamine, etc.), and the like.

The protective group (R¹²) on the tetrazole compound (X) leaves to form the tetrazole compound (V) as illustrated in Scheme G. Reaction conditions may vary depending on the protective group (R¹²) used. When R¹² is triphenylmethyl (trityl), 2-tetrahydropyranyl, methoxymethyl, ethoxymethyl, or the like, the leaving of the protective group is conveniently 30 conducted in aqueous alcohols (e.g. methanol, ethanol, etc) containing from about 0.5N to about 2N hydrochloric acid or acetic acid, or in a mixture of trifluoroacetic acid and water (1:2 ~5) at room temperature for 1-10 hours.

The compounds (I) thus produced via the reaction processes as depicted in Schemes A, B, C, D, E, F and G can be isolated and purified from the reaction mixture according to conventional methods such as, for example, evaporation of solvents, extraction by water or organic solvents, concentration, neutralization, recrystallization, distillation, column 35 chromatography and the like, to obtain a crystalline or oily product.

The compounds (I) of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include but are not limited to the following: salts with inorganic acids such as hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts include salts with alkali metals or alkaline earth metals, 40 such as sodium, potassium, calcium or magnesium or with organic bases.

The starting materials (II) can be easily prepared by or according to the known techniques, for example, as disclosed in:

(1) P. Blaszkiewicz, H. Vorbruggen and H. J. Kesler (Schering AG): DOS 2, 447,477 (15. 4. 76); Chem. Abst., 85,

45 46627 (1976).

(2) Y. Kuwada, K. Meguro, Y. Sato and T. Fugono (Takeda Chem.): DOS 2, 435,025 (6. 25. 75); Chem. Abst., 82, 156252 (1975), etc.

Among the starting materials (III), the compounds wherein n is 1 (the compounds (IIIa)) is prepared by the known

50 techniques as disclosed in Japanese Patent Laid Open No. 23868/1988; and No. 117876/1989, and European Patent Laid Open No. 0323841.

As illustrated in Scheme H, the compounds (IIIa) can also be easily prepared by halogenomethylation of the compounds (X) commercially available or easily prepared according to methods described in known literatures such as, for example, A. A. Vansheidt et al., Khim. Nauka i Prom., 2, 799 (1957).

Scheme H

5




15 wherein each group has the above-defined meaning.

The compound (III) wherein n is 2 (the compounds (IIb)) can be prepared from the compounds (IIIa) according to the methods as illustrated in Scheme I.

Scheme I

20



wherein each group has the above-defined meaning.

The compounds (I) and salts thereof according to the present invention strongly inhibit vasoconstriction and hypertension derived by angiotensin II and therefore possess potent anti-hypertensive activity in animals, more specifically 45 mammal animals (e.g. humans, dogs, rabbits, rats, etc.). Further, the compounds (I) and salts thereof according to the present invention are of quite low toxicity and useful in treating not only hypertension but also circulatory system diseases such as heart diseases, strokes and the like.

For therapeutic use, the compounds (I) and salts thereof can be administered as pharmaceutical compositions (e.g., powders, granules, tablets, pills, capsules, injections, solutions and the like) comprising at least one such compound 50 alone or in admixture with pharmaceutically acceptable carriers, excipients and/or diluents. The pharmaceutical compositions can be formulated in accordance with conventional methods.

Specific dose levels for any particular patient will be employed depending upon a variety of factors including the activity of specific compounds employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. 55 When used for treating adult essential hypertension, the active ingredient will preferably be administered in an appropriate amount, for example, selected from the range of about 10 mg to 100 mg a day orally and from the range of about 5 mg to 50 mg a day intravenously. The active ingredient will preferably be administered in equal doses two or three times a day.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention.

5 Example

The invention is further illustrated but in no way limited by the following reference examples, working examples, pharmaceutical examples and experimental examples.

In the specification of the present application, examples of the abbreviations used are given below. Me: Methyl, Et: Ethyl, Pr: Propyl, Bu: Butyl, iBu: Isobutyl, tBu: Tert-butyl, Ph: Phenyl, DMF: Dimethylformamide.

Reference Example 1

Isobutyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate

15 A mixture of 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylic acid (200 mg, 0.9 mmol) and boron trifluoride-ethyl ether (47 %, 0.5 ml) in isobutyl alcohol (10ml) was heated under reflux for 5 hours. The reaction mixture was allowed to cool and concentrated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/ethyl acetate (3:1) to give 80 mg (31 %) of the title compound as colorless crystals.
20 m.p. 156-158 °C.
IR (KBr)cm⁻¹: 1700, 1595, 1520.

NMR (CDCl₃) δ : 1.05(6H, d, J=6.6Hz), 1.40(3H, t, J=7.4Hz), 2.0-2.2(1H, m), 2.94(2H, q, J=7.4, 15.0Hz),
25 4.20(2H, d, J=6.6Hz), 7.16(1H, s), 8.84(1H, s).

Elemental Analysis for C ₁₄ H ₁₇ NO ₃ · H ₂ O			
	C (%)	H (%)	N (%)
Calcd:	C, 63.38;	H, 5.70;	N, 15.84
Found:	C, 63.70;	H, 5.44;	N, 15.50.

Reference Example 2

2-Methoxyethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate

A mixture of 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylic acid (380 mg, 1.7 mmol) and DMF (0.13 ml, 1.7 mmol) in benzene (5 ml) was heated to 60 °C and to the reaction mixture was added thionyl chloride (0.15 ml, 2.1 mmol).
40 The mixture was stirred at 60 °C for 3 hours and then allowed to cool with an ice bath. The precipitated product was collected by filtration and washed with benzene. The resulting precipitate (223 mg) was dissolved in a mixture of 2-methoxyethanol (0.3 ml) and CH₂Cl₂ (5 ml) and then triethylamine (0.7 ml) were added to the solution. The mixture was stirred for 30 minutes and poured into chloroform. The resulting mixture was washed with 1N hydrochloric acid, dried (MgSO₄) and evaporated in vacuo. The resulting residue was purified by flash column chromatography on silica gel.
45 The column was eluted with ethyl acetate/hexane/chloroform (1:1:1) and then chloroform/methanol (9:1) to give 200 mg (41 %) of the title compound as colorless powders.
IR (KBr)cm⁻¹: 1700, 1590, 1530, 1480.

NMR (CDCl₃) δ : 1.39(3H, t, J=7.4Hz), 2.94(2H, q, J=7.4, 15.0Hz), 3.45(3H, s), 3.7-3.8(2H, m), 4.5-4.6(2H, m),
50 7.17(1H, s), 8.87(1H, s).

Elemental Analysis for C ₁₃ H ₁₅ NO ₄ S			
	C (%)	H (%)	N (%)
Calcd:	C, 55.50;	H, 5.37;	N, 4.98
Found:	C, 55.47;	H, 5.38;	N, 4.95

Reference Example 3

Ethyl 2-ethyl-4-hydroxy-3-nitrothieno[2,3-b]pyridine-5-carboxylate

5 A solution of ethyl 2-ethyl-4-hydroxythieno-[2,3-b]pyridine-5-carboxylate (1.0 g, 4.0 mmol) in conc. sulfuric acid (10 ml) was cooled to -5 °C and a solution of sodium nitrate (370 mg, 4.3 mmol) in conc. sulfuric acid (5 ml) was added dropwise to the chilled solution. The reaction mixture was stirred at -3 °C - -5 °C for 1 hour and poured into ice-water. The precipitated product was collected by filtration and washed with cold water and then ethanol. The resulting precipitate was dissolved in chloroform, washed with a saturated aqueous sodium chloride, dried ($MgSO_4$) and evaporated in vacuo.
 10 The resulting yellow solid was washed with a mixture of ether/hexane, and dried to give 960 mg (81 %) of the title compound. m.p. 194-201 °C (dec.).
 IR (KBr) cm^{-1} : 1700, 1600, 1590, 1530.

NMR (CDCl_3) δ : 15 1.42(3H, t, $J=7.4\text{Hz}$), 1.47(3H, t, $J=7.2\text{Hz}$), 3.05(2H, q, $J=7.4, 15.0\text{Hz}$), 4.50(2H, q, $J=7.2, 14.4\text{Hz}$), 8.93(1H, s).

Elemental Analysis for $C_{12}\text{H}_{12}\text{N}_2\text{O}_5\text{S}$			
	C (%)	H (%)	N (%)
Calcd:	C, 48.64;	H, 4.08;	N, 9.45
Found:	C, 48.48;	H, 4.01;	N, 9.28

25 Reference Example 4

Ethyl 2-ethyl-7-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate

To a solution of ethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate (1.00 g, 4 mmol) in 20 ml of DMF was 30 added sodium hydride (60 % dispersion in oil, 160 mg) and the mixture was stirred for 10 minutes. To the reaction mixture was added 4-[2'-(N-trityltetrazol-5-yl)phenyl]benzyl bromide (2.23 g, 4 mmol) and the mixture was heated at 90 °C for 1 hour with stirring. The reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried ($MgSO_4$), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with ethyl acetate/dichloromethane (1:1) to give 2.24 g (77 %) of 35 the title compound as white crystals. m.p. 195-198 °C.
 IR (KBr) cm^{-1} : 1730, 1705, 1620.

NMR (CDCl_3) δ : 40 1.27(3H, t, $J=9.6\text{Hz}$), 1.39(3H, t, $J=6.8\text{Hz}$), 2.72(2H, q, $J=8.9, 15.0\text{Hz}$), 4.38(2H, q, $J=7.2, 13.8\text{Hz}$), 5.02(2H, s), 6.80-8.0(9H, m), 8.29(1H, s).

40

Elemental Analysis for $C_{45}\text{H}_{37}\text{N}_5\text{O}_3\text{S}$			
	C (%)	H (%)	N (%)
Calcd:	C, 74.26;	H, 5.12;	N, 9.62
Found:	C, 74.09;	H, 5.18;	N, 9.50

The following compounds (II) can be easily prepared by or according to the known techniques, for example, as 50 disclosed in:

- (1) P. Blaszkiewicz, H. Vorbruggen and H. J. Kesler (Schering AG): DOS 2, 447,477 (15. 4. 76); Chem. Abst., 85, 46627 (1976),
- (2) Y. Kuwada, K. Meguro, Y. Sato and T. Fugono (Takeda Chem.): DOS 2, 435,025 (6. 25. 75); Chem. Abst., 82, 55 156252 (1975),
- (3) R. K. Russell, J. B. Plress, R. A. Rampulla, J. J. McNally, R. Falotico, J. A. Keiser, D. A. Bright and A. Tobia, J. Med. Chem., 31, 1786 (1988),
- (4) M. Suwada, T. Sakamoto, K. Tabata, K. Endo, K. Ito, M. Kobayashi and H. Fuumi, Chem. Pharm. Bull., 37, 2091 (1989),


(5) M. Sugiyama, T. Sakamoto, K. Tabata and H. Fuumi, Chem. Pharm. Bull., 37, 2717 (1989).
 (6) G. D. Madding and M. D. Thompson, J. Heterocyclic Chem., 24, 581 (1987).
 (7) J. Barker, P. R. Huddleston and D. Holmes, J. Chem. Research (S), 1985, 214.
 (8) J. Barker, P. R. Huddleston and D. Holmes, J. Chem. Research (S), 1986, 122.
 5 (9) M. A. Khan and A. E. Guarconi, J. Heterocyclic Chem., 14, 807 (1977).
 (10) K. Ogawa, I. Yamawaki, Y. Matsusita, N. Nomura and I. Okazaki, WO 89/02432.

The compounds (III) can alternatively be prepared in the same manner as described in Reference Example 1, 2, or 3.

10

TABLE 1

15



20


Reference Example No.	R ¹	R ²	R ³	R ⁶	mp (°C)
25 5-1	Br	H	COOEt	H	208-209
5-2	H	H	COOEt	H	105-108
30 6	Me	H	COOEt	H	122-124
7	Pr	H	COOEt	H	74- 75
35 8	Et	H	COOCH ₂ CH ₂ OMe	H	powder
9	Et	H	CH ₂ OH	H	> 260 (decomp.)

40

45


50

55

TABLE 2

15	Reference Example No.	R¹	R²	R³	mp. (°C)
20	10	Et	H	Bu	217-220
25	11	Et	H	-CH₂-	259-262
30	12	Et	H	Et	243-244
35	13	Et	H	--F	>290
40	14	Et	H	--Cl	268-275
45	15	Et	H	-	285-288
50	16	Et	H	-CH₂COOEt	201-204
	17	Et	H	-CH₂CH₂NN-OMe	239-241

The following compounds (Reference Examples 18-32) were prepared in the same manner as in Reference Example 4.

TABLE 35
1015
20
25
30
35
40
45


Reference Example No.	R ¹	R ²	R ³	R ¹²	Yield (%)	^{mp} (°C)
18	Et	H	-COOCH ₂ CH ₂ OCH ₃	-C(Ph),	30	192-198
19	Et	H	-COO <i>i</i> Bu	-C(Ph),	40	209-212
20	Et	NO ₂	-COOEt	-C(Ph),	34	
21	Me	H	-COOEt	-C(Ph),	53	205-207
22	Pr	H	-COOEt	-C(Ph),	51	181-187
23	Br	H	-COOEt	-C(Ph),	47	129-133
24	H	H	-COOEt	-C(Ph),	50	137-139
25	Et	H	-CH ₂ OH	-C(Ph),	46	powder
26	Et	H	H	-C(Ph),	46	
27	Et	H	-CHO	-C(Ph),	67	150-156
28	Et	H	-CH=CH-COO <i>t</i> Bu	-C(Ph),	56	powder
29	Et	H	-COOEt	-COOtBu	62	
30	CN	H	-COOEt	-C(Ph),	21	129-131
31	Et	H	-CONCH ₂ Ph CH ₃	-C(Ph),	56	169-171
32	Et	H	-CH ₂ OMe	-C(Ph),	26	powder

50

The following compounds (Reference Examples 33-40) were prepared in the same manner as in Reference Example 4.

55

TABLE 4a



Reference Example No.	R'	mp (°C)	Yield (%)
33	Bu	173-176	57
34	-CH ₂ - 	204-207	47
35	Et	117-122	57
36	-  -F	192-193	67
37	-  -Cl	193-197	79
38	-  -	141-144	48
39	-CH ₂ COOEt	181-183	63
40	-CH ₂ CH ₂ N  N-  -OMe	powder	93

TABLE 4b

Reference Example No.	¹ H-NMR (200MHz, CDCl ₃)δ
33	0.96(3H, t), 1.24(3H, t), 1.3-1.5(2H, m), 1.5-1.7(2H, m), 2.66(2H, q), 4.04(2H, t), 5.01(2H, s), 7.00(1H, s), 6.8-7.5(22H, m), 7.9-8.0(1H, m)
34	1.22(3H, t), 2.65(2H, q), 5.00(2H, s), 5.23(2H, s), 7.00(1H, s), 6.8-8.0(28H, m)
35	1.24(3H, t), 1.27(3H, t), 2.66(2H, q), 4.11(2H, q), 5.01(2H, s), 6.8-7.5(23H, m), 7.9-8.0(1H, m),
36	1.28(3H, t), 2.72(2H, q), 5.03(2H, s), 6.8-8.0(28H, m)
37	1.26(3H, t), 2.68(2H, q), 5.06(2H, q), 6.8-8.0(27H, m)
38	1.23(3H, t), 1.2-2.6(10H, m), 2.65(2H, q), 4.8-5.0(1H, m), 4.97(2H, s), 6.8-7.9(24H, m)
39	1.23(3H, t), 1.29(3H, t), 2.65(2H, q), 4.24(2H, q), 4.79(2H, s), 5.02(2H, s), 6.8-8.0(24H, m)
40	1.23(3H, t), 2.64(2H, q), 2.7-3.2(10H, m), 3.85(3H, s), 4.2-4.4(2H, m), 5.03(2H, s), 6.8-7.5(27H, m), 7.9-8.0(1H, m)

Working Example 1.

A: Ethyl 2-ethyl-7-[2'-cyanobiphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate

Ethyl 2-ethyl-4-hydroxythieno[2,3-b]-pyridine-5-carboxylate (250 mg, 1 mmol) and 4-(2'-cyanophenyl)benzyl chloride (250 mg, 1.1 mmol) were dissolved in 5 ml of N,N-dimethylformamide (DMF). To the solution was added potassium carbonate (150 mg) and the mixture was stirred at 90 °C for 2 hours. The reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with ethyl acetate/dichloromethane (1:1) to give 254 mg (60 %) of the title compound as crystals.

NMR (CDCl₃) δ : 1.30(3H, t, J=6Hz), 1.39(3H, t, J=6Hz), 2.81(2H, q, J=6, 15Hz), 4.40(2H, q, J=6, 13.5Hz), 5.27(2H, s), 7.25-8.0(9H, m), 8.37(1H, s).

B: Ethyl 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate and 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid

A solution of the compound (250 mg, 0.59 mmol) prepared in Working Example 1A, sodium azide (390 mg, 5.9 mmol) and ammonium chloride (300 mg, 5.9 mmol) in DMF (15 ml) was stirred at 110 °C for 10 days. After cooling, the reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (9:1) to give 37 mg (13 %) of ethyl 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate as pale yellow powders.
IR (KBr)cm⁻¹: 1720, 1600, 1550, 1505.

NMR (CD₃OD) δ : 1.31(3H, t, J=7.6Hz), 1.36(3H, t, J=7.0Hz), 2.85(2H, q, J=7.6, 15.0Hz), 4.33(2H, q, J=7.0, 14.2Hz), 5.45(2H, s), 7.15(2H, d, J=8.6Hz), 7.21(1H, s), 7.28(2H, d, J=8.6Hz), 7.5-7.7(4H, m), 8.75(1H, s).

The column was further eluted with chloroform/methanol (9:1) to give 7 mg (2.7 %) of 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid as white solids.
IR (KBr)cm⁻¹: 1650, 1605, 1580, 1540, 1505.

NMR (CD₃OD) δ : 1.34(3H, t, J=7.6Hz), 2.89(2H, q, J=8.6, 15.0Hz), 5.47(2H, s), 7.15(2H, d, J=8.2Hz), 7.24(1H, s), 7.28(2H, d, J=8.2Hz), 7.5-7.7(4H, m).

Working Example 2

Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate


5 A solution of the compound (727 mg, 1 mmol) prepared in Reference Example 4 in 20 ml of trifluoroacetic acid/water (1:3) was stirred at room temperature for 1 hour. The reaction mixture was poured into water followed by extraction with chloroform. The organic layer was washed with water, dried (MgSO_4), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (9:1) to give 1.28 g (86 %) of the title compound as colorless crystals. This product was identified by comparing with NMR and
 10 IR spectra of the compound obtained in Working Example 1B.
 M.p. 161-164 °C.

15

Elemental Analysis for $\text{C}_{26}\text{H}_{23}\text{N}_5\text{O}_3\text{S} \cdot \text{H}_2\text{O}$			
	C (%)	H (%)	N (%)
Calcd:	C, 62.01;	H, 5.00;	N, 13.91
Found:	C, 62.05;	H, 4.59;	N, 13.78

20 The following compounds as listed in Table 5 were prepared in the same manner as in Working Examples 2.

TABLE 5a



Working Example No.	R ¹	R ²	R ³	mp (°C)	IR(KBr) (cm ⁻¹)
3	Br	H	Et	254-260 (decomp.)	1725, 1680, 1610, 1560, 1500
4	H	H	Et	245-249	1720, 1600, 1560
5	Me	H	Et	249-253	1710, 1675, 1605, 1560, 1505
6	n-Pr	H	Et	108-110	1720, 1605, 1550, 1505
7	Et	H	i-Bu	256-259 (decomp.)	1720, 1670, 1605, 1560, 1500
8	Et	H	CH ₂ CH ₂ OMe	201-210	1720, 1680, 1605, 1560, 1505
9	Et	NO ₂	Et	214 ~ (decomp.)	1720, 1700, 1615, 1550, 1510

TABLE 5b

	Working Example No.	NMR (DMSO-d ₆) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
5	3	1.29(3H,t,J=7.2Hz),4.24(2H,q, J=7.2,14.2Hz),5.46(2H,s),7.13(2H, d,J=8.2Hz),7.29(2H,d,J=8.2Hz), 7.5-7.7(5H,m),8.79(1H,s)	C ₂₄ H ₁₈ BrN ₅ O ₃ S 53.74;3.38;13.06 53.57;3.34;12.80
10	4	1.29(3H,t,J=7.2Hz),4.24(2H,q, J=7.2,14.2Hz),5.51(2H,s),7.13(2H, d,J=8.0Hz),7.27(2H,d,J=8.0Hz), 7.3-7.8(8H,m),8.80(1H,s)	C ₂₄ H ₁₉ N ₅ O ₃ S · 0.5H ₂ O 61.79;4.32;15.01 61.94;4.17;14.80
15	5	1.29(3H,t,J=7.2Hz),2.44(3H,d, J=1.0Hz),4.23(2H,q,J=7.2,14.2Hz), 5.45(2H,s),7.08(1H,d,J=1.0Hz), 7.13(2H,d,J=8.0Hz),7.25(2H,d, J=8.0Hz),7.5-7.7(4H,m),8.74(1H,s)	C ₂₅ H ₂₁ N ₅ O ₃ S 63.68;4.49;14.85 63.39;4.47;14.67
20	6	0.91(3H,t,J=7.2Hz),1.28(3H,t, J=7.0Hz),1.61(2H,q,J=7.2,15.0Hz), 2.76(2H,t,J=7.6Hz),4.23(2H,q, J=7.0,14.2Hz),5.45(2H,s),7.10(1H, s),7.12(2H,d,J=8.4Hz),7.26(2H,d, J=8.4Hz),7.5-7.7(4H,m),8.74(1H,s)	C ₂₇ H ₂₆ N ₅ O ₃ S · H ₂ O 62.65;5.26;13.53 62.55;4.84;13.38
25	7	0.96(6H,d,J=6.8Hz),1.23(3H,t, J=7.4Hz),1.9-2.1(1H,m),2.80(2H, q,J=7.4,15.0Hz),3.97(2H,d, J=6.6Hz),5.46(2H,s),7.11(1H, s),7.13(2H,d,J=8.0Hz),7.27(2H,d, J=8.0Hz),7.5-7.7(4H,m),8.70(1H,s)	C ₂₈ H ₂₇ N ₅ O ₃ S · 0.5H ₂ O 64.35;5.40;13.40 64.22;5.24;13.47
30	8	1.23(3H,t,J=7.4Hz),2.81(2H,q, J=7.4,15.0Hz),3.30(3H,s),3.62 2H,t,J=4.8Hz),4.31(2H,t,J=4.8Hz) 5.46(2H,s),7.11(1H,s),7.12(2H,d, J=8.0Hz),7.25(2H,d,J=8.0Hz), 7.5- 7.7(4H,m),8.73(1H,s)	
35	9	1.20(3H,t,J=7.4Hz),1.29(3H,t, J=7.0Hz),2.83(2H,q,J=7.4,15.4Hz), 4.24(2H,q,J=7.0,14.0Hz),5.53(2H, s),7.14(2H,d,J=8.2Hz),7.30(2H,d, J=8.2Hz),7.5-7.7(4H,m),8.86(1H,s)	C ₂₆ H ₂₂ N ₆ O ₅ S · H ₂ O 56.93;4.41;15.32 57.12;4.05;15.26
40			
45			

Working Example 10

2-Ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid

Ethyl 2-ethyl-7-[2'-(1H-tetrazol-5-yl) biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate (600 mg, 1.235 mmol) was dissolved in 6 ml of 1N sodium hydroxide and the mixture was heated at 100 °C for 20 minutes with stirring. After cooling, 7 ml of 1N hydrochloric acid was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was washed with water, dried ($MgSO_4$), and evaporated to dryness. The resulting crystal was washed with dichloromethane and dried 550 mg of the title compound as colorless crystals. This product was identified by comparing with NMR and IR spectra of the compound obtained in Working Example 1B. M.p. 153-157 °C.

5

Elemental Analysis for C ₂₄ H ₁₉ N ₅ O ₃ S · 3.5H ₂ O			
	C (%)	H (%)	N (%)
Calcd:	C, 55.38;	H, 5.03;	N, 13.48
Found:	C, 54.75;	H, 3.93;	N, 13.15

10

Working Example 11

A: Ethyl 2-ethyl-7-[(2'-t-butoxycarbonylbiphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate

15 A mixture of ethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate (200 mg, 0.8 mmol), 4-(2-t-butoxycarbonyl-phenyl)benzyl bromide (300 mg, 0.9 mmol) and cesium carbonate (650 mg, 2.0 mmol) in DMF (10 ml) was stirred at 60 °C for 3 hours and further at 100 °C for an additional hour. After cooling, the reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel to give 258 mg (62 %) of the title compound as crystals.

20 IR (KBr)cm⁻¹: 1720, 1705, 1690, 1510.

25 NMR (CDCl₃) δ : 1.20(9H, s), 1.32(3H, t, J=7.6Hz), 1.41(3H, t, J=7.2Hz), 2.81(2H, q, J=7.6, 14.6Hz), 4.40(2H, q, J=7.2, 14.2Hz), 5.23(2H, s), 7.2-7.5(8H, m), 7.81(1H, dd, J=1.6, 7.6Hz), 8.42(1H, s).

25

30

Elemental Analysis for C ₃₀ H ₃₁ NO ₅ S			
	C (%)	H (%)	N (%)
Calcd:	C, 69.61;	H, 6.04;	N, 2.71
Found:	C, 69.85;	H, 6.15;	N, 2.37

35

B: Ethyl 2-ethyl-7-[(2'-carboxybiphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate

35 To 5 ml of trifluoroacetic acid under ice-cooling were added the compound (200 mg, 0.39 mmol) prepared in Working Example 11A and anisole (0.1 ml) and the mixture was stirred for 2.5 hours. The reaction mixture was concentrated to dryness in vacuo. To the resulting residue was added dichloromethane followed by evaporation to dryness in vacuo. These treatments were repeated twice and ether was added to the resulting residue to precipitate solids which were filtered and dried to give 167 mg (93 %) of the title compound as pale yellow powders.

40 IR (KBr)cm⁻¹: 1715, 1680, 1605.

45

50

Elemental Analysis for C ₂₆ H ₂₃ NO ₅ S · 0.3H ₂ O			
	C (%)	H (%)	N (%)
Calcd:	C, 66.88;	H, 5.09;	N, 3.00
Found:	C, 67.03;	H, 5.14;	N, 2.95

55

Working Example 12

2-Ethyl-5-(N-benzylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-B]pyridin-4(7H)-one

5 A mixture of the compound (123 mg, 0.25 mmol) prepared in Working Example 2 and benzylamine (2 ml) was stirred at 60 °C for 3 days. After cooling, the reaction mixture was poured into chloroform, washed twice with 1N hydrochloric acid, dried ($MgSO_4$), and concentrated. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (19:1 to 9:1) to give 63 mg (45 %) of the title compound as crystals.

10 m p 177-180 °C.

IR (KBr) cm^{-1} : 1650, 1590, 1550, 1500.

15 NMR (DMSO- d_6) δ : 1.25(3H, t, $J=7.4\text{Hz}$), 2.83(2H, q, $J=7.4\text{Hz}, 14.2\text{Hz}$), 4.56(2H, d, $J=5.8\text{Hz}$), 5.57(2H, s), 7.0-7.7(14H, m), 8.95(1H, s).


15

Elemental Analysis for $C_{31}H_{26}N_6O_2S$			
	C (%)	H (%)	N (%)
Calcd:	C, 68.11; H, 4.79; N, 15.37		
Found:	C, 68.06; H, 4.79; N, 15.17		

The following compounds as listed in Table 6 were prepared in the same manner as in Working Examples 12.

25

TABLE 6a



Working Example No.	R ¹	mp (°C)	IR(KBr) (cm ⁻¹)
---------------------	----------------	---------	-----------------------------

40 13 H 267-270 1635, 1575, 1540, 1500

45 14 $\text{CH}_2\text{CH}(\text{Me})_2$ 248-251 (decomp.) 1655, 1590, 1555, 1525, 1510

50 15 $\text{CH}_2\text{CH}_2\text{OH}$ 155-159 1655, 1595, 1550, 1520

16 C_6H_5 215-218 1655, 1595, 1545, 1505

55

TABLE 6b

Working Example No.	NMR (DMSO-d ₆) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
13	1.25(3H,t,J=7.6Hz),2.83(2H,q, J=7.6,14.8Hz),5.54(2H,s),7.12(2H, d,J=8.2Hz),7.22(1H,s),7.26(2H,d, J=8.2Hz),7.5-7.7(4H,m),8.91(1H,s), 9.46(1H,bs)	C ₂₄ H ₂₀ N ₆ O ₂ S · H ₂ O 60.75;4.67;17.71 61.09;4.41;17.37
14	0.93(6H,d,J=6.6Hz),1.25(3H,t, J=7.4Hz),1.7-1.9(1H,m),2.84(2H,d, J=7.4,14.0Hz),3.18(2H,t,J=6.2Hz), 5.55(2H,s),7.11(2H,d,J=8.2Hz), 7.19(1H,s),7.25(2H,d,J=8.2Hz), 7.5- 7.7(4H,m),8.90(1H,s)	C ₂₈ H ₂₈ N ₆ O ₂ S · H ₂ O 63.38;5.70;15.84 63.70;5.44;15.50
15	1.25(3H,t,J=7.4Hz),2.84(2H,q, J=7.4,16.0Hz),3.3-3.6(4H,m), 4.81(1H,bs),5.55(2H,s),7.11(2H, d,J=8.2Hz),7.18(1H,s),7.24(2H,d J=8.2Hz),7.5-7.7(4H,m),8.31(1H,s), 8.90(1H,s)	
16	1.27(3H,t,J=7.4Hz),2.87(2H,q, J=7.4,14.6Hz),5.59(2H,s),7.0-7.8 (14H,m),9.05(1H,s)	C ₃₀ H ₂₄ N ₆ O ₂ S · 0.5H ₂ O 66.53;4.65;15.52 66.28;4.51;15.26

30 Working Example 17

Ethyl 3-acetylamino-2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate

35 Ethyl 2-ethyl-3-nitro-7-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate (200 mg, 0.26 mmol) was dissolved in a mixture of acetic anhydride (6 ml), acetic acid (6 ml), dioxane (4 ml) and tetrahydrofuran (5 ml) and the solution was heated to 70 °C. To the heated solution were added zinc powders (85 mg) and the reaction mixture was stirred for 2 hours. The insoluble material was removed from the reaction mixture by filtration and the filtrate was concentrated to dryness *in vacuo*. The resulting oil was dissolved in a mixture of trifluoroacetic acid (8 ml) and water (1 ml) and the solution was stirred at room temperature for 5 hours. The reaction mixture was poured into water and extracted with chloroform. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (20:1) to give 59 mg (42 %) of the title compound as white crystals.
mp 163-166 °C.

45 IR (KBr)cm⁻¹ : 1720, 1700, 1615, 1550, 1510.

NMR (CDCl₃) δ : 1.14(3H, t, J=7.4Hz), 1.29(3H, t, J=7.0Hz), 2.03(3H, s), 2.63(2H, q, J=7.4, 15.0Hz), 4.23(2H, q, J=7.0, 14.2Hz), 5.45(2H, s), 7.13(2H, d, J=8.2Hz), 7.28(2H, d, J=8.2Hz), 7.5-7.7(4H, m), 8.74(1H, s), 9.66(1H, bs).

50


Elemental Analysis for C ₂₈ H ₂₈ N ₆ O ₄ S · H ₂ O			
	C (%)	H (%)	N (%)
Calcd:	C, 59.99;	H, 5.03;	N, 14.99
Found:	C, 59.50;	H, 4.56;	N, 14.76

EP 0 443 568 B1

The following compounds (Working Examples 18-20) as listed in Table 7 were prepared in the same manner as in Working Examples 12.

5

TABLE 7a



10

15

20

25

Working Example No.	R ¹	R ²	mp (°C)	Yield (%)
18	H	Me	167-170	30
19	Br	Me	227-231	77
20	CN	H	250-256	20

30

TABLE 7b

35

40

45


Working Example No.	NMR (DMSO-d ₆) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
18	1.28(3H,t),2.47(3H,s),4.22(2H,q), 5.44(2H,s),6.92(1H,s),7.10(2H,d), 7.23(2H,d),7.5-7.7(4H,m),8.70(1H, s)	C ₂₅ H ₂₁ N ₅ O ₃ S · 0.2H ₂ O 63.20;4.54;14.74 63.00;4.37;14.80
19	1.29(3H,t),2.45(3H,s),4.23(2H,q), 5.43(2H,s),7.13(1H,d),7.27(2H,d), 7.5- 7.8(4H,m),8.73(1H,s)	C ₂₅ H ₂₀ BrN ₅ O ₃ S 54.55;3.66;12.72 54.82;3.63;12.83
20	1.29(3H,t),4.25(2H,q),5.52(2H,s), 7.13(2H,d),7.31(2H,d),7.5-7.8 (4H,m),8.25(1H,s),8.89(1H,s)	

50

55


The following compounds (Working Examples 21-36) were prepared in the same manner as in Working Example 12.

TABLE 8a



Working Example No.	R ¹	mp (°C)	Yield (%)
21	-CH ₂ -	134-148	42
22	-CH ₂ -	223-225	67
23	-CH ₂ -	202-204	54
24	-CH ₂ -	powder	72
25	-CH ₂ -	154-157	55
26	-CH ₂ -	146-149	33

TABLE 8a

Working Example No.	R ¹	mp (°C)	Yield (%)
27	-CH ₂ - 	170-173	45
28	-CH ₂ - 	207-209	62
29	-CH ₂ - 	150-154	57
30	-CH ₂ - 	223-226	38
31	-CH ₂ - 	205-209	30
32	-CH ₂ - 	244-248	63
33	-CH ₂ - 	powder	72

40

45

50

55

TABLE 8b

5

	Working Example No.	NMR (200MHz, CDCl ₃) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
10	21	1.36(3H,t), 2.89(2H,q), 3.88(3H,s), 4.61(2H,d), 5.12(2H,s), 6.8-7.6 (12H,m), 8.05-8.15(1H,m), 8.30(1H,s)	
15	22	1.37(3H,t), 2.89(2H,q), 3.78(3H,s), 4.57(2H,s), 5.20(2H,s), 7.6-8.0 (13H,m), 8.39(1H,s)	C _{3.2} H _{2.8} N ₆ O ₃ S · H ₂ O 64.63; 5.08; 14.13 64.92; 4.74; 13.99
20	23	1.38(3H,t), 2.91(2H,q), 4.60(2H,d), 5.18(2H,s), 6.9-7.6(12H,m), 8.1-8.2 (1H,m), 8.29(1H,s), 10.99(1H,brs)	C _{3.1} H _{2.5} FN ₆ O ₂ S 65.94; 4.46; 14.88 65.94; 4.45; 14.71
25	24	1.37(3H,t), 2.90(2H,q), 4.61(2H,d), 5.16(2H,s), 6.8-7.6(12H,m), 8.05-8.15(1H,m), 8.34(1H,s)	
30	25	1.38(3H,t), 1.58(3H,d), 2.91(2H,q), 5.13(2H,s), 5.22(1H,t), 7.1-7.6 (13H,m), 8.1-8.2(1H,m), 8.20(1H,s), 11.05(1H,bs)	C _{3.2} H _{2.8} N ₆ O ₂ S · 0.5H ₂ O 67.47; 5.13; 14.75 67.64; 4.99; 14.52
35	26	1.37(3H,t), 2.90(2H,q), 4.67(2H,d), 5.16(2H,s), 7.0-7.6(12H,m), 8.05- 8.15(1H,m), 8.29(1H,s), 10.97 (1H,brs)	C _{3.1} H _{2.5} FN ₆ O ₂ S · 1.5H ₂ O 62.93; 4.77; 14.20 63.02; 4.30; 14.03

35

40

45

50

55

TABLE 8b

5

	Working Example No.	NMR (200MHz) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
10	27	1.35(3H,t), 2.86(2H,q), 5.07(2H,s), 5.10(2H,s), 7.1-7.9(14H,m), 8.07 (2H,d), 8.31(1H,brs), 11.01(1H,brs) ;(CDCl ₃)	C ₁₅ H ₂₈ N ₆ O ₂ S · 0.5H ₂ O 69.40; 4.83; 13.87 69.40; 4.65; 13.64
15	28	1.37(3H,t), 2.31(3H,s), 2.90(2H,q), 4.57(2H,d), 5.15(2H,s), 7.0-7.6 (12H,m), 8.0-8.2(1H,m), 8.27(1H,brs) ;(CDCl ₃)	C ₁₂ H ₂₈ N ₆ O ₂ S · 0.5H ₂ O 67.47; 5.13; 14.75 67.54; 5.14; 14.57
20	29	1.37(3H,t), 2.38(3H,s), 2.90(2H,q), 4.61(2H,d), 5.16(2H,s), 7.0-7.6 (12H,m), 8.0-8.2(1H,m), 8.25(1H,brs) ;(CDCl ₃)	C ₁₂ H ₂₈ N ₆ O ₂ S · 0.2H ₂ O 68.11; 5.07; 14.89 68.01; 4.85; 14.94
25	30	1.32(3H,t), 2.83(3H,q), 4.65(2H,d), 5.35(2H,s), 7.0-8.1(13H,m), 9.34(1H, s), 11.05(1H,t);(CDCl ₃)	C ₁₀ H ₂₅ N ₇ O ₂ S · HCl 0.5H ₂ O 60.75; 4.59; 16.53 60.83; 4.29; 16.36
30	31	1.38(3H,t), 2.91(2H,q), 4.90(2H,s), 5.34(2H,s), 7.20(2H,d), 7.28(2H,d), 7.37(1H,s), 7.5-7.8(4H,m), 7.96(2H, d), 8.62(1H,s), 8.78(2H,d);(CDCl ₃)	SIMS; 548(MH ⁺)
35	32	1.25(3H,t), 2.85(2H,q), 4.73(2H,d), 5.57(2H,s), 7.12(2H,d), 7.20(1H,s), 7.26(2H,d), 7.5-8.9(8H,m), 8.93(1H, s), 10.71(1H,t);(DMSO-d ₆)	C ₁₀ H ₂₅ N ₇ O ₂ S · HCl · 0.5H ₂ O 58.11; 4.88; 15.81 57.86; 4.34; 15.60
40	33	1.26(3H,t), 1.3-1.9(6H,m), 2.86(2H, q), 3.0-3.7(5H,m), 5.57(2H,s), 7.14 (2H,d), 7.21(1H,s), 7.23(2H,d), 7.4-7.7(4H,m), 8.6(1H,brs), 8.91(1H, s), 10.40(1H,t);(DMSO-d ₆)	SIMS; 554(MH ⁺)


45

50

55

The following compounds (Working Examples 34-41) were prepared in the same manner as in Working Example 12.

TABLE 9a



Working Example No.	R¹	R²	mp (°C)	Yield (%)
34	-CH ₂ OH	H	>260 (dec.)	73
35	H	H	249-253	83
36	-CHO	H	powder	66
37	-CH=CHCOOtBu	H	powder	100
38	-CH ₂ OMe	H	213-216	82
39	-COOH	CH ₃	162-167	
40	-CONH-	CH ₃	175-180	
41	-COOMe	-CH ₂ COOMe		

40

45

50

55

TABLE 9b

	Working Example No.	NMR (200MHz) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
5	34	1.24(3H,t),2.79(2H,q),4.40(2H,s), 7.05(1H,s),7.11(2H,d),7.22(2H,d), 7.5- 7.8(4H,m),7.98(1H,s);(DMSO-d ₆)	C ₂₄ H ₂₁ N ₅ O ₂ S · 0.8H ₂ O 62.95;4.97;15.29 63.18;4.88;14.86
10	35	1.24(3H,t),2.80(2H,q),5.35(2H,s), 6.21(1H,d),7.07(1H,s),7.11(2H,d), 7.24(2H,d),7.4-7.8(4H,m), 8.08(1H,d);(DMSO-d ₆)	C ₂₃ H ₁₉ N ₅ OS · H ₂ O 64.02;4.91;16.23 63.87;4.44;15.90
15	36	1.24(3H,t),2.82(2H,q),5.50(2H,s), 7.12(2H,d),7.20(1H,s),7.28(2H,d), 7.5- 7.7(4H,m),8.69(1H,s),10.28(1H, s);(DMSO-d ₆)	
20	37	1.25(3H,t),1.37(9H,s),2.80(2H,q), 5.35(2H,s),6.93(1H,d),7.1-7.9(10H, m),8.55(1H,s);(DMSO-d ₆)	
25	38	1.21(3H,t),2.69(2H,q),3.44(3H,s), 4.09(2H,s),5.21(2H,s), 7.9(10H,m);(CDCl ₃)	C ₂₅ H ₂₃ N ₅ O ₂ S · 0.7H ₂ O 63.87;5.23;14.90 64.00;4.99;14.69
30	39	1.27(3H,t),2.88(2H,q),2.95(3H,s), 5.68(2H,s),7.11(4H,s),7.29(1H,s), 7.5- 7.8(4H,m);(DMSO-d ₆)	C ₂₅ H ₂₁ N ₅ O ₃ S · 0.5H ₂ O 62.49;4.61;14.57 62.28;4.36;14.39
35	40	1.39(3H,t),2.75(3H,s),2.99(2H,q), 5.85(2H,s),7.1-7.8(14H,m);(CD ₃ OD)	SIMS; 547(MH ⁺)
	41	1.32(3H,t),2.86(2H,q),3.66(3H,s), 3.88(3H,s),3.94(2H,s),5.55(2H,s), 6.98(2H,d),7.13(2H,d),7.22(1H,s) 7.4- 7.7(4H,m);(CD ₃ OD)	SIMS; 544(MH ⁺)

40

45


50

55

EP 0 443 568 B1

The following compounds (Working Examples 42-48) were prepared in the same manner as in Working Example 2.

TABLE 10a



Working Example No.	R ⁷	mp (°C)	Yield (%)
42	Bu	127-130	32
43	-CH ₂ -	202-205	65
44	Et	210-212	59
45	--F	246-250	70
46	--Cl	powder	31
47	-	207-221	57
48	-CH ₂ COOEt	167-169	44

TABLE 10b

Working Example No.	¹ H-NMR (CDCl ₃) δ	E. Anal. (Calcd/Found) C(%), H(%), N(%)
42	0.92(3H,t),1.30(3H,t),1.2-1.5(2H,m),1.5-1.8(2H,m),2.77(2H,q),4.01(2H,t),5.15(2H,s),7.00(1H,s),7.23(2H,d),7.42(2H,d),7.5-7.7(3H,m),8.1-8.2(1H,m)	C ₂₈ H ₂₆ N ₆ O ₂ S 64.18;5.39;17.27 64.00;5.51;17.18
43	1.21(3H,t),2.75(2H,q),5.12(2H,s),5.15(2H,s),7.02(1H,s),7.09(2H,d),7.2-7.8(11H,m)	C ₂₉ H ₂₄ N ₆ O ₂ S · 0.4H ₂ O 65.99;4.74;15.92 66.17;4.91;15.63
44	1.25(3H,t),1.30(3H,t),2.78(2H,q),4.08(2H,q),5.16(2H,s),7.01(1H,s),7.23(2H,d),7.43(2H,d),7.5-7.7(3H,m),8.1-8.2(1H,m)	C ₂₄ H ₂₂ N ₆ O ₂ S · 0.5H ₂ O 61.65;4.96;17.97 61.70;4.83;17.80
45	1.32(3H,t),2.81(2H,q),5.14(2H,s),7.06(1H,s),7.1-7.8(12H,m)	C ₂₈ H ₂₁ FN ₆ O ₂ S 64.11;4.04;16.02 63.82;3.97;15.77
46	1.33(3H,t),2.81(2H,q),5.20(2H,q),7.07(1H,s),7.2-8.2(11H,m)	C ₂₈ H ₂₀ N ₆ O ₂ SCl ₂ · 0.6H ₂ O 57.36;3.64;14.33 57.74;3.75;13.75
47	1.29(3H,t),1.2-2.6(10H,m),2.76(2H,q),4.7-5.0(1H,m),5.13(2H,s),6.99(1H,s),7.24(2H,d),7.42(2H,d),7.5-7.7(3H,m),8.1-8.2(1H,m)	C ₂₈ H ₂₈ N ₆ O ₂ S · 0.4H ₂ O 64.69;5.58;16.17 64.81;5.50;15.95
48	1.29(3H,t),1.31(3H,t),2.79(2H,q),4.23(2H,q),4.80(2H,s),5.17(2H,s),7.03(1H,s),7.22(2H,d),7.4-7.7(5H,m),8.1-8.2(1H,m)	C ₂₈ H ₂₄ N ₆ O ₄ S 60.45;4.68;16.27 60.33;4.59;16.17

Pharmaceutical Examples

The compounds (I) of the present invention are employed, for example, when used as agents for treating circulatory system diseases such as hypertension, heart diseases, strokes and the like, in the following formulations.

1. Capsule

(1) Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno-[2,3-b]pyridine-5-carboxylate	10 mg
(2) Lactose	90 mg
(3) Microcrystalline cellulose	70 mg
(4) Magnesium stearate	10 mg
One capsule	180 mg

The ingredients (1), (2), and (3) and a half of the ingredient (4) were blended together and granulated. To this mixture was added the remaining half of the ingredient (4) and distributed into gelatine capsules.

2. Tablet

5	(1) Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno-[2,3-b]pyridine-5-carboxylate	10 mg
10	(2) Lactose	35 mg
	(3) Maize starch	150 mg
	(4) Microcrystalline cellulose	30 mg
	(5) Magnesium stearate	5 mg
	One tablet	230 mg

15 Two third each of the ingredients (1), (2), (3) and (4) and a half of the ingredient (5) were blended together and granulated. To these granules were added the remaining ingredients (4) and (5) and then compressed to form tablets.

3. Injection

20	(1) 2-Ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid sodium salt	10 mg
25	(2) Inositol	100 mg
	(3) Benzyl alcohol	20 mg
	One ampule	130 mg

30 The ingredients (1), (2) and (3) were dissolved in distilled water for injection to a total volume of two ml and distributed into ampules. Total processes were carried out under sterile conditions.

Experimental Example 1

Inhibition of binding of angiotensin-II to angiotensin receptor

35 [Method]

40 An experiment of inhibition on the binding of angiotensin-II (A-II) to A-II-receptor was conducted by modifying the method of Douglas et al. [Endocrinology, 102, 685-696 (1978)]. An A-II-receptor was prepared from the membrane fraction of bovine adrenal cortex.

45 The compound of the present invention (10^{-9} M to 3×10^{-5} M) and ^{125}I -A-II (1.85 kBq/50 μ l) were added to the receptor membrane fraction, and the mixture was incubated at room temperature for one hour. The receptor-bound and free ^{125}I -A-II were separated through a filter (Whatman GF/B filter), and the radioactivity of ^{125}I -A-II bound to the receptor was measured.

45 [Results]

The results relating to the compounds of the present invention are shown in Table 11.

50 Experimental Example 2

Inhibitory effect of the compound of the present invention on pressor action of A-II

55 [Method]

Jcl : SD rats (9 week old, male) were used. On the day previous to the experiment, these animals were applied with cannulation into the femoral artery and vein under anesthesia with pentobarbital Na. The animals were fasted but allowed to access freely to drinking water until the experiment was started. Just on the day of conducting the experiment, the artery cannula was connected with a blood-pressure transducer, and the average blood pressure was recorded by means

of polygraph. Before administration of the drug, the pressor action due to intravenous administration of A-II (100 ng/kg) as the control was measured. The drugs were orally administered, and then, at each point of the measurement, A-II was administered intravenously, and the pressor action was similarly measured. By comparing the pressor action before and after administration of the drug, the percent inhibition by the drug on A-II-induced pressor action was evaluated.

5

[Results]

The results relating to the compounds of the present invention are shown in Table 11.

10

TABLE 11

15

Working Example No.	Radio Receptor Assay IC ₅₀ (μM)	Pressor Response (30 mg/Kg, p.o.)
2	0.05	NT ^a
3	0.07	NT
4	0.20	NT
5	0.05	NT
6	0.09	NT
7	0.17	NT
8	0.01	NT
10	0.04	+ ^b
11	0.21	NT
12	0.06	++
13	0.02	NT
14	0.13	NT
15	0.05	NT
16	0.12	++
20	0.67	NT
21	0.25	++
23	0.17	++
24	0.19	++
25	0.78	++
26	0.21	++
28	0.22	+
29	0.12	++
30	0.02	++

^a: NT , not tested.

^b : (% Inhibition), ++ ≥ 70 % > + ≥ 50 %.

30

It is understood that the preceding representative examples may be varied within the scope of the present invention by one skilled in the art to achieve essentially the same results.

As many widely different embodiments of this invention may be made without departing from the spirit and scope thereof, it is to be understood that this invention is not limited to the specific embodiments thereof except as defined in the appended claims.


40

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

5 1. A compound of the formula:

10




15

20

wherein W is

25



30

R¹ and R² which may be the same or different, are each independently

- (1) hydrogen,
- (2) halogen,
- (3) cyano,
- (4) nitro,

35

(5) a group having the formula: R⁸CONH- wherein R⁸ is hydrogen or (C₁₋₈)alkyl group which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, (C₁₋₄)alkanoyloxy, benzyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or naphthyl, or

40

(6) a hydrocarbon residue selected from the group consisting of (i) (C₁₋₈)alkyl, (ii) (C₂₋₈)alkenyl, (iii) (C₂₋₈)alkynyl, (iv) (C₃₋₈)cycloalkyl, (v) an aromatic hydrocarbon selected from the group consisting of phenyl and naphthyl, wherein said hydrocarbon residue may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, (C₁₋₄)alkanoyloxy, benzyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy, (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;

50

R³ is

- (1) hydrogen,
- (2) (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino, or

5 (3) -COD wherein D is hydrogen, C₁₋₄-alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino, wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro or lower (C₁₋₄) alkoxy;


10 R⁴ is hydrogen, halogen or nitro;

R⁵ is carboxyl, lower (C₁₋₄)alkoxycarbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide, phosphoric acid or sulfonic acid;

15 R⁶ is hydrogen or (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;

20 R⁷ is a hydrocarbon residue which may be substituted like R¹ and R²; A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group selected from the group consisting of (C₁₋₄)alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, or -CH=CH-; and n is an integer of 1 or 2; and a pharmaceutically acceptable salt thereof.

25 2. A compound according to claim 1, which is a compound of the formula (Ia):



30 wherein R¹ and R² are as defined in claim 1;

35 R³ is hydrogen, formyl, optionally substituted alkyl or alkenyl as defined in claim 1, or -COD wherein D is alkoxy, hydroxy, halogen, or optionally substituted amino as defined in claim 1;


40 R⁴ is hydrogen, halogen or nitro;

R⁵ is as defined in claim 1;

R⁶, A and n are as defined in claim 1

and a pharmaceutically acceptable salt thereof.

45 3. A compound according to claim 1, which is a compound of the formula (Ib):



wherein R¹ and R² are as defined in claim 1;
 R⁴ is hydrogen, halogen or nitro;
 R⁵ is as defined in claim 1;
 R⁷, A and n are as defined in claim 1;
 and a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein an optionally substituted amino as defined in claim 1 for the substituents of said hydrocarbon residue is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, or N-(m-methoxy)phenylpiperazino.


10 5. A compound according to claim 1, wherein said D' is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino.

15 6. A compound according to claim 1, wherein said D is amino, N-(C₁₋₄)alkyl amino, N,N-di(C₁₋₄)alkyl amino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-phenylpiperazino, or N-(p-fluorophenyl)piperazino wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro or lower (C₁₋₄)alkoxy.

20 7. A compound according to claim 1, wherein said R⁵ is tetrazolyl.

8. A compound according to claim 1, wherein said R⁵ is in the ortho position.


25 9. A compound according to claim 1, which is a compound of the formula (Ia'):



40 wherein R¹ is (C₁₋₈)alkyl; R³ is
 (1) hydrogen,
 (2) (C₁₋₈)alkyl which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, halogen, (C₁₋₄)alkoxy or -COD" wherein D" is (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino, or
 (3) -COD wherein D is hydrogen, (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl;

55 or a pharmaceutically acceptable salt thereof.

10. A compound according to claim 1, which is a compound of the formula (Ib):



wherein R¹ is (C₁₋₈)alkyl; R⁷ is (C₁₋₈)alkyl which may be optionally substituted with phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, or -COD' wherein D' is (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthyl-amino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino or N-phenylpiperazino, (C₃₋₆)cycloalkyl, or phenyl or naphthyl which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, (C₁₋₄)alkanoyloxy, benzoxyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy, (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmeth-ylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl; or a pharmaceutically acceptable salt thereof.

30

11. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of ethyl 2-ethyl-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate, 2-ethyl-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid, methoxyethyl 2-ethyl-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate, 2-ethyl-5-(N-benzylcarbamoyl)-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one, 2-ethyl-5-(N-phenylcarbamoyl)-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one, and 2-ethyl-5-(N-2-pyridylmethylcarbamoyl)-7-[[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one.

35

12. A compound according to claim 10, wherein R¹ is ethyl, R⁵ is 1H-tetrazol-5-yl and R⁷ is butyl, benzyl, ethyl, p-fluorophenyl, 2,5-dichlorophenyl, cyclohexyl, ethoxycarbonylmethyl, or 2-[4-(o-methoxyphenyl)-piperazino]ethyl.

40

13. A pharmaceutical composition for antagonizing angiotensin II which comprises a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutical acceptable carrier, excipient or diluent.

45


14. A use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for antagonizing angiotensin II.

50

55

15. A method for producing a compound of the formula (I):

5




10

15

wherein W, R1, R2, R3, R4, R5, R6, R7, A and n Claim 1 have the meaning as defined in Claim 1 or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of the formula (II):

20




25

30

wherein R1, R2, and W have the above-defined meanings, with a compound of the formula (III):

35



40

wherein R4, R5, A and n have the above-defined meanings, and X is halogen, and, (i) if desired, converting a compound of the formula (I) wherein R5 is cyano or protected tetrazolyl, and R1, R2, R4, R5, A, W and n have the above-defined meanings, into a compound of the formula (I) wherein R5 is tetrazolyl and R1, R2, R4, R5, A, W and n have the above-defined meanings, (ii) if desired, converting a compound of the formula (I) wherein -R3 is lower (C1-4) alkoxy carbonyl or halogeno carbonyl, and R1, R2, R4, R5, R6, A and n have the above-defined meanings, into a compound of the formula (I) wherein R3 is carboxyl, or optionally substituted carbamoyl and R1, R2, R4, R5, R6, A and n have the above-defined meanings, or (iii) if desired, converting a compound of the formula (I) wherein -R3 is carboxyl, and R1, R2, R4, R5, R6, A and n have the above-defined meanings, into a compound of the formula (I) wherein R3 is halogeno carbonyl and R1, R2, R4, R5, R6, A and n have the above-defined meanings, and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof.

55


Claims for the following Contracting States : ES, GR

1. A method for producing a compound of the formula (I):

5

10


15



wherein W is

20

25



R¹ and R² which may be the same or different, are each independently


30 (1) hydrogen,
 (2) halogen,
 (3) cyano,
 (4) nitro, (5) a group having the formula: R⁸CONH- wherein R⁸ is
 hydrogen or (C₁₋₈)alkyl group which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro,
 35 amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenyl-piperazino, (C₁₋₄)alkanoyloxy, benzoxyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy,
 (C₁₋₄)alkyl at an optional position on the phenyl ring, or naphthyl, or
 (6) a hydrocarbon residue selected from the group consisting of (i) (C₁₋₈)alkyl, (ii) (C₂₋₈)alkenyl, (iii) (C₂₋₈)alky-
 40 nyl, (iv) (C₃₋₈)cycloalkyl, (v) an aromatic hydrocarbon selected from the group consisting of phenyl and naphthyl,
 wherein said hydrocarbon residue may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro,
 amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino,
 45 naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiper-
 azino, (C₁₋₄)alkanoyloxy, benzoxyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy,
 (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy,
 (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino,
 benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;

R³ is


50 (1) hydrogen,
 (2) (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with
 hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -
 COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower
 55 (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino,
 piperazino, or N-phenylpiperazino, or
 (3) -COD where D is hydrogen, C₁₋₄-alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower
 (C₁₋₄)alkyl amino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, mor-
 pholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino, wherein
 said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl,

isobutyl, sec-butyl, hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro or lower (C₁₋₄) alkoxy;

R⁴ is hydrogen, halogen or nitro;
 5 R⁵ is carboxyl, lower (C₁₋₄)alkoxycarbonyl, cyano, tetrazoyl, trifluoromethanesulfonic amide, phosphoric acid or sulfonic acid;
 R⁶ is hydrogen or (C₁₋₈)alkyl or (C₂₋₈)alkenyl, which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, halogen, lower (C₁₋₄)alkoxy, or -COD" wherein D" is lower (C₁₋₄)alkoxy, hydroxy, halogen, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkyl amino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino;
 10 R⁷ is a hydrocarbon residue which may be substituted like R¹ and R²; A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group selected from the group consisting of (C₁₋₄)alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, or -CH=CH-; and n is an integer of 1 or 2;
 15 or a pharmaceutically acceptable salt thereof, which comprises reacting a compound of the formula (II):



wherein R¹, R², and W have the above-defined meanings, with a compound of the formula (III):




40 wherein R⁴, R⁵, A and n have the above-defined meanings, and X is halogen,
 and, (i) if desired, converting a compound of the formula (I) wherein R⁵ is cyano or protected tetrazoyl, and R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, into a compound of the formula (I) wherein R⁵ is tetrazoyl and R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, (ii) if desired, converting a compound of the formula (I) wherein -R³ is lower (C₁₋₄) alkoxycarbonyl or halogenocarbonyl, and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, into a compound of the formula (I) wherein R³ is carboxyl, or optionally substituted carbamoyl and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, or (iii) if desired, converting a compound of the formula (I) wherein -R³ is carboxyl, and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, into a compound of the formula (I) wherein R³ is halogenocarbonyl and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable salt thereof.

45

50

2. A method according to claim 1 for producing a compound of the formula (Ia):

5



10

(Ia)


15

wherein R^1 and R^2 are as defined in claim 1;
 R^3 is hydrogen, formyl, optionally substituted alkyl or alkenyl as defined in claim 1, or -COD wherein D is alkoxy, hydroxy, halogen, or optionally substituted amino as defined in claim 1;
 R^4 is hydrogen, halogen or nitro;
 R^5 is as defined in claim 1;
 R^6 , A and n are as defined in claim 1
and a pharmaceutically acceptable salt thereof.

25

3. A method according to claim 1 for producing a compound of the formula (Ib):

30



35

(Ib)

40

45

wherein R^1 and R^2 are as defined in claim 1;
 R^4 is hydrogen, halogen or nitro;
 R^5 is as defined in claim 1;
 R^7 , A and n are as defined in claim 1;
and a pharmaceutically acceptable salt thereof.

50


55

4. A method according to claim 1, wherein an optionally substituted amino as defined in claim 1 for the substituents of said hydrocarbon residue is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, or N-(m-methoxy)phenylpiperazino.
5. A method according to claim 1, wherein said D' is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino.
6. A method according to claim 1, wherein said D is amino, N- (C_{1-4}) alkyl amino, N,N-di (C_{1-4})alkyl amino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-phenylpiperazino, or N-(p-fluorophenyl)piperazino wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, hydroxyl, amino, N-lower (C_{1-4})alkyl amino, N,N-dilower (C_{1-4})alkylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, halogen, nitro or lower (C_{1-4})alkoxy.

7. A method according to claim 1, wherein said R⁵ is tetrazolyl.

8. A method according to claim 1, wherein said R⁵ is in the ortho position.

5 9. A method according to claim 1 for producing a compound of the formula (Ia'):



20 wherein R¹ is (C₁₋₈)alkyl; R³ is


(1) hydrogen,

(2) (C₁₋₈)alkyl which may be straight or branched and may be optionally substituted with hydroxyl, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, halogen, (C₁₋₄)alkoxy or -COD" wherein D" is (C₁₋₄)alkoxy, hydroxy, halogen, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino, or

25 (3) -COD wherein D is hydrogen, (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkyl amino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, benzylamino, naphthylmethylamino, pyridylamino, pyridylmethylamino, morpholino, piperidino, piperazino, piperidylmethyl, N-(p-fluorophenyl)piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl; or a pharmaceutically acceptable salt thereof.

30

10. A method according to claim 1 for producing a compound of the formula (Ib'):



wherein R¹ is (C₁₋₈)alkyl; R⁷ is (C₁₋₈)alkyl which may be optionally substituted with phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, or -COD' wherein D' is (C₁₋₄)alkoxy, hydroxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino or N-phenylpiperazino, (C₃₋₈)cycloalkyl, or phenyl or naphthyl which may be substituted with hydroxyl, (C₁₋₄)alkoxy, (C₁₋₄)alkyl, halogen, nitro, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmethylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, N-(m-methoxy)phenylpiperazino, (C₁₋₄)alkanoyloxy, benzoyloxy, phenyl which may be substituted with halogen, nitro, (C₁₋₄)alkoxy, (C₁₋₄)alkyl at an optional position on the phenyl ring, or a group having the formula: -COD' wherein D' is hydroxy, (C₁₋₄)alkoxy, amino, N-lower (C₁₋₄)alkylamino, N,N-dilower (C₁₋₄)alkylamino, phenylamino, naphthylamino, benzylamino, naphthylmeth-

50

55

ylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino; and R⁵ is carboxyl or tetrazolyl; or a pharmaceutically acceptable salt thereof.

11. A method according to claim 1 for producing a compound which is selected from the group consisting of ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate, 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylic acid, methoxyethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxylate, 2-ethyl-5-(N-benzylcarbamoyl)-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one, 2-ethyl-5-(N-phenylcarbamoyl)-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one, and 2-ethyl-5-(N-2-pyridylmethylcarbamoyl)-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridin-4(7H)-one or a pharmaceutically acceptable salt thereof.

12. A method according to claim 10, wherein R¹ is ethyl, R⁵ is 1H-tetrazol-5-yl and R⁷ is butyl, benzyl, ethyl, p-fluorophenyl, 2,5-dichlorophenyl, cyclohexyl, ethoxycarbonylmethyl, or 2-[4-(o-methoxyphenyl)-piperazino]ethyl.


13. A method for producing a pharmaceutical composition for antagonizing angiotensin II which comprises admixing a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutical acceptable carrier, excipient or diluent.

14. A use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for antagonizing angiotensin II.

Patentansprüche

25 Patentansprüche für folgende Vertragsstaaten : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Verbindung der Formel



worin W



ist,

R¹ und R², die gleich oder verschieden sein können, jeweils unabhängig

55 (1) Wasserstoff,
 (2) Halogen,
 (3) Cyanoreste,
 (4) Nitroreste,

(5) Gruppen mit der Formel R⁸CONH-, worin R⁸ Wasserstoff oder eine (C₁-C₈)-Alkylgruppe ist, die mit Hydroxyl-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkyl-, Halogen-, Nitro-, Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Benzylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, (C₁-C₄)-Alkanoyloxy-, Benzoxyloxy-, Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position am Phenylring substituiert sein können, oder Naphthylresten substituiert sein kann, oder


5 (6) Kohlenwasserstoffreste sind, ausgewählt aus der Gruppe bestehend aus (i) (C₁-C₈)-Alkylresten, (ii) (C₂-C₈)-Alkenylresten, (iii) (C₂-C₈)-Alkinylresten, (iv) (C₃-C₈)-Cycloalkylresten, (v) einem aromatischen Kohlenwasserstoffrest ausgewählt aus der Gruppe bestehend aus Phenyl- und Naphthylresten, wobei der Kohlenwasserstoffrest mit Hydroxyl-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkyl-, Halogen-, Nitro-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m-Methoxy)phenylpiperazino-, (C₁-C₄)-Alkanoyloxy-, Benzoxyloxy-, Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position am Phenylring substituiert sein können, oder einer Gruppe der Formel -COD' substituiert sein kann, worin D' ein Hydroxy-, (C₁-C₄)-Alkoxy-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist;

20 R³ (1) Wasserstoff,
 (2) ein (C₁-C₈)-Alkyl- oder (C₂-C₈)-Alkenylrest, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Halogen-, Niedrig(C₁-C₄)alkoxyresten oder -COD" substituiert sein kann, worin D" ein Niedrig(C₁-C₄)-alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist oder
 25 (3) -COD ist, worin D Wasserstoff, ein (C₁-C₄)-Alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C₁-C₄)-alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethylamino-, Morpholino-, Piperidino-, Piperazino-, Piperidylmethyl-, N-(p-Fluorophenyl)piperazino- oder N-Phenylpiperazinorest ist, worin die Alkyl-, Aryl- und Heteroarylgruppen gegebenenfalls mit Methyl-, Ethyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, sek.-Butyl-, Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, Halogen-, Nitro- oder Niedrig(C₁-C₄)-alkoxyresten substituiert sein können;

30 R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;
 R⁵ ein Carboxyl-, Niedrig(C₁-C₄)alkoxycarbonyl-, Cyano-, Tetrazolyl-, Trifluormethansulfonsäureamid-, Phosphorsäure- oder Sulfonsäurerest ist;
 R⁶ Wasserstoff oder ein (C₁-C₈)-Alkyl- oder (C₂-C₈)-Alkenylrest ist, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Halogen-, Niedrig(C₁-C₄)alkoxyresten oder -COD" substituiert sein kann, worin D" ein Niedrig(C₁-C₄)-alkoxy-, Hydroxy-, Halogen-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist;
 40 R⁷ ein Kohlenwasserstoffrest ist, der wie R¹ und R² substituiert sein kann; A eine direkte Bindung oder ein Abstandshalter mit einer Atomlänge von 2 oder weniger zwischen der Phenylengruppe und der Phenylgruppe ist ausgewählt aus der Gruppe bestehend aus einem (C₁-C₄)-Alkylenrest, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂- oder -CH=CH- und n eine ganze Zahl von 1 oder 2 ist und

45 ein pharmazeutisch annehmbares Salz davon.

2. Verbindung nach Anspruch 1, die eine Verbindung der Formel (Ia) ist:



worin R¹ und R² wie in Anspruch 1 definiert sind;


R³ Wasserstoff, ein Formylrest, ein gegebenenfalls substituierter Alkyl- oder Alkenylrest, wie in Anspruch 1 definiert, ist oder -COD ist, worin D ein Alkoxy-, Hydroxy-, Halogen- oder gegebenenfalls substituierter Aminorest, wie in Anspruch 1 definiert, ist;

R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;

R⁵ wie in Anspruch 1 definiert ist;

R⁶, A und n wie in Anspruch 1 definiert sind und ein pharmazeutisch annehmbares Salz davon.

25 3. Verbindung nach Anspruch 1, die eine Verbindung der Formel (Ib) ist:



40 worin R¹ und R² wie in Anspruch 1 definiert sind;

R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;

R⁵ wie in Anspruch 1 definiert ist;

R⁷, A und n wie in Anspruch 1 definiert sind und ein pharmazeutisch annehmbares Salz davon.

45 4. Verbindung nach Anspruch 1, worin ein wie für die Substituenten des Kohlenwasserstoffrestes in Anspruch 1 defi-
nierter gegebenenfalls substituierter Aminorest ein Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Benzyl-
amino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino- oder N-(m-Methoxy)-phenylpiperazinorest ist.


50 5. Verbindung nach Anspruch 1, worin D' ein Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Benzylamino-,
Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist.

55 6. Verbindung nach Anspruch 1, worin D ein Amino-, N-(C₁-C₄)Alkylamino-, N,N-Di(C₁-C₄)alkylamino-, Phenylamino-,
Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethylamino-, Morpholino-, Piperidino-, Piperazino-,
Piperidylmethyl-, N-Phenylpiperazino- oder N-(p-Fluorphenyl)piperazinorest ist, worin die Alkyl-, Aryl- und Hete-
roarylgruppen gegebenenfalls mit Methyl-, Ethyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, sek.-Butyl-, Hydroxyl-, Amino-,
N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, Halogen-, Nitro- oder Niedrig(C₁-C₄)alkoxyresten substituiert sein können.

7. Verbindung nach Anspruch 1, worin R⁵ ein Tetrazolylrest ist.

8. Verbindung nach Anspruch 1, worin R⁵ in ortho-Position ist.

5 9. Verbindung nach Anspruch 1, die eine Verbindung der Formel (Ia') ist:




20 worin R¹ ein (C₁-C₈)-Alkylrest ist;
R³

(1) Wasserstoff,
25 (2) ein (C₁-C₈)-Alkylrest ist, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig-(C₁-C₄)alkylamino-, Halogen-, (C₁-C₄)-Alkoxyresten oder -COD" substituiert sein kann, worin D" ein (C₁-C₄)-Alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist oder
30 (3) -COD ist, worin D Wasserstoff, ein (C₁-C₄)-Alkoxy-, Hydroxy-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethamino-, Morpholino-, Piperidino-, Piperazino-, Piperidylmethyl-, N-(p-Fluorphenyl)piperazino- oder N-Phenylpiperazinorest ist und R⁵ ein Carboxyl- oder Tetrazolylrest ist oder

35 ein pharmazeutisch annehmbares Salz davon.

10. Verbindung nach Anspruch 1, die eine Verbindung der Formel (Ib') ist:



50 worin R¹ ein (C₁-C₈)-Alkylrest ist; R⁷ ein (C₁-C₈)-Alkylrest ist, der gegebenenfalls mit Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position am Phenylring, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m-Methoxy)phenylpiperazinoresten oder -COD" substituiert sein kann, worin D' ein (C₁-C₄)-Alkoxy-, Hydroxy-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazino-, (C₃-C₈)-Cycloalkyl- oder Phenyl- oder Naphthylrest ist, der mit Hydroxyl-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkyl-, Halogen-, Nitro-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-nied-

rig(C₁-C₄)-alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m-Methoxy)-phenylpiperazino-, (C₁-C₄)-Alkanoyloxy-, Benzoyleoxy-, Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position des Phenylrings substituiert sein können, oder einer Gruppe der Formel -COD' substituiert sein kann, worin D' ein Hydroxy-, (C₁-C₄)-Alkoxy-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist; und R⁵ ein Carboxyl- oder Tetrazolylrest ist oder ein pharmazeutisch annehmbares Salz davon.


11. Verbindung nach Anspruch 1 oder pharmazeutisch annehmbares Salz davon, die ausgewählt ist aus der Gruppe bestehend aus Ethyl-2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-5-carboxylat, 2-Ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-5-carbonsäure, Methoxyethyl-2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-5-carboxylat, 2-Ethyl-5-(N-benzylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on, 2-Ethyl-5-(N-phenylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on und 2-Ethyl-5-(N-2-pyridylmethylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on.

12. Verbindung nach Anspruch 10, worin R¹ ein Ethylrest ist, R⁵ ein 1H-Tetrazol-5-yl-rest ist und R⁷ ein Butyl-, Benzyl-, Ethyl-, p-Fluorophenyl-, 2,5-Dichlorphenyl-, Cyclohexyl-, Ethoxycarbonylmethyl- oder 2-[4-(o-Methoxyphenyl)-piperazino]ethylrest ist.


13. Pharmazeutische Zusammensetzung zur Antagonisierung von Angiotensin-II umfassend eine therapeutisch wirksame Menge einer Verbindung nach Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon in Mischung mit einem pharmazeutisch annehmbaren Träger, Hilfsstoff oder Verdünnungsmittel.

14. Verwendung einer Verbindung nach Anspruch 1 oder eines pharmazeutisch annehmbaren Salzes davon zur Herstellung eines Arzneimittels, um Angiotensin-II zu antagonisieren.

15. Verfahren zur Herstellung einer Verbindung der Formel (I):




worin W, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, A und n die in Anspruch 1 definierten Bedeutungen haben oder eines pharmazeutisch annehmbaren Salzes davon, umfassend, daß man eine Verbindung der Formel (II):



worin R¹, R² und W die oben angegebenen Bedeutungen haben mit einer Verbindung der Formel (III):

5




10 worin R⁴, R⁵, A und n die oben angegebenen Bedeutungen haben und X Halogen ist, umsetzt und (i) falls erwünscht, eine Verbindung der Formel (I) worin R⁵ ein Cyanorest oder ein geschützter Tetrazolyrest ist und R¹, R², R⁴, R⁵, A, W und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R⁵ ein Tetrazolyrest ist und R¹, R², R⁴, R⁵, A, W und n die oben angegebenen Bedeutungen haben, (ii) falls erwünscht, eine Verbindung der Formel (I), worin -R³ ein Niedrig(C₁-C₄)alkylcarbonyl- oder Halogencarbonylrest ist und R¹, R², R⁴, R⁵, A und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R³ ein Carboxylrest oder ein gegebenenfalls substituierter Carbamoylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben oder (iii) falls erwünscht, eine Verbindung der Formel (I), worin -R³ ein Carboxylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R³ ein Halogencarbonylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben und, falls erwünscht, eine Verbindung der Formel (I) in ein pharmazeutisch annehmbares Salz davon umwandelt.

Patentansprüche für folgende Vertragsstaaten : ES, GR

25 1. Verfahren zur Herstellung einer Verbindung der Formel (I):


30



35

40 worin W

45



50

ist,

R¹ und R², die gleich oder verschieden sein können, jeweils unabhängig

55

- (1) Wasserstoff,
- (2) Halogen,
- (3) Cyanoreste,
- (4) Nitroreste,

(5) Gruppen der Formel R⁸CONH-, worin R⁸ Wasserstoff oder eine (C₁-C₈)-Alkylgruppe ist, die mit Hydroxyl-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkyl-, Halogen-, Nitro-, Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Ben-


zylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, (C₁-C₄)-Alkanoyloxy-, Benzoyloxy-, Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position an dem Phenylring substituiert sein können, oder Naphthylresten substituiert sein kann oder

5 (6) Kohlenwasserstoffreste sind, ausgewählt aus der Gruppe bestehend aus (i) (C₁-C₈)-Alkylresten, (ii) (C₂-C₈)-Alkenylresten, (iii) (C₂-C₈)-Alkinylresten, (iv) (C₃-C₈)-Cycloalkylresten, (v) einem aromatischen Kohlenwasserstoff ausgewählt aus der Gruppe bestehend aus Phenyl- und Naphthylresten, wobei der Kohlenwasserstoffrest mit Hydroxyl-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkyl-, Halogen-, Nitro-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m-Methoxy)phenylpiperazino-, (C₁-C₄)-Alkanoyloxy-, Benzoyloxy-, Phenylresten, die mit Halogen-, Nitro-, (C₁-C₄)-Alkoxy-, (C₁-C₄)-Alkylresten an freigewählter Position am Phenylring substituiert sein können, oder einer Gruppe der Formel -COD' substituiert sein kann, worin D' ein Hydroxy-, (C₁-C₄)-Alkoxy-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist;

15 R³ (1) Wasserstoff,
 (2) ein (C₁-C₈)-Alkyl- oder (C₂-C₈)-Alkenylrest, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Halogen-, Niedrig(C₁-C₄)alkoxyresten oder -COD" substituiert sein kann, worin D" ein Niedrig(C₁-C₄)-alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C₁-C₄)-alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist oder
 (3) -COD ist, worin D Wasserstoff, ein (C₁-C₄)-Alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C₁-C₄)-alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethylamino-, Morpholino-, Piperidino-, Piperazino-, Piperidylmethyl-, N-(p-Fluorphenyl)piperazino- oder N-Phenylpiperazinorest ist, worin die Alkyl-, Aryl- und Heteroarylgruppen gegebenenfalls mit Methyl-, Ethyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, sek.-Butyl-, Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)-alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, Halogen-, Nitro- oder Niedrig-(C₁-C₄)-alkoxyresten substituiert sein können;


R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;
 R⁵ ein Carboxyl-, Niedrig(C₁-C₄)-alkoxycarbonyl-, Cyano-, Tetrazolyl-, Trifluormethansulfonsäureamid-, Phosphorsäure- oder Sulfonsäurerest ist;
 35 R⁶ Wasserstoff oder ein (C₁-C₈)-Alkyl- oder (C₂-C₈)-Alkenylrest ist, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Halogen-, Niedrig(C₁-C₄)-alkoxyresten oder -COD" substituiert sein kann, worin D" ein Niedrig(C₁-C₄)-alkoxy-, Hydroxy-, Halogen-, N-Niedrig(C₁-C₄)-alkylamino-, N,N-Di-niedrig(C₁-C₄)-alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist;
 40 R⁷ ein Kohlenwasserstoffrest ist, der wie R¹ und R² substituiert sein kann; A eine direkte Bindung oder ein Abstandshalter mit einer Atomlänge von 2 oder weniger zwischen der Phenylengruppe und der Phenylgruppe ist ausgewählt aus der Gruppe bestehend aus einem (C₁-C₄)-Alkylenrest, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂- oder -CH=CH- und n eine ganze Zahl von 1 oder 2 ist

45 und eines pharmazeutisch annehmbaren Salzes davon umfassend, daß man eine Verbindung der Formel (II):



worin R¹, R² und W die oben angegebenen Bedeutungen haben mit einer Verbindung der Formel (III):

5



10

worin R⁴, R⁵, A und n die oben angegebenen Bedeutungen haben und X Halogen ist, umsetzt und (i) falls erwünscht, eine Verbindung der Formel (I) worin R⁵ ein Cyanorest oder ein geschützter Tetrazolylrest ist und R¹, R², R⁴, R⁵, A, W und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R⁵ ein Tetrazolylrest ist und R¹, R², R⁴, R⁵, A, W und n die oben angegebenen Bedeutungen haben, (ii) falls erwünscht, eine Verbindung der Formel (I), worin -R³ ein Niedrig(C₁-C₄)alkylcarbonyl- oder Halogencarbonylrest ist und R¹, R², R⁴, R⁵, A und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R³ ein Carboxylrest oder ein gegebenenfalls substituierter Carbamoylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben oder (iii) falls erwünscht, eine Verbindung der Formel (I), worin -R³ ein Carboxylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben, in eine Verbindung der Formel (I) umwandelt, worin R³ ein Halogencarbonylrest ist und R¹, R², R⁴, R⁵, R⁶, A und n die oben angegebenen Bedeutungen haben und, falls erwünscht, eine Verbindung der Formel (I) in ein pharmazeutisch annehmbares Salz davon umwandelt.

15


20

2. Verfahren nach Anspruch 1 zur Herstellung einer Verbindung der Formel (Ia):

25

30

35



worin R¹ und R² wie in Anspruch 1 definiert sind;

40

R³ Wasserstoff, ein Formylrest, ein gegebenenfalls substituierter Alkyl- oder Alkenylrest, wie in Anspruch 1 definiert, ist oder -COD ist, worin D ein Alkoxy-, Hydroxy-, Halogen- oder gegebenenfalls substituierter Aminorest ist, wie in Anspruch 1 definiert;

R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;

R⁵ wie in Anspruch 1 definiert ist;


45

R⁶, A und n wie in Anspruch 1 definiert sind und eines pharmazeutisch annehmbaren Salzes davon.

50

55

3. Verfahren nach Anspruch 1 zur Herstellung einer Verbindung der Formel (Ib):



worin R¹ und R² wie in Anspruch 1 definiert sind;

R⁴ Wasserstoff, Halogen oder ein Nitrorest ist;

R⁵ wie in Anspruch 1 definiert ist;

20 R⁷, A und n wie in Anspruch 1 definiert sind und eines pharmazeutisch annehmbaren Salzes davon.

4. Verfahren nach Anspruch 1, worin ein wie für die Substituenten des Kohlenwasserstoffrestes in Anspruch 1 defi-
nierter gegebenenfalls substituierter Aminorest ein Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Benzyl-
amino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino- oder N-(m-Methoxy)-phenylpiperazinorest ist.


25 5. Verfahren nach Anspruch 1, worin D' ein Amino-, Methylamino-, Dimethylamino-, Phenylamino-, Benzylamino-, Mor-
pholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist.

30 6. Verfahren nach Anspruch 1, worin D ein Amino-, N-(C₁-C₄)Alkylamino-, N,N-Di(C₁-C₄)alkylamino-, Phenylamino-,
Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethylamino-, Morpholino-, Piperidino-, Piperazino-,
Piperidylmethyl-, N-Phenylpiperazino- oder N-(p-Fluorphenyl)piperazinorest ist, worin die Alkyl-, Aryl- und Hete-
roarylgruppen gegebenenfalls mit Methyl-, Ethyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, sek.-Butyl-, Hydroxyl-, Amino-,
N-Niedrig(C₁-C₄)alkylamino-, N,N-Di-niedrig(C₁-C₄)alkylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, Halogen-, Nitro- oder Niedrig(C₁-C₄)alkoxyresten substituiert sein können.

35 7. Verfahren nach Anspruch 1, worin R⁵ ein Tetrazolylrest ist.

8. Verfahren nach Anspruch 1, worin R⁵ in ortho-Position ist.

40 9. Verfahren nach Anspruch 1, zur Herstellung einer Verbindung der Formel (Ia'):



55 worin R¹ ein (C₁-C₈)-Alkylrest ist;
R3

(1) Wasserstoff,

(2) ein (C_1 - C_8)-Alkylrest ist, der geradkettig oder verzweigt sein kann und gegebenenfalls mit Hydroxyl-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Diniedrig(C_1 - C_4)alkylamino-, Halogen-, (C_1 - C_4)-Alkoxyresten oder -COD" substituiert sein kann, worin D" ein (C_1 - C_4)-Alkoxy-, Hydroxy-, Halogen-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Di-niedrig(C_1 - C_4)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist oder

(3) -COD ist, worin D Wasserstoff, ein (C_1 - C_4)-Alkoxy-, Hydroxy-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Di-niedrig(C_1 - C_4)alkylamino-, Phenylamino-, Benzylamino-, Naphthylmethylamino-, Pyridylamino-, Pyridylmethoxy-, Morpholino-, Piperidino-, Piperazino-, Piperidylmethyl-, N-(p -Fluorphenyl)piperazino- oder N-Phenylpiperazinorest ist und R⁵ ein Carboxyl- oder Tetrazolylrest ist oder


10 eines pharmazeutisch annehmbaren Salzes davon.

10. Verfahren nach Anspruch 1 zur Herstellung einer Verbindung der Formel (Ib'):

15

20

25



worin R¹ ein (C_1 - C_8)-Alkylrest ist; R⁷ ein (C_1 - C_8)-Alkylrest ist, der gegebenenfalls mit Phenylresten, die mit Halogen-, Nitro-, (C_1 - C_4)-Alkoxy-, (C_1 - C_4)-Alkylresten an freigewählter Position am Phenylring substituiert sein können, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Diniedrig(C_1 - C_4)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m -Methoxy)phenylpiperazinoresten oder -COD' substituiert sein kann, worin D' ein (C_1 - C_4)-Alkoxy-, Hydroxy-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Di-niedrig(C_1 - C_4)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazino-, (C_3 - C_8)-Cycloalkyl- oder Phenyl- oder Naphthylrest ist, der mit Hydroxyl-, (C_1 - C_4)-Alkoxy-, (C_1 - C_4)-Alkyl-, Halogen-, Nitro-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Diniedrig(C_1 - C_4)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino-, N-Phenylpiperazino-, N-(m -Methoxy)phenylpiperazino-, (C_1 - C_4)-Alkanoyloxy-, Benzoyloxy-, Phenylresten, die mit Halogen-, Nitro-, (C_1 - C_4)-Alkoxy-, (C_1 - C_4)-Alkylresten an freigewählter Position des Phenylrings substituiert sein können, oder einer Gruppe der Formel -COD' substituiert sein kann, worin D' ein Hydroxy-, (C_1 - C_4)-Alkoxy-, Amino-, N-Niedrig(C_1 - C_4)alkylamino-, N,N-Di-niedrig(C_1 - C_4)alkylamino-, Phenylamino-, Naphthylamino-, Benzylamino-, Naphthylmethylamino-, Morpholino-, Piperidino-, Piperazino- oder N-Phenylpiperazinorest ist; und R⁵ ein Carboxyl- oder Tetrazolylrest ist oder eines pharmazeutisch annehmbaren Salzes davon.

45 11. Verfahren nach Anspruch 1 zur Herstellung einer Verbindung, die ausgewählt ist aus der Gruppe bestehend aus Ethyl-2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-5-carboxylat, 2-Ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-5-carbonsäure, Methoxyethyl-2-ethyl-7-[2'-(1H-tetrazol-5-yl)-biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]-pyridin-5-carboxylat, 2-Ethyl-5-(N-benzylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on, 2-Ethyl-5-(N-phenylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on und 2-Ethyl-5-(N-2-pyridylmethylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl]-4-oxo-4,7-Dihydrothieno[2,3-b]pyridin-4(7H)-on, oder eines pharmazeutisch annehmbaren Salzes davon.

55 12. Verfahren nach Anspruch 10, worin R¹ ein Ethylrest ist, R⁵ ein 1H-Tetrazol-5-yl-rest ist und R⁷ ein Butyl-, Benzyl-, Ethyl-, p-Fluorphenyl-, 2,5-Dichlorphenyl-, Cyclohexyl-, Ethoxycarbonylmethyl- oder 2-[4-(*o*-Methoxyphenyl)-piperazino]ethylrest ist.


13. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, um Angiotensin-II zu antagonisieren, das umfaßt, daß man eine therapeutisch wirksame Menge einer Verbindung nach Anspruch 1 oder ein pharmazeutisch annehmbares Salz davon mit einem pharmazeutisch annehmbaren Träger, Hilfsstoff oder Verdünnungsmittel vermischt.

5
14. Verwendung einer Verbindung nach Anspruch 1 oder eines pharmazeutisch annehmbaren Salzes davon zur Herstellung eines Arzneimittels, um Angiotensin-II zu antagonisieren.


Revendications

10 Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

15 1. Composé de formule



dans laquelle W est un groupe



35 R¹ et R², identiques ou différents, représentent chacun indépendamment (1) un atome d'hydrogène, (2) un atome d'halogène, (3) un groupe cyano, (4) un groupe nitro, (5) un groupe de formule R⁸CO-NH-, où R⁸ représente un atome d'hydrogène ou un groupe alkyle en C₁₋₈ pouvant être substitué par un groupe hydroxyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, un atome d'halogène, un groupe nitro, amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, alcanoxy en C₁₋₄, benzoxyloxy, phényle pouvant porter un substituant halogéné, nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe naphtyle, ou (6) un résidu hydrocarboné choisi dans le groupe formé par (i) un groupe alkyle en C₁₋₈, (ii) alcényle en C₂₋₈, (iii) alcynyle en C₂₋₈, (iv) cycloalkyle en C₃₋₈, (v) un résidu hydrocarboné aromatique choisi dans le groupe formé par les résidus phényle et naphtyle, ledit résidu hydrocarboné pouvant être substitué par un résidu hydroxyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, halogéné, nitro, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, N-(m-méthoxy)phénylpipérazino, alcanoxyloxy en C₁₋₄, benzoxyloxy, phényle pouvant porter un substituant halogéné, nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe de formule -COD', où D' représente un groupe hydroxy, alcoxy en C₁₋₄, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;

40 R³ représente (1) un atome d'hydrogène, (2) un groupe alkyle en C₁₋₈ ou alcényle en C₂₋₈, linéaires ou ramifiés et qui peuvent être substitués par un groupe hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéné, alcoxy en C₁₋₄, ou un groupe de formule -COD', où D" représente un groupe alcoxy en C₁₋₄, hydroxy, halogéné, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino; ou (3) un groupe -COD où D représente un atome d'hydrogène, un groupe alcoxy en C₁₋₄, hydroxy, halogéné, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-(p-fluorophényle)pipérazino ou N-phénylpipérazino, lesdits

groupes alkyle, aryle et hétéroaryle pouvant être substitué par un groupe méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec-butyle, hydroxyde, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, halogéné, nitro ou alcoxy en C₁₋₄;


5 R⁴ est un atome d'hydrogène, d'halogène ou un groupe nitro, R⁵ est un groupe carboxyle, (alcoxy en C₁₋₄)-carbonyle, cyano, tétrazolyde, acide trifluorométhanesulfonique, acide phosphorique ou acide sulfonique,

R⁶ représente un atome d'hydrogène ou un groupe alkyle en C₁₋₈ ou alcényle en C₂₋₈ à chaîne linéaire ou ramifiée et pouvant être substitué par un groupe hydroxyde, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéné, alcoxy inférieur en C₁₋₄ ou un groupe - COD" où D" représente un groupe alcoxy en C₁₋₄, hydroxy, halogéné, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphthylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;

10 R⁷ représente un résidu hydrocarboné pouvant être substitué comme R¹ et R²; A est une liaison directe ou un bras de liaison long de 2 atomes ou moins entre le groupe phénylène et le groupe phényle, choisi dans le groupe formé par les résidus alkylène en C₁₋₄, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂- ou -CH=CH-, et n est un nombre entier égal à 1 ou 2;

15 et un sel pharmacologiquement acceptable d'un tel composé.

2. Composé conforme à la revendication 1 qui est un composé de formule (Ia) :



dans laquelle R¹ et R² sont définis comme dans la revendication 1,


R³ représente un atome d'hydrogène, un groupe formyle, un groupe alkyle ou alcényle éventuellement substitués, définis dans la revendication 1, ou un groupe-COD où D représente un groupe alcoxy, hydroxy, halogéné ou amino éventuellement substitué de la manière définie dans la revendication 1;

35 R⁴ représente un atome d'hydrogène ou d'halogène ou un groupe nitro;

R⁵ est défini comme dans la revendication 1;

R⁶, A et n sont définis comme dans la revendication 1; et un sel pharmacologiquement acceptable d'un tel composé.

40 3. Composé conforme à la revendication 1 qui est un composé de formule (Ib)



55 dans laquelle R¹ et R² sont définis comme dans la revendication 1;

R⁴ représente un atome d'hydrogène ou d'halogène ou un groupe nitro; R⁵ est défini comme dans la revendication 1;

R⁷, A et n sont définis comme dans la revendication 1;

et un sel pharmacologiquement acceptable d'un tel composé.

4. Composé conforme à la revendication 1 dans lequel un groupe amino éventuellement substitué défini dans la revendication 1 pour les substituants dudit résidu hydrocarboné est un groupe amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino ou N-(m-méthoxy)phénylpipérazino.

5. Composé conforme à la revendication 1 dans lequel ledit résidu D' est un résidu amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino.


6. Composé conforme à la revendication 1 dans lequel ledit résidu D est un groupe amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-phénylpipérazino ou N-(p-fluorophényl)pipérazino où lesdits groupes alkyle, aryle et hétéroaryl peuvent être substitués par un groupe méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec-butyle, hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, halogéné, nitro ou alcoxy en C₁₋₄.

15. 7. Composé conforme à la revendication 1 dans lequel ledit groupe R⁵ est un résidu tétrazolyte.

8. Composé conforme à la revendication 1 dans lequel ledit résidu R⁵ est en position ortho.

9. Composé conforme à la revendication 1 qui est un composé de formule (Ia') :

20




30

dans laquelle R¹ est un groupe alkyle en C₁₋₈, R³ est (1) un atome d'hydrogène, (2) un groupe alkyle en C₁₋₈, linéaire ou ramifié, pouvant être substitué par un groupe hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéné, alcoxy en C₁₋₄, ou un groupe -COD" où D" représente un groupe alcoxy en C₁₋₄, hydroxy, halogéné, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino; ou (3) un groupe -COD où D représente un atome d'hydrogène, un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-(p-fluorophényl)pipérazino ou N-phénylpipérazino, et R⁵ est un groupe carboxyle ou tétrazolyte, ou un sel pharmaceutiquement acceptable d'un tel composé.

45

10. Composé conforme à la revendication 1 qui est un composé de formule (Ib') :

45



55

dans laquelle R¹ est un groupe alkyle en C₁₋₈, R⁷ est un groupe alkyle en C₁₋₈ pouvant être substitué par un groupe phényle qui, à son tour peut être substitué par un atome d'halogène, un groupe nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄

en une position choisie du noyau phényle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamoно, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino, N-(m-méthoxy)phénylpipérazino, ou un groupe -COD' où D' représente un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamoно, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, cycloalkyle en C₃₋₈, ou phényle ou naphtyle pouvant être substitué par un groupe hydroxyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, halogéno, nitro, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamoно, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, N-(m-méthoxy)phénylpipérazino, alcanoxy en C₁₋₄, benzoxyloxy, phényle pouvant être substitué par un atome d'halogène, un groupe nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe de formule -COD' où D' représente un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamoно, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;

R⁵ est un groupe carboxyle ou tétrazolyde ou un sel pharmacologiquement acceptable d'un tel composé.


15 11. Composé conforme à la revendication 1 ou un sel pharmaceutiquement acceptable d'un tel composé, qui est choisi dans le groupe formé par
le 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylate d'éthyle,
20 l'acide 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylique, le 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylate de méthoxyéthyle, la 2-éthyl-5-(N-benzylcarbamoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridin-4(7H)-one,
25 la 2-éthyl-5-(N-phénylcaramoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-4(7H)-one, et la 2-éthyl-5-(N-2-pyridylméthylcarbamoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridin-4(7H)-one.

30 12. Composé conforme à la revendication 10 dans lequel R¹ est un groupe éthyle, R⁵ un groupe 1H-tétrazol-5-yle et R⁷ est un groupe butyle, benzyle, éthyle, p-fluorophényle, 2,5-dichlorophényle, cyclohexyle, éthoxycarbonylméthyle ou 2-[4-(o-méthoxyphényl)-pipérazino]éthyle.

35 13. Composition pharmaceutique à effet antagoniste de l'angiotensine II comprenant une quantité thérapeutiquement efficace d'un composé conforme à la revendication 1 ou d'un sel pharmaceutiquement acceptable d'un tel composé mélangé avec un véhicule, excipient ou diluant pharmaceutiquement acceptables.

40 14. Utilisation d'un composé conforme à la revendication 1 ou d'un sel pharmaceutiquement acceptable d'un tel composé pour la fabrication d'un médicament à effet antagoniste de l'angiotensine II.


15. Procédé de préparation d'un composé de formule (I)



55 dans laquelle W, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, A et n ont la signification indiquée dans la revendication 1, ou d'un sel pharmaceutiquement acceptable d'un tel composé,
lequel procédé consiste à faire réagir un composé de formule (II)

5

(II)




10

dans laquelle R¹, R² et W ont les significations indiquées ci-dessus, avec un composé de formule (III)

15

(III)



20


dans laquelle R⁴, R⁵, A et n ont les significations indiquées ci-dessus, et X est un atome d'halogène, et, (i) si on le souhaite, à convenir un composé de formule (I) où R⁵ est un groupe cyano ou un groupe tétrazolyde protégé, et R¹, R², R⁴, R⁵, A, W et n ont la signification indiquée ci-dessus, en un composé de formule (I) où R⁵ représente un groupe tétrazolyde et R¹, R², R⁴, R⁵, A, W et n ont la signification indiquée ci-dessus, (ii) si on le souhaite, à convertir un composé de formule (I) où -R³ est un groupe alcoxycarbonyle en C₁₋₄ ou halogénocarbonyle, et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, en un composé de formule (I) où -R³ est un groupe carboxyle ou carbamoyle éventuellement substitué, et R¹, R², R³, R⁴, R⁵, R⁶, R⁷, A et n ont la signification ci-dessus, ou (iii) si on le souhaite, à convertir d'un composé de formule (I) où R³ est un groupe carboxyle et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, en un composé de formule (I) dans laquelle R³ est un résidu halogénocarbonyle et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, et si on le souhaite, à convertir un composé de formule (I) en un sel pharmaceutiquement acceptable.

Revendications pour les Etats contractants suivants : ES, GR

35 1. Procédé de préparation d'un composé de formule

40


(I)



45

dans laquelle W est un groupe

50



55

R¹ et R², identiques ou différents, représentent chacun indépendamment (1) un atome d'hydrogène, (2) un atome d'halogène, (3) un groupe cyano, (4) un groupe nitro, (5) un groupe de formule R⁸CO-NH-, où R⁸ représente un atome d'hydrogène ou un groupe alkyle en C₁₋₈ pouvant être substitué par un groupe hydroxyle, alcoxy en C₁₋₄.

alkyle en C₁₋₄, un atome d'halogène, un groupe nitro, amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, alcanoxy en C₁₋₄, benzoxyloxy, phényle pouvant porter un substituant halogéno, nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe naphtyle, ou (6) un résidu hydrocarboné choisi dans le groupe formé par (i) un groupe alkyle en C₁₋₈, (ii) alcényle en C₂₋₈, (iii) alcynyle en C₂₋₈, (iv) cycloalkyle en C₃₋₈, (v) un résidu hydrocarboné aromatique choisi dans le groupe formé par les résidus phényle et naphtyle, ledit résidu hydrocarboné pouvant être substitué par un résidu hydroxyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, halogéno, nitro, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, N-(m-méthoxy)phénylpipérazino, alcanoxy en C₁₋₄, benzoxyloxy, phényle pouvant porter un substituant halogéno, nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe de formule -COD', où D' représente un groupe hydroxy, alcoxy en C₁₋₄, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;

R³ représente (1) un atome d'hydrogène, (2) un groupe alkyle en C₁₋₈ ou alcényle en C₂₋₈, linéaires ou ramifiés et qui peuvent être substitués par un groupe hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéno, alcoxy en C₁₋₄, ou un groupe de formule -COD', où D" représente un groupe alcoxy en C₁₋₄, hydroxy, halogéno, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino; ou (3) un groupe -COD où D représente un atome d'hydrogène, un groupe alcoxy en C₁₋₄, hydroxy, halogéno, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-(p-fluorophényle)pipérazino ou N-phénylpipérazino, lesdits groupes alkyle, aryle et hétéroaryle pouvant être substitué par un groupe méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec-butyle, hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, halogéno, nitro ou alcoxy en C₁₋₄;

R⁴ est un atome d'hydrogène, d'halogène ou un groupe nitro,


R⁵ est un groupe carboxyle, (alcoxy en C₁₋₄)-carbonyle, cyano, tétrazolyde, acide trifluorométhanesulfonique, acide phosphorique ou acide sulfonique,

R⁶ représente un atome d'hydrogène ou un groupe alkyle en C₁₋₈ ou alcényle en C₂₋₈ à chaîne linéaire ou ramifiée et pouvant être substitué par un groupe hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéno, alcoxy inférieur en C₁₋₄ ou un groupe - COD" où D" représente un groupe alcoxy en C₁₋₄, hydroxy, halogéno, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;


R⁷ représente un résidu hydrocarboné pouvant être substitué comme R¹ et R²; A est une liaison directe ou un bras de liaison long de 2 atomes ou moins entre le groupe phényle et le groupe phényle, choisi dans le groupe formé par les résidus alkylène en C₁₋₄, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂- ou -CH=CH-, et n est un nombre entier égal à 1 ou 2;

et un sel pharmacologiquement acceptable d'un tel composé,

lequel procédé consiste à faire réagir un composé de formule (II)



dans laquelle R¹, R² et W ont les significations indiquées ci-dessus, avec un composé de formule (III)




5 dans laquelle R⁴, R⁵, A et n ont les significations indiquées ci-dessus, et X est un atome d'halogène, et, (i) si on le souhaite, à convertir un composé de formule (I) où R⁵ est un groupe cyano ou un groupe tétrazolylique protégé, et R¹, R², R⁴, R⁵, A, W et n ont la signification indiquée ci-dessus, en un composé de formule (I) où R⁵ représente un groupe tétrazolylique et R¹, R², R⁴, R⁵, A, W et n ont la signification indiquée ci-dessus, (ii) si on le souhaite, à convertir un composé de formule (I) où -R³ est un groupe alcoxy carbonyle en C₁₋₄ ou halogénocarbonyle, et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, en un composé de formule (I) où -R³ est un groupe carboxyle ou carbamoylique éventuellement substitué, et R¹, R², R³, R⁴, R⁵, R⁶, R⁷, A et n ont la signification indiquée ci-dessus, ou (iii) si on le souhaite, à convertir d'un composé de formule (I) où R³ est un groupe carboxyle et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, en un composé de formule (I) dans laquelle R³ est un résidu halogénocarbonylique et R¹, R², R⁴, R⁵, R⁶, A et n ont la signification indiquée ci-dessus, et si on le souhaite, à convertir un composé de formule (I) en un sel pharmaceutiquement acceptable.

15 2. Procédé conforme à la revendication 1 pour la préparation d'un composé de formule (Ia) :

15

20

25



dans laquelle R¹ et R² sont définis comme dans la revendication 1,

30 R³ représente un atome d'hydrogène, un groupe formyle, un groupe alkyle ou alcénylique éventuellement substitués, définis dans la revendication 1, ou un groupe-COD où D représente un groupe alkoxy, hydroxy, halogéno ou amino éventuellement substitué de la manière définie dans la revendication 1;

35 R⁴ représente un atome d'hydrogène ou d'halogène ou un groupe nitro;

R⁵ est défini comme dans la revendication 1;

R⁶, A et n sont définis comme dans la revendication 1;


et d'un sel pharmacologiquement acceptable d'un tel composé.

40 3. Procédé conforme à la revendication 1 pour la préparation d'un composé de formule (Ib)

40

45

50



dans laquelle R¹ et R² sont définis comme dans la revendication 1; R⁴ représente un atome d'hydrogène ou d'halogène ou un groupe nitro; R⁵ est défini comme dans la revendication 1;

R⁷, A et n sont définis comme dans la revendication 1;

et d'un sel pharmacologiquement acceptable d'un tel composé.

55

4. Procédé conforme à la revendication 1 dans lequel un groupe amino éventuellement substitué défini dans la revendication 1 pour les substituants dudit résidu hydrocarboné est un groupe amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino, N-phénylpipérazino ou N-(m-méthoxy)phénylpipérazino.


5. Procédé conforme à la revendication 1 dans lequel ledit résidu D' est un résidu amino, méthylamino, diméthylamino, phénylamino, benzylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino.

5 6. Procédé conforme à la revendication 1 dans lequel ledit résidu D est un groupe amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-phénylpipérazino ou N-(p-fluorophényle)pipérazino où lesdits groupes alkyle, aryle et hétéroaryl peuvent être substitués par un groupe méthyle, éthyle, propyle, isopropyle, butyle, isobutyle, sec-butyle, hydroxyle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, morpholino, pipéridino, pipérazino, N-phénylpipérazino, halogéno ou alcoxy en C₁₋₄.

10 7. Procédé conforme à la revendication 1 dans lequel ledit groupe R⁵ est un résidu tétrazolyte.


8. Procédé conforme à la revendication 1 dans lequel ledit résidu R⁵ est en position ortho.

15 9. Procédé conforme à la revendication 1 pour la préparation d'un composé de formule (Ia') :



dans laquelle R¹ est un groupe alkyle en C₁₋₈,
 R³ est (1) un atome d'hydrogène, (2) un groupe alkyle en C₁₋₈, linéaire ou ramifié, pouvant être substitué par un groupe hydroxyle, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, halogéno, alcoxy en C₁₋₄, ou un groupe -COD' où D' représente un groupe alcoxy en C₁₋₄, hydroxy, halogéno, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino; ou
 35 (3) un groupe -COD où D représente un atome d'hydrogène, un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, benzylamino, naphtylméthylamino, pyridylamino, pyridylméthylamino, morpholino, pipéridino, pipérazino, pipéridylméthyle, N-(p-fluorophényle)pipérazino ou N-phénylpipérazino, et
 R⁵ est un groupe carboxyle ou tétrazolyte, ou d'un sel pharmaceutiquement acceptable d'un tel composé.

40 10. Procédé conforme à la revendication 1 pour la préparation d'un composé de formule (Ib') :



55 dans laquelle R¹ est un groupe alkyle en C₁₋₈, R⁷ est un groupe alkyle en C₁₋₈ pouvant être substitué par un groupe phényle qui, à son tour peut être substitué par un atome d'halogène, un groupe nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino, N(m-méthoxy)phénylpipérazino, ou un groupe -COD' où D' représente un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-

amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, cycloalkyle en C₃₋₈, ou phényle ou naphtyle pouvant être substitué par un groupe hydroxyle, alcoxy en C₁₋₄, alkyle en C₁₋₄, halogéno, nitro, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino, N-(m-méthoxy)phénylpipérazino, alcanoxy en C₁₋₄, benzoxyloxy, phényle pouvant être substitué par un atome d'halogène, un groupe nitro, alcoxy en C₁₋₄, alkyle en C₁₋₄ en une position choisie du noyau phényle, ou un groupe de formule -COD' où D' représente un groupe alcoxy en C₁₋₄, hydroxy, amino, N-(alkyle en C₁₋₄)-amino, N,N-di(alkyle en C₁₋₄)-amino, phénylamino, naphtylamino, benzylamino, naphtylméthylamino, morpholino, pipéridino, pipérazino ou N-phénylpipérazino;

R⁵ est un groupe carboxyle ou tétrazolyte
ou d'un sel pharmacologiquement acceptable d'un tel composé.

11. Procédé conforme à la revendication 1 pour la préparation d'un composé choisi dans le groupe formé par
le 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylate
d'éthyle,
l'acide 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylique,
le 2-éthyl-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyridine-5-carboxylate de
méthoxyéthyle,
la 2-éthyl-5-(N-benzylcarbamoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyri-
din-4(7H)-one,
la 2-éthyl-5-(N-phénylcaramoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydrothiéno[2,3-b]pyri-
dine-4(7H)-one, et
la 2-éthyl-5-(N-2-pyridylméthylcarbamoyl)-7-[[2'-(1H-tétrazol-5-yl)biphényl-4-yl]méthyl]-4-oxo-4,7-dihydro-
thiéno[2,3-b]pyridin4(7H)-one.
12. Procédé conforme à la revendication 10 dans lequel R¹ est un groupe éthyle, R⁵ un groupe 1H-tétrazol-5-yle et R⁷
est un groupe butyle, benzyle, éthyle, p-fluorophényle, 2,5-dichlorophényle, cyclohexyle, éthoxycarbonylméthyle ou
2-[4-(o-méthoxyphényle)-pipérazino]éthyle.
13. Procédé de préparation d'une composition pharmaceutique à effet antagoniste de l'angiotensine II comprenant la
mélangeage d'une quantité thérapeutiquement efficace d'un composé conforme à la revendication 1 ou d'un sel
pharmaceutiquement acceptable d'un tel composé avec un véhicule, excipient ou diluant pharmaceutiquement
acceptables.
14. Utilisation d'un composé conforme à la revendication 1 ou d'un sel pharmaceutiquement acceptable d'un tel com-
posé pour la fabrication d'un médicament à effet antagoniste de l'angiotensine II.

40

45

50

55



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 443 568 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91102513.8

(51) Int. Cl.5: **C07D 495/04, A61K 31/435,**
//((C07D495/04,333:00,221:00),
(C07D495/04,333:00,239:00)

(22) Date of filing: 21.02.91

(30) Priority: 22.02.90 JP 42125/90
17.01.91 JP 3958/91

7-8, Ueikeda 1-chome
Ikeda, Osaka 563(JP)
Inventor: Nishikawa, Kohel
5-19, Oharano-kamisatotorimicho
Nishikyo-ku, Kyoto 610-11(JP)
Inventor: Naka, Takehiko
15-711, 4 Kamokogahara 1-chome
Higashinada-ku, Kobe, Hyogo 658(JP)

(43) Date of publication of application:
28.08.91 Bulletin 91/35

(74) Representative: Keller, Günter et al
Lederer, Keller & Riederer
Lucile-Grahn-Strasse 22
W-8000 München 80(DE)


(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: TAKEDA CHEMICAL INDUSTRIES,
LTD.
3-6, Doshomachi 2-chome Chuo-ku
Osaka(JP)

(72) Inventor: Morimoto, Akira

(54) Fused thiophene derivatives, their production and use.


(57) Novel fused thiophene derivatives of the formula (I):



wherein W is



or



R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted; R³ is hydrogen, optionally substituted alkyl or alkenyl, or -COD wherein D is hydrogen, alkoxy, hydroxy, halogen, or optionally substituted amino; R⁴ is hydrogen, halogen or nitro; R⁶ is a residue capable of forming an anion or a residue convertible into an anion; R⁵ is hydrogen or optionally substituted alkyl or alkenyl; R⁷ is a hydrocarbon residue which may be substituted; A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2; and the pharmaceutically acceptable salts thereof have potent angiotensin II antagonist activity and antihypertensive activity, thus being useful as therapeutic agents for treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.

FIELD OF THE INVENTION

The present invention relates to novel fused thiophene derivatives having potent pharmacological activity and intermediates for the preparation thereof. More particularly, the present invention relates to 5 compounds having potent angiotensin II antagonist activity and antihypertensive activity, which are useful as therapeutic agents for treating circulatory diseases such as hypertensive diseases, heart diseases, strokes, etc.

BACKGROUND OF THE INVENTION

10 The renin-angiotensin system is involved in the homeostatic function to control systemic blood pressure, the volume of body fluid, balance among the electrolytes, etc., associated with the aldosterone system. Development of angiotensin II converting enzyme inhibitors (ACE inhibitor) (this converting enzyme produces angiotensin II which possesses strong vasoconstrictive activity) has clarified the relation between 15 the renin-angiotensin system and hypertension. Since angiotensin II elevates blood pressure via the angiotensin II receptors on cell membranes, angiotensin II antagonists as well as the ACE inhibitor would be useful in treating hypertension.

It has been reported that various angiotensin II analogues such as saralasin, [Sar¹,Ile⁸]A II, and the like, possess potent angiotensin II antagonist activity.

20 It has, however, been reported that, when peptide antagonists are administered parenterally, their actions are not prolonged and, when administered orally, they are ineffective (M. A. Ondetti and D. W. Cushman, Annual Reports in Medicinal Chemistry, 13, 82-91 (1978)).

Non-peptide angiotensin II antagonists are disclosed in Japanese Patent Laid Open No. 71073/1981; No. 71074/1981; No. 92270/1982; No. 157768/1983; No. 240683/1987; No. 23868/1988; and No. 25 117876/1989, and European Patent Laid Open No. 0323841, etc.

Imidazole derivatives having angiotensin II antagonist activity are disclosed in A. T. Chiu et al., Eur. J. Pharm., 157, 13 (1981), P. C. Wong et al., J. Pharmacol. Exp. Ther., 247, 1 (1988), P. C. Wong et al., Hypertension, 13, 489 (1989), etc.

It has not yet been known that fused thiophene derivatives possess potent angiotensin II antagonist 30 activity.

SUMMARY OF THE INVENTION


The present inventors made extensive investigations to prepare useful compounds which have 35 angiotensin II antagonist activity. As a result of these researches, the present inventors have succeeded in synthesizing fused thiophene derivatives possessing excellently potent angiotensin II antagonist activity and developed their work to accomplish the present invention.

The present invention provides fused thiophene derivatives having the formula I:

40

45


50



wherein W is

55

5



R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;

10 R³ is hydrogen, optionally substituted alkyl or alkenyl, or -COD wherein D is hydrogen, alkoxy, hydroxy, halogen, or optionally substituted amino;

R⁴ is hydrogen, halogen or nitro;

R⁵ is a residue capable of forming an anion or a residue convertible into an anion;

R⁶ is hydrogen or optionally substituted alkyl or alkenyl;

15 R⁷ is a hydrocarbon residue which may be substituted;

A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2;

and the pharmaceutically acceptable salts thereof.

These compounds are potent angiotensin II antagonists which are of value in the treatment of 20 circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc.

Another aspect of the present invention relates to pharmaceutical compositions comprising an effective amount of the fused thiophene derivative having the formula I and a pharmaceutically acceptable carrier useful in treating circulatory system diseases such as hypertensive diseases, heart diseases, strokes, etc., and processes for preparing such compounds and compositions.

25 Still another aspect of the present invention relates to a method for treating said circulatory system diseases of hosts, which comprises administering an effective amount of the fused thiophene derivative having the formula I or the pharmaceutical composition thereof to said host.

DETAILED DESCRIPTION OF THE INVENTION

30

The present invention provides fused thiophene derivatives having the formula I and the pharmaceutically acceptable salts thereof, which possess potent angiotensin II antagonist activity and are of value in the treatment of circulatory diseases such as hypertensive diseases, heart diseases, strokes, etc., pharmaceutical compositions comprising an effective amount of the fused thiophene derivative having the formula I and


35 a pharmaceutically acceptable carrier useful in treating said circulatory diseases and processes for preparing such compounds and compositions.

The present invention further provides a method for treating said circulatory system diseases of hosts, which comprises administering an effective amount of the fused thiophene derivative having the formula I or the pharmaceutical composition thereof to said host.

40 An important group of compounds according to the present invention are the compounds of the formula Ia:

45

50



55 wherein R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;

R³ is hydrogen, optionally substituted alkyl or alkenyl, or -COD wherein D is hydrogen, alkoxy, hydroxy, halogen, or optionally substituted amino;


R⁴ is hydrogen, halogen or nitro;
R⁵ is a residue capable of forming an anion or a residue convertible into an anion;
R⁶ is hydrogen or optionally substituted alkyl or alkenyl;
A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the
5 phenyl group; and n is an integer of 1 or 2;
and the pharmaceutically acceptable salts thereof.

Another important group of compounds according to the present invention are the compounds of the formula Ib:

10

15

20



wherein R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;
R⁴ is hydrogen, halogen or nitro;
25 R⁵ is a residue capable of forming an anion or a residue convertible into an anion;
R⁷ is a hydrocarbon residue which may be substituted;
A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and
n is an integer of 1 or 2;
30 and the pharmaceutically acceptable salts thereof.

With regard to the foregoing formula (I), halogen for R¹ and R² include fluorine, chlorine, bromine, and iodine.

The acylamino groups for R¹ and R² include a group having the formula: R⁸CONH- wherein R⁸ is hydrogen or a hydrocarbon residue which may be substituted.

35 Examples of hydrocarbon residues for R⁸ include acyclic hydrocarbon residues such as lower alkyl of 1 to about 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, and the like), lower alkenyl of 2 to about 8 carbon atoms (e.g. vinyl, allyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-octenyl, and the like), and lower alkynyl of 2 to about 8 carbon atoms (e.g. ethynyl, 2-butynyl, 2-pentyne, 2-octyne, and the like); cyclic hydrocarbon residues such as 40 alicyclic hydrocarbon residues of 3 to about 8 carbon atoms (e.g. cyclopropyl, cyclopentyl, cyclohexyl, 2-cyclohexen-1-yl, cyclooctyl and the like), aromatic hydrocarbon residues of about 6 to 12 carbon atoms (e.g. phenyl, naphthyl and the like); etc.

45 Examples of hydrocarbon residues for R¹, R² and R⁷ include acyclic hydrocarbon residues such as lower alkyl of 1 to about 8 carbon atoms (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl, i-pentyl, hexyl, heptyl, octyl, and the like), lower alkenyl of 2 to about 8 carbon atoms (e.g. vinyl, allyl, isopropenyl, 2-butenyl, 2-pentenyl, 2-hexenyl, 2-octenyl, and the like), and lower alkynyl of 2 to about 8 carbon atoms (e.g. ethynyl, 2-butynyl, 2-pentyne, 2-octyne, and the like); cyclic hydrocarbon residues such as alicyclic hydrocarbon residues of 3 to about 8 carbon atoms (e.g. cyclopropyl, cyclopentyl, cyclohexyl, 50 2-cyclohexen-1-yl, cyclooctyl and the like), aromatic hydrocarbon residues of about 6 to 12 carbon atoms (e.g. phenyl, naphthyl and the like); etc.

Said hydrocarbon residues for R¹, R² and R⁷ may be optionally substituted with hydroxyl, lower (C₁-4) alkoxy (e.g. methoxy, ethoxy, and the like), lower (C₁-4) alkyl (e.g. methyl, ethyl, and the like), halogen (e.g. F, Cl, Br and the like), nitro, optionally substituted amino such as amino, N-lower (C₁-4) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C₁-4) alkyl amino (e.g. dimethylamino, diethylamino, etc.), N-arylamino (e.g. phenylamino, naphthylamino, etc.), N-aralkylamino (e.g. benzylamino, naphthylmethylamino, etc.) and alicyclic amino (e.g. morpholino, piperidino, piperazino, piperidylmethyl, N-phenylpiperazino, N-(p-fluorophenyl)piperazino, N-(m-methoxyphenyl)piperazino, etc.), acyloxy such as lower (C₁-4) alkanoyloxy (e.g. acetoxy, etc.) and aroyloxy (e.g. benzoyloxy, etc.), aryl such as phenyl and naphthyl (e.g. phenyl

which may be optionally substituted with halogen, nitro, lower (C_1 - 4) alkoxy, lower (C_1 - 4) alkyl or the like at an optional position on the phenyl ring), or a group having the formula: -COD' wherein D' is hydroxy, lower (C_1 - 4) alkoxy (e.g. methoxy, ethoxy, and the like), or optionally substituted amino such as amino, N-lower (C_1 - 4) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C_1 - 4) alkyl amino (e.g. dimethylamino, diethylamino, etc.), N-aryl amino (e.g. phenylamino, naphthylamino, etc.), N-aralkylamino (e.g. benzylamino, naphthylmethylamino, etc.) and alicyclic amino (e.g. morpholino, piperidino, piperazino, N-phenylpiperazino, etc.). Said hydrocarbon residues for R¹ and R² may also be optionally taken together to form a ring.

Alkyl or alkenyl groups for R³ and R⁶ are lower alkyl of 1 to about 8 carbon atoms and lower alkenyl of 2 to about 8 carbon atoms which may be straight or branched. Examples of such alkyl and alkenyl groups for R³ and R⁶ include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, vinyl, allyl, isopropenyl, 2-butynyl, 2-pentenyl, 2-hexenyl, 2-octenyl, and the like. Said alkyl or alkenyl groups for R³ and R⁶ may be optionally substituted with hydroxyl, optionally substituted amino such as amino, N-lower (C_1 - 4) alkyl amino (e.g. methylamino, ethylamino, etc.), N,N-dilower (C_1 - 4) alkyl amino (e.g. dimethylamino, diethylamino, etc.), halogen, lower (C_1 - 4) alkoxy (e.g. methoxyl, ethoxyl, and the like) and -COD" wherein D" is lower (C_1 - 4) alkoxy (e.g. methoxy, ethoxy, and the like), hydroxy, halogen, or optionally substituted amino as defined above (e.g. amino, N-lower (C_1 - 4) alkyl amino such as methylamino and ethylamino, N,N-dilower (C_1 - 4) alkyl amino such as dimethylamino and diethylamino, N-aryl amino such as phenylamino and naphthylamino, N-aralkylamino such as benzylamino and naphthylmethylamino, alicyclic amino such as morpholino, piperidino, piperazino and N-phenylpiperazino, etc.).


Where R³ is a group having the formula: -COD, alkoxy groups for D include lower (C_1 - 4) alkoxy (e.g. methoxy, ethoxy, and the like). For D, examples of halogen include Cl, Br and the like, examples of optionally substituted amino include amino, N-lower (C_1 - 4) alkyl amino (e.g. methylamino, and the like), N,N-dilower (C_1 - 4) alkyl amino (e.g. dimethylamino, and the like), N-aryl amino (e.g. phenylamino, and the like), N-aralkyl amino (e.g. benzylamino, naphthylmethylamino, and the like), N-heteroaryl amino (e.g. pyridylamino, and the like), N-heteroaralkyl amino (e.g. pyridylmethylamino, and the like), alicyclic amino (e.g. morpholino, piperidino, piperazino, piperidylmethyl, N-phenylpiperazino, N-(p-fluorophenyl)piperazino, and the like), wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with alkyl (e.g. methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and the like), hydroxyl, optionally substituted amino (e.g. amino, N-lower (C_1 - 4) alkyl amino (e.g. methylamino, ethylamino, and the like), N,N-dilower (C_1 - 4) alkyl amino (e.g. dimethylamino, and the like), alicyclic amino (e.g. morpholino, piperidino, piperazino, N-phenylpiperazino, and the like)), halogen, nitro, lower (C_1 - 4) alkoxy (e.g. methoxyl, ethoxyl), or the like. The compounds wherein D is halogen are useful as synthetic intermediates for the preparation of those wherein D is alkoxy.

R⁴ represents hydrogen, halogen (e.g. chlorine, bromine, and the like) or nitro, which may be in the ortho or meta position to the -A- group.

Examples of residues capable of forming an anion and residues convertible into the anion for R⁵ include carboxyl, lower (C_1 - 4) aloxycarbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide (-NHSO₂CF₃)-, phosphoric acid, sulfonic acid, and the like. Such residues may include those which are capable of forming anions either chemically or under biological and/or physiological conditions. R⁵ is preferable in the ortho position. The compounds wherein R⁵ is a residue capable of forming an anion or convertible thereto chemically (e.g. by oxidation, reduction or hydrolysis) (e.g. cyano and the like), are useful as synthetic intermediates.

A shows that the adjacent phenylene group is bonded to the phenyl group directly or through a spacer whose atomic chain is 2 or less. As the spacer, any one can be exemplified, so long as it is a divalent chain in which the number of atoms constituting the straight chain is 1 or 2, and it may have a side chain. Examples of such spacers include lower (C_1 - 4) alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, -CH=CH-, etc.


A preferred embodiment of the invention is a compound of the formula (Ia'):



15 wherein R¹ is lower (C₁-8) alkyl; R³ is hydrogen, optionally substituted lower (C₁-8) alkyl (e.g. lower (C₁-4) carbalkoxyvinyl, lower (C₁-4) alkoxyethyl, and the like) or COD wherein D is hydrogen, lower (C₁-4) alkoxy, hydroxy, or optionally substituted amino (e.g. amino, N-lower (C₁-4) alkylamino, N,N-dilower (C₁-4) alkyl amino, phenylamino, methoxybenzylamino, halogenobenzylamino, pyridylmethylamino, piperidylmethylamino, pyridylpiperazinoalkylamino, piperidinoalkylamino, optionally substituted arylpiperazinoalkylamino and the like); and R⁵ is carboxyl or tetrazolyl (*inter alia* tetrazolyl);

20 and the pharmaceutically acceptable salts thereof.

A further preferred embodiment of the invention is a compound of the formula (Ib'):



wherein R¹ is lower (C₁-8) alkyl; R⁷ is hydrogen, lower (C₁-8) alkyl which may be optionally substituted with optionally substituted aryl, optionally substituted amino (e.g. amino, N-lower (C₁-4) alkyl amino, N,N-dilower (C₁-4) alkyl amino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, and the like) or COD wherein D is lower (C₁-4) alkoxy, hydroxy, or optionally substituted amino (e.g. amino, N-lower (C₁-4) alkyl amino, N,N-dilower (C₁-4) alkyl amino, phenylamino, benzylamino, and the like), (C₃-8) cycloalkyl or optionally substituted aryl (e.g. halogenophenyl);

40 and R⁵ is carboxyl or tetrazolyl (*inter alia* tetrazolyl);

45 and the pharmaceutically acceptable salts thereof.

The compounds (I) of the present invention may be prepared by several reaction schemes, as illustrated below for a preferred compound.

50

55




Scheme A

5

10

15

20




25 wherein R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, and X is halogen.

Scheme B

30

35

40




45 wherein each group is of the same meaning as defined above.

50

55

Scheme C

5



10

15

wherein R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, and R⁹ is lower (C₁-4) alkyl.


Scheme D

20

25

30

35




wherein R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, and R¹⁰ and R¹¹ are each independently hydrogen or a hydrocarbon residue.

Scheme E

40

45

50




wherein R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, and X is halogen.

55


Scheme F

5



wherein R¹, R², R⁴, R⁵, R⁶, R¹⁰, R¹¹, X, A and n have the above-defined meanings.

20

Scheme G

35

wherein R¹, R², R⁴, A, W and n have the above-defined meanings and R¹² is a protective group.

The reaction as illustrated in Scheme A is an alkylation using an alkylating agent in the presence of a base. One molar portion of the compound (II) is employed with 1 to 3 moles of the base and about 1 to 40 about 3 moles of the alkylating agent. The reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, dimethylsulfoxide, acetonitrile, acetone, ethylmethylketone, and the like. Examples of such bases include sodium hydride, potassium t-butoxide, cesium carbonate, potassium carbonate, sodium carbonate, and the like. Examples of such alkylating agents include substituted halides (e.g. chlorides, bromides, iodides, and the like), substituted sulfonate esters (e.g. methyl p-toluenesulfonate esters, and the like), etc.

The reaction conditions may vary depending on the combination of the base and the alkylating agent. A temperature in the range of from ice-cooling to 100 °C is preferred and a reaction period of from about 1 to about 10 hours is preferably employed.

The cyano substituent on the benzene of the compounds (IV) is reacted with various azides to form the 50 tetrazole compounds (V) as illustrated in Scheme B. One molar portion of the compound (IV) is employed with about 1 to about 10 moles of the azide. The reaction is conventionally conducted in solvents such as dimethylformamide, dimethylacetamide, toluene, benzene, and the like.

Examples of such azides include trialkyl-tin azide, triphenyl-tin azide, hydrogen azide, and the like. In 55 the case where the organo-tin azide compound is employed, the reaction is carried out in toluene or benzene by heating under reflux for a period of from about 10 to about 30 hours. When the hydrogen azide is used, 5 moles of sodium azide and ammonium chloride per compound (IV) are employed and the reaction is conducted in dimethylformamide at a temperature ranging from about 100 °C to about 130 °C for 1 to 10 days. During this reaction, it is preferable to facilitate working by adding an appropriate amount of

sodium azide and ammonium chloride.

The reaction as illustrated in Scheme C is hydrolysis of the ester (VI) into the carboxylic acid (VII) in the presence of an alkali. One molar portion of the compound (VI) is employed with 1 to 3 moles of the alkali. The reaction is conventionally conducted in solvents such as alcohols containing water (e.g. methanol, ethanol, methylcellosolve, and the like). Examples of such alkalis include sodium hydroxide, potassium hydroxide, and the like. The reaction is preferably conducted at a temperature in the range from room temperature to 100 °C for a period from about 1 to about 10 hours.

5 The compounds (VI) are reacted with various amines to form the amide compounds (VIII) as illustrated in Scheme D. One molar portion of the compound (VI) is employed with about 2 to 50 moles of the amine.

10 The reaction is conventionally conducted in solvents such as alcohols (e.g. methanol, ethanol, and the like) or without a solvent. The reaction is preferably conducted at a temperature in the range from room temperature to 200 °C. Examples of such amines include ammonia, alkylamines (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, butylamine, hydroxyethylamine, etc.), aralkylamines (e.g. benzylamine, phenethylamine, N-benzyl-N-methylamine, o-methoxybenzylamine, etc.), arylamines (e.g. 15 aniline, N-methylaniline, etc.), heteroaralkylamines (e.g. 2-, 3- or 4-pyridylmethylamine, etc.), alicyclic amines (e.g. morpholine, piperidine, piperazine, N-phenylpiperazine, 2-piperidylmethylamine, 3-(p-fluorophenyl)piperazino)propylamine, etc.), and the like.

10 The compounds (VII) are treated with various halogenating agents to form the acid halides (IX) as illustrated in Scheme E. One molar portion of the compound (VII) is employed with about 1 to 5 moles of the halogenating agent. The reaction is conventionally conducted in solvents such as halogenated hydrocarbons (e.g. CHCl₃, CH₂Cl₂, ClCH₂CH₂Cl, and the like), ethers (e.g. tetrahydrofuran, dioxane, and the like) and aromatic hydrocarbons (e.g. benzene, toluene, and the like). Examples of such halogenating agents include oxalyl chloride, thionyl chloride, phosphorous oxychloride, phosphorous trichloride, phosphorous pentachloride, etc. The reaction is preferably conducted at a temperature in the range from room temperature to 100 °C for a period from about 1 to about 10 hours.

15 The acid halides (IX) are reacted with various amines to form the amide compounds (VIII) as illustrated in Scheme F. One molar portion of the compound (IX) is employed with about 2 to 50 moles of the amine. The reaction is conventionally conducted in solvents such as alcohols (e.g. methanol, ethanol, and the like) and ethers (e.g. ethyl ether, tetrahydrofuran, dioxane, and the like). Examples of such amines include 20 ammonia, alkylamines (e.g. methylamine, ethylamine, propylamine, dimethylamine, diethylamine, butylamine, hydroxyethylamine, etc.), aralkylamines (e.g. benzylamine, phenethylamine, N-benzyl-N-methylamine, o-methoxybenzylamine, etc.), arylamines (e.g. aniline, N-methylaniline, etc.), heteroaralkylamines (e.g. 2-, 3- or 4-pyridylmethylamine, etc.), alicyclic amines (e.g. morpholine, piperidine, 25 piperazine, N-phenylpiperazine, 2-piperidylmethylamine, 3-(p-fluorophenyl)piperazino)propylamine, etc.), and the like.

25 The protective group (R¹²) on the tetrazole compound (X) leaves to form the tetrazole compound (V) as illustrated in Scheme G. Reaction conditions may vary depending on the protective group (R¹²) used. When R¹² is triphenylmethyl (trityl), 2-tetrahydropyranyl, methoxymethyl, ethoxymethyl, or the like, the leaving of the protective group is conveniently conducted in aqueous alcohols (e.g. methanol, ethanol, etc) containing 30 from about 0.5N to about 2N hydrochloric acid or acetic acid, or in a mixture of trifluoroacetic acid and water (1:2 ~5) at room temperature for a period from about 1 to about 10 hours.

35 The compounds (I) thus produced via the reaction processes as depicted in Schemes A, B, C, D, E, F and G can be isolated and purified from the reaction mixture according to conventional methods such as, for example, evaporation of solvents, extraction by water or organic solvents, concentration, neutralization, 40 recrystallization, distillation, column chromatography and the like, to obtain a crystalline or oily product.

45 The compounds (I) of the present invention can be used in the form of salts derived from pharmaceutically or physiologically acceptable acids or bases. These salts include but are not limited to the following: salts with inorganic acids such as hydrochloric acid, sulphuric acid, nitric acid, phosphoric acid and, as the case may be, such organic acids as acetic acid, oxalic acid, succinic acid, and maleic acid. Other salts 50 include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.

The starting materials (II) can be easily prepared by or according to the known techniques, for example, as disclosed in:

55 (1) P. Blaszkiewicz, H. Vorbruggen and H. J. Kesler (Schering AG): DOS 2, 447,477 (15. 4. 76); Chem. Abst., 85, 46627 (1976),
(2) Y. Kuwada, K. Meguro, Y. Sato and T. Fugono (Takeda Chem.): DOS 2, 435,025 (6. 25. 75); Chem. Abst., 82, 156252 (1975), etc.

Among the starting materials (III), the compounds wherein n is 1 (the compounds (IIIa)) is prepared by


the known techniques as disclosed in Japanese Patent Laid Open No. 23868/1988; and No. 117876/1989, and European Patent Laid Open No. 0323841.

As illustrated in Scheme H, the compounds (IIIa) can also be easily prepared by halogenomethylation of the compounds (X) commercially available or easily prepared according to methods described in known literatures such as, for example, A. A. Vansheidt et al., Khim. Nauka i Prom., 2, 799 (1957).

Scheme H

10

15



wherein each group has the above-defined meaning.

20 The compound (III) wherein n is 2 (the compounds (IIIb)) can be prepared from the compounds (IIIa) according to the methods as illustrated in Scheme I.

Scheme I


25

30

35

40

45



wherein each group has the above-defined meaning.

The compounds (I) and salts thereof according to the present invention strongly inhibit vasoconstriction and hypertension derived by angiotensin II and therefore possess potent anti-hypertensive activity in animals, more specifically mammal animals (e.g. humans, dogs, rabbits, rats, etc.). Further, the compounds (I) and salts thereof according to the present invention are of quite low toxicity and useful in treating not only hypertension but also circulatory system diseases such as heart diseases, strokes and the like.

For therapeutic use, the compounds (I) and salts thereof can be administered as pharmaceutical compositions (e.g. powders, granules, tablets, pills, capsules, injections, solutions and the like) comprising at least one such compound alone or in admixture with pharmaceutically acceptable carriers, excipients and/or diluents. The pharmaceutical compositions can be formulated in accordance with conventional methods.

Specific dose levels for any particular patient will be employed depending upon a variety of factors including the activity of specific compounds employed, the age, body weight, general health, sex, diet, time

of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy. When used for treating adult essential hypertension, the active ingredient will preferably be administered in an appropriate amount, for example, selected from the range of about 10 mg to 100 mg a day orally and from the range of about 5 mg to 50 mg a day intravenously. The active ingredient will preferably be administered in equal doses two or three times a day.

The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention.

10 Example

The invention is further illustrated but in no way limited by the following reference examples, working examples, pharmaceutical examples and experimental examples.

In the specification of the present application, examples of the abbreviations used are given below. Me: Methyl, Et: Ethyl, Pr: Propyl, Bu: Butyl, iBu: Isobutyl, tBu: Tert-butyl, Ph: Phenyl, DMF: Dimethylformamide.

Reference Example 1

Isobutyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate

To 10 ml of isobutyl alcohol were added 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylic acid (200 mg, 0.9 mmol) and boron trifluoride-ethyl ether (47 %, 0.5 ml) and the mixture was heated under reflux for 5 hours. The reaction mixture was allowed to cool and concentrated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/ethyl acetate (3:1) to give 80 mg (31 %) of the title compound as colorless crystals.

M.p. 156-158 °C.

IR (KBr)cm⁻¹: 1700, 1595, 1520.

NMR (CDCl₃) δ : 1.05(6H, d, J=6.6Hz), 1.40(3H, t, J=7.4Hz), 2.0-2.2(1H, m), 2.94(2H, q, J=7.4, 15.0Hz), 4.20(2H, d, J=6.6Hz), 7.16(1H, s), 8.84(1H, s).

30

Elemental Analysis for C₁₄H₁₇NO₃ · H₂O

C (%)	H (%)	N (%)
-------	-------	-------

35

Calcd: C, 63.38; H, 5.70; N, 15.84

Found: C, 63.70; H, 5.44; N, 15.50.

40

Reference Example 2

2-Methoxyethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate

45

To 5 ml of benzene were added 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylic acid (380 mg, 1.7 mmol) and DMF (0.13 ml, 1.7 mmol) and the mixture was heated to 60 °C. To the reaction mixture was added thionyl chloride (0.15 ml, 2.1 mmol) and the mixture was stirred at 60 °C for 3 hours and allowed to cool on an ice bath. The precipitated product was collected by filtration and washed with benzene. The resulting precipitate (223 mg) was dissolved in a mixture of 2-methoxyethanol (0.3 ml) and CH₂Cl₂ (5 ml) and triethylamine (0.7 ml) were added to the solution. The mixture was stirred for 30 minutes and poured into chloroform. The resulting mixture was washed with 1N hydrochloric acid, dried (MgSO₄) and evaporated in vacuo. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with ethyl acetate/hexanes/chloroform (1:1:1) and then chloroform/methanol (9:1) to give 200 mg (41 %) of the title compound as colorless powders.

IR (KBr)cm⁻¹: 1700, 1590, 1530, 1480.

NMR (CDCl₃) δ : 1.39(3H, t, J=7.4Hz), 2.94(2H, q, J=7.4, 15.0Hz), 3.45(3H, s), 3.7-3.8(2H, m), 4.5-4.6(2H, m), 7.17(1H, s), 8.87(1H, s).

Elemental Analysis for C₁₁H₁₅NO₄S

C (%) H (%) N (%)

Calcd: C, 55.50; H, 5.37; N, 4.98

Found: C, 55.47; H, 5.38; N, 4.95

10

Reference Example 3

Ethyl 2-ethyl-4-hydroxy-3-nitrothieno[2,3-b]pyridine-5-carboxylate

15

A solution of ethyl 2-ethyl-4-hydroxythieno-[2,3-b]pyridine-5-carboxylate (1.0 g, 4.0 mmol) in conc. sulfuric acid (10 ml) was cooled to -5 °C and a solution of sodium nitrate (370 mg, 4.3 mmol) in conc. sulfuric acid (5 ml) was added dropwise to the chilled solution. The reaction mixture was stirred at -3 °C to -5 °C for 1 hour, and poured into ice-water. The precipitated product was collected by filtration and washed with cold water and then ethanol. The resulting precipitate was dissolved in chloroform, washed with a saturated aqueous sodium chloride, dried (MgSO₄) and evaporated in vacuo. The resulting yellow solid was washed with a mixture of ether/hexanes, and dried to give 960 mg (81 %) of the title compound. M.p. 194-201 °C (dec.).

IR (KBr)cm⁻¹: 1700, 1600, 1590, 1530.
25 NMR (CDCl₃) δ : 1.42(3H, t, J = 7.4Hz), 1.47(3H, t, J = 7.2Hz), 3.05(2H, q, J = 7.4, 15.0Hz), 4.50(2H, q, J = 7.2, 14.4Hz), 8.93(1H, s).

Elemental Analysis for C₁₂H₁₂N₂O₅S

C (%) H (%) N (%)

Calcd: C, 48.64; H, 4.08; N, 9.45

35

Found: C, 48.48; H, 4.01; N, 9.28

40

Reference Example 4

Ethyl 2-ethyl-7-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate

To a solution of ethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate (1.00 g, 4 mmol) in 20 ml of DMF) was added sodium hydride (60 % dispersion in oil, 160 mg) and the mixture was stirred for 10 minutes. To the reaction mixture was added 4-[2'-(N-trityltetrazol-5-yl)phenyl]benzyl bromide (2.23 g, 4 mmol) and the mixture was heated at 90 °C for 1 hour with stirring. The reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with ethyl acetate/dichloromethane (1:1) to give 2.24 g (77 %) of the title compound as white crystals. M.p. 195-198 °C.

IR (KBr)cm⁻¹: 1730, 1705, 1620.NMR (CDCl₃) δ : 1.27(3H, t, J = 9.6Hz), 1.39(3H, t, J = 6.8Hz), 2.72(2H, q, J = 8.9, 15.0Hz), 4.38(2H, q, J = 7.2, 13.8Hz), 5.02(2H, s), 6.80-8.0(9H, m), 8.29(1H, s).

55

Elemental Analysis for C₄H₇N₅O₃S

C (%) H (%) N (%)

5 Calcd: C, 74.26; H, 5.12; N, 9.62


Found: C, 74.09; H, 5.18; N, 9.50

10 The following compounds (II) can be easily prepared by or according to the known techniques, for example, as disclosed in:

- (1) P. Blaszkiewicz, H. Vorbruggen and H. J. Kestler (Schering AG): DOS 2, 447,477 (15. 4. 76); Chem. Abst., 85, 46627 (1976),
- (2) Y. Kuwada, K. Meguro, Y. Sato and T. Fugono (Takeda Chem.): DOS 2, 435,025 (6. 25. 75); Chem. Abst., 82, 156252 (1975),
- (3) R. K. Russell, J. B. Piress, R. A. Rampulla, J. J. McNally, R. Falotico, J. A. Keiser, D. A. Bright and A. Tobia, J. Med. Chem., 31, 1786 (1988),
- (4) M. Suwada, T. Sakamoto, K. Tabata, K. Endo, K. Ito, M. Kobayashi and H. Fuumi, Chem. Pharm. Bull., 37, 2091 (1989),
- (5) M. Sugiyama, T. Sakamoto, K. Tabata and H. Fuumi, Chem. Pharm. Bull., 37, 2717 (1989),
- (6) G. D. Madding and M. D. Thompson, J. Heterocyclic Chem., 24, 581 (1987),
- (7) J. Barker, P. R. Huddleston and D. Holmes, J. Chem. Research (S), 1985, 214,
- (8) J. Barker, P. R. Huddleston and D. Holmes, J. Chem. Research (S), 1986, 122,
- (9) M. A. Khan and A. E. Guarconi, J. Heterocyclic Chem., 14, 807 (1977),
- (10) K. Ogawa, I. Yamawaki, Y. Matsusita, N. Nomura and I. Okazaki, WO 89/02432.


25 The compounds (III) can alternatively be prepared in the same manner as described in Reference Example 1, 2, or 3.

30

TABLE 1


40

	Reference Example No.	R¹	R²	R³	R⁴	MP. (°C)
45	5-1	Br	H	COOEt	H	208-209
	5-2	H	H	COOEt	H	105-108
50	6	Me	H	COOEt	H	122-124
	7	Pr	H	COOEt	H	74- 75
	8	Et	H	COOCH ₂ CH ₂ OMe	H	powder
55	9	Et	H	CH ₂ OH	H	> 260 (decomp.)

TABLE 2

Reference Example No.	R¹	R²	R³	MP (°C)
10	Et	H	Bu	217-220
11	Et	H	-CH ₂ -	259-262
12	Et	H	Et	243-244
13	Et	H	--F	>290
14	Et	H	--Cl	268-275
15	Et	H	-	285-288
16	Et	H	-CH ₂ COOEt	201-204
17	Et	H	-CH ₂ CH ₂ N-N--OMe	239-241

45 The following compounds (Reference Examples 18-32) were prepared in the same manner as in Reference Example 4.


TABLE 3

Reference Example No.	R ¹	R ²	R ³	R ^{1,2}	Yield (%)	MP (°C)
18	Et	H	-COOCH ₂ CH ₂ OCH ₃	-C(Ph),	30	192-198
19	Et	H	-COO <i>i</i> Bu	-C(Ph),	40	209-212
20	Et	NO ₂	-COOEt	-C(Ph),	34	
21	Me	H	-COOEt	-C(Ph),	53	205-207
22	Pr	H	-COOEt	-C(Ph),	51	181-187
23	Br	H	-COOEt	-C(Ph),	47	129-133
24	H	H	-COOEt	-C(Ph),	50	137-139
25	Et	H	-CH ₂ OH	-C(Ph),	46	powder
26	Et	H	H	-C(Ph),	46	
27	Et	H	-CHO	-C(Ph),	67	150-156
28	Et	H	-CH=CH-COO <i>t</i> Bu	-C(Ph),	56	powder
29	Et	H	-COOEt	-COOtBu	62	
30	CN	H	-COOEt	-C(Ph),	21	129-131
31	Et	H	-CONCH ₂ Ph CH ₃	-C(Ph),	56	169-171
32	Et	H	-CH ₂ OMe	-C(Ph),	26	powder

The following compounds (Reference Examples 33-40) were prepared in the same manner as in Reference Example 4.

TABLE 4a

5



10

15

20

25

30

35

40

45

Reference Example No.	R ⁷	MP (°C)	Yield (%)
33	Bu	173-176	57
34	-CH ₂ -	204-207	47
35	Et	117-122	57
36	--F	192-193	67
37	--Cl	193-197	79
38	-	141-144	48
39	-CH ₂ COOEt	181-183	63
40	-CH ₂ CH ₂ N-N--OMe	powder	93

50

55

TABLE 4b

5	Reference Example No.	¹ H-NMR (200MHz, CDCl ₃) δ
10	33	0.96(3H, t), 1.24(3H, t), 1.3-1.5(2H, m), 1.5-1.7(2H, m), 2.66(2H, q), 4.04(2H, t), 5.01(2H, s), 7.00(1H, s), 6.8-7.5(22H, m), 7.9-8.0(1H, m)
15	34	1.22(3H, t), 2.65(2H, q), 5.00(2H, s), 5.23(2H, s), 7.00(1H, s), 6.8-8.0(28H, m)
20	35	1.24(3H, t), 1.27(3H, t), 2.66(2H, q), 4.11(2H, q), 5.01(2H, s), 6.8-7.5(23H, m), 7.9-8.0(1H, m),
25	36	1.28(3H, t), 2.72(2H, q), 5.03(2H, s), 6.8-8.0(28H, m)
30	37	1.26(3H, t), 2.68(2H, q), 5.06(2H, q), 6.8-8.0(27H, m)
35	38	1.23(3H, t), 1.2-2.6(10H, m), 2.65(2H, q), 4.8-5.0(1H, m), 4.97(2H, s), 6.8-7.9(24H, m)
40	39	1.23(3H, t), 1.29(3H, t), 2.65(2H, q), 4.24(2H, q), 4.79(2H, s), 5.02(2H, s), 6.8-8.0(24H, m)
45	40	1.23(3H, t), 2.64(2H, q), 2.7-3.2(10H, m), 3.85(3H, s), 4.2-4.4(2H, m), 5.03(2H, s), 6.8-7.5(27H, m), 7.9-8.0(1H, m)

35

Working Example 1

40 A: Ethyl 2-ethyl-7-[2'-cyanobiphenyl-4-yl)methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylate

45 Ethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate (250 mg, 1 mmol) and 4-(2'-cyanophenyl)-benzyl chloride (250 mg, 1.1 mmol) were dissolved in 5 ml of N,N-dimethylformamide (DMF). To the solution was added potassium carbonate (150 mg) and the mixture was stirred at 90 °C for 2 hours. The reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with ethyl acetate/dichloromethane (1:1) to give 254 mg (60 %) of the title compound as crystals.

50 NMR (CDCl₃) δ : 1.30(3H, t, J=6Hz), 1.39(3H, t, J=6Hz), 2.81(2H, q, J=6, 15Hz), 4.40(2H, q, J=6, 13.5Hz), 5.27(2H, s), 7.25-8.0(9H, m), 8.37(1H, s).

B: Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate and 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylic acid

55 A solution of the compound (250 mg, 0.59 mmol) prepared in Working Example 1A, sodium azide (390 mg, 5.9 mmol) and ammonium chloride (300 mg, 5.9 mmol) in DMF (15 ml) was stirred at 110 °C for 10 days. After cooling, the reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue

was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (9:1) to give 37 mg (13 %) of ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate as pale yellow powders.

IR (KBr)cm⁻¹: 1720, 1600, 1550, 1505.

5 NMR (CD₃OD) δ : 1.31(3H, t, J = 7.6Hz), 1.36(3H, t, J = 7.0Hz), 2.85(2H, q, J = 7.6, 15.0Hz), 4.33(2H, q, J = 7.0, 14.2Hz), 5.45(2H, s), 7.15(2H, d, J = 8.6Hz), 7.21(1H, s), 7.28(2H, d, J = 8.6Hz), 7.5-7.7(4H, m), 8.75(1H, s).

The column was further eluted with chloroform/methanol (9:1) to give 7 mg (2.7 %) of 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylic acid as white solids.

10 IR (KBr)cm⁻¹: 1650, 1605, 1580, 1540, 1505.

NMR (CD₃OD) δ : 1.34(3H, t, J = 7.6Hz), 2.89(2H, q, J = 8.6, 15.0Hz), 5.47(2H, s), 7.15(2H, d, J = 8.2Hz), 7.24(1H, s), 7.28(2H, d, J = 8.2Hz), 7.5-7.7(4H, m).

Working Example 2

15

Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate

A solution of the compound (727 mg, 1 mmol) prepared in Reference Example 4 in 20 ml of trifluoroacetic acid/water (1:3) was stirred at room temperature for 1 hour. The reaction mixture was poured into water followed by extraction with chloroform. The organic layer was washed with water, dried (MgSO₄), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (9:1) to give 1.28 g (86 %) of the title compound as colorless crystals. This product was identified by comparing with NMR and IR spectra of the compound obtained in Working Example 1B.

25 M.p. 161-164 °C.

Elemental Analysis for C₂₆H₂₃N₅O₃S · H₂O

30

C (%)	H (%)	N (%)
-------	-------	-------

Calcd: C, 62.01; H, 5.00; N, 13.91

35

Found: C, 62.05; H, 4.59; N, 13.78


The following compounds as listed in Table 5 were prepared in the same manner as in Working Examples 2.

40

45

50

55

TABLE 5a

Working Example No.	R¹	R²	R³	MP. (°C)	IR(KBr) (cm⁻¹)
3	Br	H	Et	254-260 (decomp.)	1725, 1680, 1610, 1560, 1500
4	H	H	Et	245-249	1720, 1600, 1560
5	Me	H	Et	249-253	1710, 1675, 1605, 1560, 1505
6	n-Pr	H	Et	108-110	1720, 1605, 1550, 1505
7	Et	H	i-Bu	256-259 (decomp.)	1720, 1670, 1605, 1560, 1500
8	Et	H	CH₂CH₂OMe	201-210	1720, 1680, 1605, 1560, 1505
9	Et	NO₂	Et	214 ~ (decomp.)	1720, 1700, 1615, 1550, 1510

40

45

50

55

TABLE 5b

Working Example No.	NMR (d_6 -DMSO) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
3	1.29(3H, t, J=7.2Hz), 4.24(2H, q, J=7.2, 14.2Hz), 5.46(2H, s), 7.13(2H, d, J=8.2Hz), 7.29(2H, d, J=8.2Hz), 7.5-7.7(5H, m), 8.79(1H, s)	$C_{24}H_{18}BrN_5O_3S$ 53.74; 3.38; 13.06 53.57; 3.34; 12.80
4	1.29(3H, t, J=7.2Hz), 4.24(2H, q, J=7.2, 14.2Hz), 5.51(2H, s), 7.13(2H, d, J=8.0Hz), 7.27(2H, d, J=8.0Hz), 7.3-7.8(8H, m), 8.80(1H, s)	$C_{24}H_{19}N_5O_3S \cdot 0.5H_2O$ 61.79; 4.32; 15.01 61.94; 4.17; 14.80
5	1.29(3H, t, J=7.2Hz), 2.44(3H, d, J=1.0Hz), 4.23(2H, q, J=7.2, 14.2Hz), 5.45(2H, s), 7.08(1H, d, J=1.0Hz), 7.13(2H, d, J=8.0Hz), 7.25(2H, d, J=8.0Hz), 7.5-7.7(4H, m), 8.74(1H, s)	$C_{26}H_{21}N_5O_3S$ 63.68; 4.49; 14.85 63.39; 4.47; 14.67
6	0.91(3H, t, J=7.2Hz), 1.28(3H, t, J=7.0Hz), 1.61(2H, q, J=7.2, 15.0Hz), 2.76(2H, t, J=7.6Hz), 4.23(2H, q, J=7.0, 14.2Hz), 5.45(2H, s), 7.10(1H, s), 7.12(2H, d, J=8.4Hz), 7.26(2H, d, J=8.4Hz), 7.5-7.7(4H, m), 8.74(1H, s)	$C_{27}H_{25}N_5O_3S \cdot H_2O$ 62.65; 5.26; 13.53 62.55; 4.84; 13.38
7	0.96(6H, d, J=6.8Hz), 1.23(3H, t, J=7.4Hz), 1.9-2.1(1H, m), 2.80(2H, q, J=7.4, 15.0Hz), 3.97(2H, d, J=6.6Hz), 5.46(2H, s), 7.11(1H, s), 7.13(2H, d, J=8.0Hz), 7.27(2H, d, J=8.0Hz), 7.5-7.7(4H, m), 8.70(1H, s)	$C_{21}H_{21}N_5O_3S \cdot 0.5H_2O$ 64.35; 5.40; 13.40 64.22; 5.24; 13.47
8	1.23(3H, t, J=7.4Hz), 2.81(2H, q, J=7.4, 15.0Hz), 3.30(3H, s), 3.62 2H, t, J=4.8Hz), 4.31(2H, t, J=4.8Hz) 5.46(2H, s), 7.11(1H, s), 7.12(2H, d, J=8.0Hz), 7.25(2H, d, J=8.0Hz), 7.5-7.7(4H, m), 8.73(1H, s)	

TABLE 5b

Working Example No.	NMR (d_6 -DMSO) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
9	1.20(3H, t, J=7.4Hz), 1.29(3H, t, J=7.0Hz), 2.83(2H, q, J=7.4, 15.4Hz), 4.24(2H, q, J=7.0, 14.0Hz), 5.53(2H, s), 7.14(2H, d, J=8.2Hz), 7.30(2H, d, J=8.2Hz), 7.5-7.7(4H, m), 8.86(1H, s)	$C_{25}H_{22}N_6O_5S \cdot H_2O$ 56.93; 4.41; 15.32 57.12; 4.05; 15.26

Working Example 10

2-Ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylic acid

5 Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate (600 mg, 1.235 mmol) was dissolved in 6 ml of 1N sodium hydroxide and the mixture was heated at 100 °C for 20 minutes with stirring. After cooling, 7 ml of 1N hydrochloric acid was added to the reaction mixture and the mixture was extracted with chloroform. The organic layer was washed with water, dried ($MgSO_4$), and evaporated to dryness. The resulting crystal was washed with dichloromethane and dried to give 550 mg of
 10 the title compound as white crystals. This product was identified by comparing with NMR and IR spectra of the compound obtained in Working Example 1B. M.p. 153-157 °C.

Elemental Analysis for $C_{24}H_{19}N_5O_5S \cdot 3.5H_2O$

15

C (%) H (%) N (%)

Calcd: C, 55.38; H, 5.03; N, 13.48

20

Found: C, 54.75; H, 3.93; N, 13.15

Working Example 11

25

A: Ethyl 2-ethyl-7-[(2'-t-butoxycarbonylbiphenyl-4-yl)methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate

To 10 ml of DMF were added ethyl 2-ethyl-4-hydroxythieno[2,3-b]pyridine-5-carboxylate (200 mg, 0.8 mmol), 4-(2-t-butoxycarbonylphenyl)benzyl bromide (300 mg, 0.9 mmol) and cesium carbonate (650 mg, 2.0 mmol) and the mixture was stirred at 60 °C for 3 hours and further at 100 °C for an additional hour. After cooling, the reaction mixture was poured into water followed by extraction with ethyl acetate. The organic layer was washed with water, dried ($MgSO_4$), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel to give 258 mg (62 %) of the title compound as crystals.

IR (KBr)cm⁻¹: 1720, 1705, 1690, 1510.
 35 NMR ($CDCl_3$) δ : 1.20(9H, s), 1.32(3H, t, J=7.6Hz), 1.41(3H, t, J=7.2Hz), 2.81(2H, q, J=7.6, 14.6Hz), 4.40(2H, q, J=7.2, 14.2Hz), 5.23(2H, s), 7.2-7.5(8H, m), 7.81(1H, dd, J=1.6, 7.6Hz), 8.42(1H, s).

40

Elemental Analysis for $C_{23}H_{19}NO_5S$

C (%) H (%) N (%)

Calcd: C, 69.61; H, 6.04; N, 2.71

45

Found: C, 69.85; H, 6.15; N, 2.37

B: Ethyl 2-ethyl-7-[(2'-carboxybiphenyl-4-yl)methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate

To 5 ml of trifluoroacetic acid under ice-cooling were added the compound (200 mg, 0.39 mmol) prepared in Working Example 11A and anisole (0.1 ml) and the mixture was stirred for 2.5 hours. The reaction mixture was concentrated to dryness in vacuo. To the resulting residue was added dichloromethane followed by evaporation to dryness in vacuo. These treatments were additionally repeated twice and ether was added to the resulting residue to precipitate solids which were filtered and dried to give 167 mg (93 %) of the title compound as pale yellow powders.

IR (KBr)cm⁻¹: 1715, 1680, 1605.

NMR (d_6 -DMSO) δ : 1.23(3H, t, J =7.4Hz), 1.29(3H, t, J =7.2Hz), 2.80(2H, q, J =7.4, 15.0Hz), 4.23(2H, q, J =7.2, 13.8Hz), 5.49(2H, s), 7.11(1H, s), 7.3-7.6(7H, m), 7.73(1H, d, J =7.4Hz), 8.77(1H, s).

5

Elemental Analysis for $C_{26}H_{23}NO_5S \cdot 0.3H_2O$

C (%)	H (%)	N (%)
-------	-------	-------

10

Calcd: C, 66.88; H, 5.09; N, 3.00

Found: C, 67.03; H, 5.14; N, 2.95

15

Working Example 12

2-Ethyl-5-(N-benzylcarbamoyl)-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine

20 A mixture of the compound (123 mg, 0.25 mmol) prepared in Working Example 2 and benzylamine (2 ml) was stirred at 60 °C for 3 days. After cooling, the reaction mixture was poured into chloroform, washed twice with 1N hydrochloric acid, dried ($MgSO_4$), and concentrated. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (19:1 to 9:1) to give 63 mg (45 %) of the title compound as crystals. M.p. 177-180 °C.

25 IR (KBr)cm⁻¹: 1650, 1590, 1550, 1500.

NMR (d_6 -DMSO) δ : 1.25(3H, t, J =7.4Hz), 2.83(2H, q, J =7.4Hz, 14.2Hz), 4.56(2H, d, J =5.8Hz), 5.57(2H, s), 7.0-7.7(14H, m), 8.95(1H, s).

30

Elemental Analysis for $C_{31}H_{26}N_6O_2S$

C (%)	H (%)	N (%)
-------	-------	-------

35

Calcd: C, 68.11; H, 4.79; N, 15.37


Found: C, 68.06; H, 4.79; N, 15.17

The following compounds as listed in Table 6 were prepared in the same manner as in Working Examples 12.

45

50

55

TABLE 6a

Working Example No.	R¹	MP. (°C)	IR(KBr) (cm⁻¹)
13	H	267-270	1635, 1575, 1540, 1500
14	CH₂CH(Me)₂	248-251 (decomp.)	1655, 1590, 1555, 1525, 1510
15	CH₂CH₂OH	155-159	1655, 1595, 1550, 1520
16	C₆H₅	215-218	1655, 1595, 1545, 1505

TABLE 6b

Working Example No.	NMR (d_6 -DMSO) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
13	1.25(3H, t, J=7.6Hz), 2.83(2H, q, J=7.6, 14.8Hz), 5.54(2H, s), 7.12(2H, d, J=8.2Hz), 7.22(1H, s), 7.26(2H, d, J=8.2Hz), 7.5-7.7(4H, m), 8.91(1H, s), 9.46(1H, bs)	C₂₄H₂₀N₄O₂S · H₂O 60.75; 4.67; 17.71 61.09; 4.41; 17.37
14	0.93(6H, d, J=6.6Hz), 1.25(3H, t, J=7.4Hz), 1.7-1.9(1H, m), 2.84(2H, d, J=7.4, 14.0Hz), 3.18(2H, t, J=6.2Hz), 5.55(2H, s), 7.11(2H, d, J=8.2Hz), 7.19(1H, s), 7.25(2H, d, J=8.2Hz), 7.5-7.7(4H, m), 8.90(1H, s)	C₂₄H₂₀N₄O₂S · H₂O 63.38; 5.70; 15.84 63.70; 5.44; 15.50
15	1.25(3H, t, J=7.4Hz), 2.84(2H, q, J=7.4, 16.0Hz), 3.3-3.6(4H, m), 4.81(1H, bs), 5.55(2H, s), 7.11(2H, d, J=8.2Hz), 7.18(1H, s), 7.24(2H, d, J=8.2Hz), 7.5-7.7(4H, m), 8.31(1H, s), 8.90(1H, s)	
16	1.27(3H, t, J=7.4Hz), 2.87(2H, q, J=7.4, 14.6Hz), 5.59(2H, s), 7.0-7.8(14H, m), 9.05(1H, s)	C₂₉H₂₄N₄O₂S · 0.5H₂O 66.53; 4.65; 15.52 66.28; 4.51; 15.26

Working Example 17

Ethyl 3-acetylamino-2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate

5

Ethyl 2-ethyl-3-nitro-7-[[2'-(N-trityltetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate (200 mg, 0.26 mmol) was dissolved in a mixture of acetic anhydride (6 ml), acetic acid (6 ml), dioxane (4 ml) and tetrahydrofuran (5 ml) and the solution was heated to 70 °C. To the heated solution were added zinc powders (85 mg) and the reaction mixture was stirred for 2 hours. The insoluble material was removed from the reaction mixture by filtration and the filtrate was concentrated to dryness in vacuo. The resulting oil was dissolved in a mixture of trifluoroacetic acid (8 ml) and water (1 ml) and the solution was stirred at room temperature for 5 hours. The reaction mixture was poured into water and extracted with chloroform. The organic layer was washed with water, dried (MgSO_4), and evaporated to dryness. The resulting residue was purified by flash column chromatography on silica gel. The column was eluted with chloroform/methanol (20:1) to give 59 mg (42 %) of the title compound as white crystals. M.p. 163-166 °C.

IR (KBr) cm^{-1} : 1720, 1700, 1615, 1550, 1510.

NMR (CDCl_3) δ : 1.14(3H, t, $J = 7.4\text{Hz}$), 1.29(3H, t, $J = 7.0\text{Hz}$), 2.03(3H, s), 2.63(2H, q, $J = 7.4, 15.0\text{Hz}$), 4.23(2H, q, $J = 7.0, 14.2\text{Hz}$), 5.45(2H, s), 7.13(2H, d, $J = 8.2\text{Hz}$), 7.28(2H, d, $J = 8.2\text{Hz}$), 7.5-7.7(4H, m), 8.74(1H, s), 9.66(1H, bs).

20

Elemental Analysis for $\text{C}_{21}\text{H}_{26}\text{N}_6\text{O}_4\text{S} \cdot \text{H}_2\text{O}$

C (%)	H (%)	N (%)
-------	-------	-------

25

Calcd: C, 59.99; H, 5.03; N, 14.99

Found: C, 59.50; H, 4.56; N, 14.76

30 The following compounds (Working Examples 18- 20) as listed in Table 7 were prepared in the same manner as in Working Examples 12.


35

40

45

50

55

TABLE 7a






Working Example No.	R¹	R²	MP. (°C)	Yield (%)
18	H	Me	167-170	30
19	Br	Me	227-231	77
20	CN	H	250-256	20

TABLE 7b

Working Example No.	NMR (d_6 -DMSO) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
18	1.28(3H,t), 2.47(3H,s), 4.22(2H,q), 5.44(2H,s), 6.92(1H,s), 7.10(2H,d), 7.23(2H,d), 7.5-7.7(4H,m), 8.70(1H, s)	C ₁₈ H ₂₁ N ₅ O ₃ S • 0.2H ₂ O 63.20; 4.54; 14.74 63.00; 4.37; 14.80
19	1.29(3H,t), 2.45(3H,s), 4.23(2H,q), 5.43(2H,s), 7.13(1H,d), 7.27(2H,d), 7.5-7.8(4H,m), 8.73(1H,s)	C ₁₈ H ₂₀ BrN ₅ O ₃ S 54.55; 3.66; 12.72 54.82; 3.63; 12.83
20	1.29(3H,t), 4.25(2H,q), 5.52(2H,s), 7.13(2H,d), 7.31(2H,d), 7.5-7.8 (4H,m), 8.25(1H,s), 8.89(1H,s)	

The following compounds (Working Examples 21-36) were prepared in the same manner as in Working Example 12.

TABLE 8a

Working Example No.	R ¹	MP (°C)	Yield (%)
21	-CH ₂ - 	134-148	42
22	-CH ₂ - 	223-225	67
23	-CH ₂ - 	202-204	54
24	-CH ₂ - 	powder	72
25	-CH ₂ - 	154-157	55
26	-CH ₂ - 	146-149	33

50

55

TABLE 8a

Working Example No.	R ¹	MP (°C)	Yield (%)
27	-CH ₂ -	170-173	45
28	-CH ₂ -	207-209	62
29	-CH ₂ -	150-154	57
30	-CH ₂ -	223-226	38
31	-CH ₂ CH ₂ -	266-269	28
32	-CH ₂ -	205-209	30
33	-CH ₂ -	244-248	63
34	-CH ₂ -	powder	72
35	-(CH ₂) ₃ N-	247-248	33

45

50

55

TABLE 8a


Working Example No.	R ¹	MP (°C)	Yield (%)
36	- (CH ₂) ₄ N  - R	188-190	36

TABLE 8b

Working Example No.	NMR (200MHz, CDCl ₃) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
21	1.36(3H,t), 2.89(2H,q), 3.88(3H,s), 4.61(2H,d), 5.12(2H,s), 6.8-7.6 (12H,m), 8.05-8.15(1H,m), 8.30(1H,s)	
22	1.37(3H,t), 2.89(2H,q), 3.78(3H,s), 4.57(2H,s), 5.20(2H,s), 7.6-8.0 (13H,m), 8.39(1H,s)	C ₃₂ H ₂₈ N ₆ O ₂ S · H ₂ O 64.63; 5.08; 14.13 64.92; 4.74; 13.99
23	1.38(3H,t), 2.91(2H,q), 4.60(2H,d), 5.18(2H,s), 6.9-7.6(12H,m), 8.1-8.2 (1H,m), 8.29(1H,s), 10.99(1H,brs)	C ₃₁ H ₂₅ FN ₆ O ₂ S 65.94; 4.46; 14.88 65.94; 4.45; 14.71
24	1.37(3H,t), 2.90(2H,q), 4.61(2H,d), 5.16(2H,s), 6.8-7.6(12H,m), 8.05-8.15(1H,m), 8.34(1H,s)	
25	1.38(3H,t), 1.58(3H,d), 2.91(2H,q), 5.13(2H,s), 5.22(1H,t), 7.1-7.6 (13H,m), 8.1-8.2(1H,m), 8.20(1H,s), 11.05(1H,bs)	C ₃₂ H ₂₈ N ₆ O ₂ S · 0.5H ₂ O 67.47; 5.13; 14.75 67.64; 4.99; 14.52
26	1.37(3H,t), 2.90(2H,q), 4.67(2H,d), 5.16(2H,s), 7.0-7.6(12H,m), 8.05- 8.15(1H,m), 8.29(1H,s), 10.97 (1H,brs)	C ₃₁ H ₂₅ FN ₆ O ₂ S · 1.5H ₂ O 62.93; 4.77; 14.20 63.02; 4.30; 14.03

45

50

55

TABLE 8b

Working Example No.	NMR (200MHz) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
27	1.35(3H,t), 2.86(2H,q), 5.07(2H,s), 5.10(2H,s), 7.1-7.9(14H,m), 8.07 (2H,d), 8.31(1H,brs), 11.01(1H,brs) ;(CDCl ₃),	C ₁₁ H ₂₂ N ₆ O ₂ S · 0.5H ₂ O 69.40;4.83;13.87 69.40;4.65;13.64
28	1.37(3H,t), 2.31(3H,s), 2.90(2H,q), 4.57(2H,d), 5.15(2H,s), 7.0-7.6 (12H,m), 8.0-8.2(1H,m), 8.27(1H,brs) ;(CDCl ₃),	C ₁₂ H ₂₄ N ₆ O ₂ S · 0.5H ₂ O 67.47;5.13;14.75 67.54;5.14;14.57
29	1.37(3H,t), 2.38(3H,s), 2.90(2H,q), 4.61(2H,d), 5.16(2H,s), 7.0-7.6 (12H,m), 8.0-8.2(1H,m), 8.25(1H,brs) ;(CDCl ₃),	C ₁₂ H ₂₄ N ₆ O ₂ S · 0.2H ₂ O 68.11;5.07;14.89 68.01;4.85;14.94
30	1.32(3H,t), 2.83(3H,q), 4.65(2H,d), 5.35(2H,s), 7.0-8.1(13H,m), 9.34(1H, s), 11.05(1H,t);(CDCl ₃),	C ₁₀ H ₂₅ N ₇ O ₂ S · HCl 0.5H ₂ O 60.75;4.59;16.53 60.83;4.29;16.36
31	1.24(3H,t), 2.85(2H,q), 3.01(2H,t), 3.6-3.8(2H,m), 5.54(2H,s), 7.0-7.8 (12H,m), 8.5-8.6(1H,m), 8.88(1H,s), 10.20(1H,t);(DMSO-d ₆)	C ₁₁ H ₂₂ N ₇ O ₂ S · 0.5H ₂ O 65.25;4.95;17.18 65.27;4.79;17.13
32	1.38(3H,t), 2.91(2H,q), 4.90(2H,s), 5.34(2H,s), 7.20(2H,d), 7.28(2H,d), 7.37(1H,s), 7.5-7.8(4H,m), 7.96(2H, d), 8.62(1H,s), 8.78(2H,d);(CDCl ₃),	SIMS; 548(MH ⁺)
33	1.25(3H,t), 2.85(2H,q), 4.73(2H,d), 5.57(2H,s), 7.12(2H,d), 7.20(1H,s), 7.26(2H,d), 7.5-8.9(8H,m), 8.93(1H, s), 10.71(1H,t);(DMSO-d ₆)	C ₁₀ H ₂₅ N ₇ O ₂ S · HCl 0.5H ₂ O 58.11;4.88;15.81 57.86;4.34;15.60
34	1.26(3H,t), 1.3-1.9(6H,m), 2.86(2H, q), 3.0-3.7(5H,m), 5.57(2H,s), 7.14 (2H,d), 7.21(1H,s), 7.23(2H,d), 7.4-7.7(4H,m), 8.6(1H,brs), 8.91(1H, s), 10.40(1H,t);(DMSO-d ₆)	SIMS; 554(MH ⁺)

45

50

55

TABLE 8b

Working Example No.	NMR (200MHz) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
35	1.28(3H,t), 1.78-1.94(2H,m), 2.56- 2.94(6H,m), 3.09-3.27(4H,m), 3.39- 3.76(2H,m), 5.53(2H,s), 6.93-7.32 (6H,m), 7.43-7.66(4H,m), 8.90(1H,s) ;(DMSO-d ₆)	C ₃ H ₃ FN ₈ O ₂ S · 0.5H ₂ O 64.76;5.58;16.34 64.74;5.84;16.12
36	1.19(3H,t), 1.25(3H,t), 1.74-1.96 (2H,m), 2.66-3.56(16H,m), 5.55(2H, s), 6.90-7.31(9H,m), 7.43-7.72(4H, m), 8.92(1H,s);(DMSO-d ₆)	C ₃ H ₃ FN ₈ O ₂ S · 3.5H ₂ O 60.54;6.15;14.86 60.31;5.96;14.85

20 The following compounds (Working Examples 37-45) were prepared in the same manner as in Working Example 12.

25

30


35

40

45

50

55

TABLE 9a

Working Example No.	R¹	R²	MP (°C)	Yield (%)
37	-CH₂OH	H	>260 (dec.)	73
38	H	H	249-253	83
39	-CHO	H	powder	66
40	-CH=CHCOOtBu	H	powder	100
41	$\begin{matrix} -CON-CH_2- \text{C}_6\text{H}_4 \\ \\ CH_3 \end{matrix}$	H	>190 (dec.)	88
42	-CH₂OMe	H	213-216	82
43	-COOH	CH₂	162-167	
44	-CONH-	CH₂	175-180	
45	-COOMe	-CH₂COOMe		

40

45


50

55

TABLE 9b

Working Example No.	NMR (200MHz) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
37	1.24(3H,t), 2.79(2H,q), 4.40(2H,s), 7.05(1H,s), 7.11(2H,d), 7.22(2H,d), 7.5-7.8(4H,m), 7.98(1H,s);(DMSO-d ₆)	C ₂₄ H ₂₁ N ₅ O ₂ S . 0.8H ₂ O 62.95;4.97;15.29 63.18;4.88;14.86
38	1.24(3H,t), 2.80(2H,q), 5.35(2H,s), 6.21(1H,d), 7.07(1H,s), 7.11(2H,d), 7.24(2H,d), 7.4-7.8(4H,m), 8.08(1H,d);(DMSO-d ₆)	C ₂₃ H ₁₉ N ₅ OS . H ₂ O 64.02;4.91;16.23 63.87;4.44;15.90
39	1.24(3H,t), 2.82(2H,q), 5.50(2H,s), 7.12(2H,d), 7.20(1H,s), 7.28(2H,d), 7.5-7.7(4H,m), 8.69(1H,s), 10.28(1H, s);(DMSO-d ₆)	
40	1.25(3H,t), 1.37(9H,s), 2.80(2H,q), 5.35(2H,s), 6.93(1H,d), 7.1-7.9(10H, m), 8.55(1H,s);(DMSO-d ₆)	
41	1.19(3H,t), 1.21(3H,t), 2.69(2H,q), 2.96(3H,s), 4.58(2H,s), 4.79(2H,s), 5.38(2H,s), 6.7-7.6(13H,m), 7.9-8.0 (1H,m), 8.6(1H,brs);(CDCl ₃)	C ₂₂ H ₂₀ N ₆ O ₂ S . 0.5H ₂ O 67.47;5.13;14.75 67.64;4.99;14.52
42	1.21(3H,t), 2.69(2H,q), 3.44(3H,s), 4.09(2H,s), 5.21(2H,s), 6.8-7.9(10H,m);(CDCl ₃)	C ₂₆ H ₂₁ N ₅ O ₂ S . 0.7H ₂ O 63.87;5.23;14.90 64.00;4.99;14.69
43	1.27(3H,t), 2.88(2H,q), 2.95(3H,s), 5.68(2H,s), 7.11(4H,s), 7.29(1H,s), 7.5-7.8(4H,m);(DMSO-d ₆)	C ₂₆ H ₂₁ N ₅ O ₂ S . 0.5H ₂ O 62.49;4.61;14.57 62.28;4.36;14.39
44	1.39(3H,t), 2.75(3H,s), 2.99(2H,q), 5.85(2H,s), 7.1-7.8(14H,m);(CD ₃ OD)	SIMS; 547(MH ⁺)
45	1.32(3H,t), 2.86(2H,q), 3.66(3H,s), 3.88(3H,s), 3.94(2H,s), 5.55(2H,s), 6.98(2H,d), 7.13(2H,d), 7.22(1H,s) 7.4-7.7(4H,m);(CD ₃ OD)	SIMS; 544(MH ⁺)

The following compounds (Working Examples 46-53) were prepared in the same manner as in Working Example 2.

TABLE 10a

5

10

15

20

25

30

35

40

45

50

55

Working Example No.	R ⁷	MP (°C)	Yield (%)
46	Bu	127-130	32
47	-CH ₂ -	202-205	65
48	Et	210-212	59
49	--F	246-250	70
50	--Cl	powder	31
51	-	207-221	57
52	-CH ₂ COOEt	167-169	44
53	-CH ₂ CH ₂ NN-OMe	powder	77

TABLE 10b

Working Example No.	¹ H-NMR (CDCl ₃) δ	E. Anal. (Calcd/Found) C(%), H(%), O(%)
46	0.92(3H,t), 1.30(3H,t), 1.2-1.5(2H, m), 1.5-1.8(2H,m), 2.77(2H,q), 4.01 (2H,t), 5.15(2H,s), 7.00(1H,s), 7.23(2H,d), 7.42(2H,d), 7.5-7.7(3H, m), 8.1-8.2(1H,m)	C ₂ ,H ₂ ,N ₆ O ₂ S 64.18;5.39;17.27 64.00;5.51;17.18
47	1.21(3H,t), 2.75(2H,q), 5.12(2H,s), 5.15(2H,s), 7.02(1H,s), 7.09(2H,d), 7.2-7.8(11H,m)	C ₂ ,H ₂ ,N ₆ O ₂ S · 0.4H ₂ O 65.99;4.74;15.92 66.17;4.91;15.63
48	1.25(3H,t), 1.30(3H,t), 2.78(2H,q), 4.08(2H,q), 5.16(2H,s), 7.01(1H,s), 7.23(2H,d), 7.43(2H,d), 7.5-7.7(3H, m), 8.1-8.2(1H,m)	C ₂ ,H ₂ ,N ₆ O ₂ S · 0.5H ₂ O 61.65;4.96;17.97 61.70;4.83;17.80
49	1.32(3H,t), 2.81(2H,q), 5.14(2H,s), 7.06(1H,s), 7.1-7.8(12H,m)	C ₂ ,H ₂ ,FN ₆ O ₂ S 64.11;4.04;16.02 63.82;3.97;15.77
50	1.33(3H,t), 2.81(2H,q), 5.20(2H,q), 7.07(1H,s), 7.2-8.2(11H,m)	C ₂ ,H ₂ ,N ₆ O ₂ SCl ₂ · 0.6H ₂ O 57.36;3.64;14.33 57.74;3.75;13.75
51	1.29(3H,t), 1.2-2.6(10H,m), 2.76 (2H,q), 4.7-5.0(1H,m), 5.13(2H,s), 6.99(1H,s), 7.24(2H,d), 7.42(2H,d), 7.5-7.7(3H,m), 8.1-8.2(1H,m)	C ₂ ,H ₂ ,N ₆ O ₂ S · 0.4H ₂ O 64.69;5.58;16.17 64.81;5.50;15.95
52	1.29(3H,t), 1.31(3H,t), 2.79(2H,q), 4.23(2H,q), 4.80(2H,s), 5.17(2H,s), 7.03(1H,s), 7.22(2H,d), 7.4-7.7(5H, m), 8.1-8.2(1H,m)	C ₂ ,H ₂ ,N ₆ O ₂ S 60.45;4.68;16.27 60.33;4.59;16.17
53	1.36(3H,t), 2.84(2H,q), 2.8-3.6(8H, m), 3.83(3H,s), 4.2-4.5(4H,m), 4.97 (2H,s), 6.8-7.2(7H,m), 7.4-7.6(5H, m), 7.94(1H,d)	C ₂ ,H ₂ ,N ₆ O ₂ S · CF ₃ COOH · 2.5H ₂ O 55.01;5.24;13.87 54.51;4.74;13.45

45 Pharmaceutical Examples

The compounds (I) of the present invention are employed, for example, when used as agents for treating circulatory system diseases such as hypertension, heart diseases, strokes and the like, in the following formulations.

1. Capsule

5	(1) Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno-[2,3-b]pyridine-5-carboxylate	10 mg
10	(2) Lactose	90 mg
15	(3) Microcrystalline cellulose	70 mg
15	(4) Magnesium stearate	10 mg
	One capsule	180 mg

The ingredients (1), (2), and (3) and a half of the ingredient (4) were blended together and granulated.
20 To this mixture was added the remaining half of the ingredient (4) and distributed into gelatine capsules.

2. Tablet

25	(1) Ethyl 2-ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno-[2,3-b]pyridine-5-carboxylate	10 mg
30	(2) Lactose	35 mg
35	(3) Maize starch	150 mg
40	(4) Microcrystalline cellulose	30 mg
40	(5) Magnesium stearate	5 mg
	One tablet	230 mg

45 Two third each of the ingredients (1), (2), (3) and (4) and a half of the ingredient (5) were blended together and granulated. To these granules were added the remaining ingredients (4) and (5) and then compressed to form tablets.

50

55

3. Injection

5	(1) 2-Ethyl-7-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic acid · sodium salt	10 mg
10	(2) Inositol	100 mg
15	(3) Benzyl alcohol	20 mg
One ampule		130 mg

The ingredients (1), (2) and (3) were dissolved in distilled water for injection to a total volume of two ml
20 and distributed into ampules. Total processes were carried out under sterile conditions.

Experimental Example 1

Inhibition of binding of angiotensin-II to angiotensin receptor

25 [Method]

An experiment of inhibition on the binding of angiotensin-II (A-II) to A-II-receptor was conducted by modifying the method of Douglas et al. [Endocrinology, 102, 685-696 (1978)]. An A-II-receptor was prepared
30 from the membrane fraction of bovine adrenal cortex.

The compound of the present invention (10^{-9} M to 3×10^{-5} M) and ^{125}I -A-II (1.85 kBq/50 μ l) were added to the receptor membrane fraction, and the mixture was incubated at room temperature for one hour. The receptor-bound and free ^{125}I -A-II were separated through a filter (Whatman GF/B filter), and the radioactivity of ^{125}I -A-II bound to the receptor was measured.

35 [Results]

The results relating to the compounds of the present invention are shown in Table 11.

Experimental Example 2

Inhibitory effect of the compound of the present invention on pressor action of A-II

45 [Method]

Jcl : SD rats (9 week old, male) were used. On the day previous to the experiment, these animals were applied with cannulation into the femoral artery and vein under anesthesia with pentobarbital Na. The animals were fasted but allowed to access freely to drinking water until the experiment was started. Just on the day of conducting the experiment, the artery cannula was connected with a blood-pressure transducer,
50 and the average blood pressure was recorded by means of polygraph. Before administration of the drug, the pressor action due to intravenous administration of A-II (100 ng/kg) as the control was measured. The drugs were orally administered, and then, at each point of the measurement, A-II was administered intravenously, and the pressor action was similarly measured. By comparing the pressor action before and after administration of the drug, the percent inhibition by the drug on A-II-induced pressor action was
55 evaluated.

[Results]

The results relating to the compounds of the present invention are shown in Table 11.

TABLE 11

5

10

15

20

25

30

35

40

45

Working Example No.	Radio Receptor Assay (% Inhibition)			Pressor Response (30 mg/Kg, p.o.)
	10 ⁻⁷ (M)	10 ⁻⁶ (M)	IC ₅₀ (μM)	
2	69	94	0.05	NT**
3	51	81	0.07	NT
4	34	68	0.20	NT
5	56	88	0.05	NT
6	48	83	0.09	NT
7	40	82	0.17	NT
8	81	94	0.01	NT
10	51	86	0.04	++*
11	42	83	0.21	NT
12	57	89	0.06	++
13	78	93	0.02	NT
14	45	87	0.13	NT
15	62	90	0.05	NT
16	47	85	0.12	++
20	22	56	0.67	NT
21	36	71	0.25	++
23	40	81	0.17	++
24	37	82	0.19	++

50

55

TABLE 11 (continued)

Working Example No.	Radio Receptor Assay (% Inhibition)			Pressor Response (30 mg/Kg, p.o.)
	10 ⁻⁷ (M)	10 ⁻⁶ (M)	IC ₅₀ (μM)	
25	8	55	0.78	++
26	35	81	0.21	++
28	36	78	0.22	+
29	47	86	0.12	++
30	70	93	0.02	++

*a : NT , not tested.


*b : (% Inhibition), ++ ≥ 70 % > + ≥ 50 %.

It is understood that the preceding representative examples may be varied within the scope of the present invention by one skilled in the art to achieve essentially the same results.


As many widely different embodiments of this invention may be made without departing from the spirit and scope thereof, it is to be understood that this invention is not limited to the specific embodiments thereof except as defined in the appended claims.

Claims

1. A compound of the formula:



wherein W is




R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;
R³ is hydrogen, optionally substituted alkyl or alkenyl, or -COD wherein D is hydrogen, alkoxy, hydroxy, halogen, or optionally substituted amino;

R⁴ is hydrogen, halogen or nitro;
 R⁵ is a residue capable of forming an anion or a residue convertible into an anion;
 R⁶ is hydrogen or optionally substituted alkyl or alkenyl;
 R⁷ is a hydrocarbon residue which may be substituted;
 5 A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2;
 and a pharmaceutically acceptable salt thereof.

2. A compound according to claim 1, which is a compound of the formula (Ia):


10



wherein R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;
 25 R³ is hydrogen, formyl, optionally substituted alkyl or alkenyl, or -COD wherein D is alkoxy, hydroxy, halogen, or optionally substituted amino;
 R⁴ is hydrogen, halogen or nitro;
 R⁵ is a residue capable of forming an anion or a residue convertible into an anion;
 R⁶ is hydrogen or optionally substituted alkyl or alkenyl;
 30 A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2;
 and a pharmaceutically acceptable salt thereof.


3. A compound according to claim 1, which is a compound of the formula (Ib):

35




wherein R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;
 50 R⁴ is hydrogen, halogen or nitro;
 R⁵ is a residue capable of forming an anion or a residue convertible into an anion;
 R⁷ is a hydrocarbon residue which may be substituted;
 A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and
 55 n is an integer of 1 or 2;
 and a pharmaceutically acceptable salt thereof.

4. A compound according to claim 1, wherein the acylamino group is a group having the formula: R⁸CONH-wherein R⁸ is hydrogen or a hydrocarbon residue which may be substituted.
5. A compound according to claim 4, wherein the hydrocarbon residue is lower alkyl of 1 to about 8 carbon atoms, lower alkenyl of 2 to about 8 carbon atoms, lower alkynyl of 2 to about 8 carbon atoms, an alicyclic hydrocarbon residue of 3 to about 8 carbon atoms, or an aromatic hydrocarbon residue of about 6 to 12 carbon atoms.
10. A compound according to claim 1, wherein the hydrocarbon residue is lower alkyl of 1 to about 8 carbon atoms, lower alkenyl of 2 to about 8 carbon atoms, lower alkynyl of 2 to about 8 carbon atoms, an alicyclic hydrocarbon residue of 3 to about 8 carbon atoms, or an aromatic hydrocarbon residue of about 6 to 12 carbon atoms.
15. A compound according to claim 1, wherein said hydrocarbon residue may be optionally substituted with hydroxyl, lower (C₁-4) alkoxy, lower (C₁-4) alkyl, halogen, nitro, optionally substituted amino, acyloxy, optionally substituted phenyl, or a group having the formula: -COD' wherein D' is hydroxy, lower (C₁-4) alkoxy, or optionally substituted amino.
20. A compound according to claim 7, wherein said optionally substituted amino is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, N-phenylpiperazino, or N-(m-methoxy)phenylpiperazino.
25. 10. A compound according to claim 7, wherein said phenyl may be optionally substituted with halogen, nitro, lower (C₁-4) alkoxy, or lower (C₁-4) alkyl.
30. 11. A compound according to claim 7, wherein said D' is amino, methylamino, dimethylamino, phenylamino, benzylamino, morpholino, piperidino, piperazino, or N-phenylpiperazino.
35. 12. A compound according to claim 1, wherein said optionally substituted alkyl or alkenyl group is lower alkyl of 1 to about 8 carbon atoms or lower alkenyl of 2 to about 8 carbon atoms which may be straight or branched and may be optionally substituted with hydroxyl, optionally substituted amino, halogen, lower (C₁-4) alkoxy, or -COD" wherein D" is lower (C₁-4) alkoxy, hydroxy, halogen, or optionally substituted amino.
40. 13. A compound according to claim 1, wherein said D is amino, N-lower (C₁-4) alkyl amino, N,N-dilower (C₁-4) alkyl amino, N-aryl amino, N-aralkyl amino, N-heteroaryl amino, N-heteroaralkyl amino, or alicyclic amino, wherein said alkyl, aryl and heteroaryl groups may be optionally substituted with alkyl, hydroxyl, optionally substituted amino, halogen, nitro, lower (C₁-4) alkoxy, or alicyclic amino.
45. 14. A compound according to claim 1, wherein said R⁵ is carboxyl, lower (C₁-4) alkoxy carbonyl, cyano, tetrazolyl, trifluoromethanesulfonic amide, phosphoric acid, or sulfonic acid.
46. 15. A compound according to claim 14, wherein said R⁵ is tetrazolyl.
47. 16. A compound according to claim 14, wherein said R⁵ is in the ortho position.
48. 17. A compound according to claim 1, wherein said A is lower (C₁-4) alkylene, -C(=O)-, -O-, -S-, -NH-, -C(=O)-NH-, -O-CH₂-, -S-CH₂-, or -CH=CH-.
49. 18. A compound according to claim 1, which is a compound of the formula (Ia'):



15 wherein R¹ is lower (C_{1-8}) alkyl; R³ is hydrogen, optionally substituted lower (C_{1-8}) alkyl or COD
wherein D is hydrogen, lower (C_{1-4}) alkoxy, hydroxy, or optionally substituted amino; and R⁵ is
carboxyl or tetrazolyl;
or a pharmaceutically acceptable salt thereof.

19. A compound according to claim 1, which is a compound of the formula (Ib'):



35 wherein R¹ is lower (C_{1-8}) alkyl; R⁷ is hydrogen, lower (C_{1-8}) alkyl which may be optionally substituted
with optionally substituted aryl, optionally substituted amino or COD wherein D is lower (C_{1-4}) alkoxy,
hydroxy, or optionally substituted amino, (C_{3-8}) cycloalkyl or optionally substituted aryl; and R⁵ is
carboxyl or tetrazolyl;
or a pharmaceutically acceptable salt thereof.

40 20. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, which is selected from
the group consisting of ethyl 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]-
pyridine-5-carboxylate, 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]pyridine-
5-carboxylic acid, methoxyethyl 2-ethyl-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-oxothieno[2,3-b]-
pyridine-5-carboxylate, 2-ethyl-5-(N-benzylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-
oxothieno[2,3-b]pyridine, 2-ethyl-5-(N-phenylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-4-
oxothieno[2,3-b]pyridine, and 2-ethyl-5-(N-2-pyridylmethylcarbamoyl)-7-[2'-(1H-tetrazol-5-yl)biphenyl-4-
yl]methyl]-4-oxo-thieno[2,3-b]pyridine.

45 21. A compound according to claim 19, wherein R¹ is ethyl, R⁵ is 1H-tetrazol-5-yl and R⁷ is butyl, benzyl,
ethyl, p-fluorophenyl, 2,5-dichlorophenyl, cyclohexyl, ethoxycarbonylmethyl, or 2-[4-(o-methoxyphenyl)-
piperazino]ethyl.

22. A pharmaceutical composition for antagonizing angiotensin II which comprises a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutical acceptable carrier, excipient or diluent.


55 23. A use of a compound according to claim 1 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for antagonizing angiotensin II.

24. A method for producing a compound of the formula (I):

5

10

15



wherein W is


20



25

or

30



R¹ and R² which may be same or different, are each independently hydrogen, halogen, cyano, nitro, acylamino, or a hydrocarbon residue which may be substituted;

35 R³ is hydrogen, optionally substituted alkyl or alkenyl, or -COD wherein D is hydrogen, alkoxy, hydroxy, halogen, or optionally substituted amino;

R⁴ is hydrogen, halogen or nitro;

R⁵ is a residue capable of forming an anion or a residue convertible into an anion;

R⁶ is hydrogen or optionally substituted alkyl or alkenyl;

40 R⁷ is a hydrocarbon residue which may be substituted;

A is a direct bond or a spacer having atomic length of two or less between the phenylene group and the phenyl group; and n is an integer of 1 or 2;


or a pharmaceutically acceptable salt thereof,

which comprises


45 reacting a compound of the formula (II):

50

55



wherein R¹, R², and W have the above-defined meanings, with a compound of the formula (III):



wherein R⁴, R⁶, A and n have the above-defined meanings, and X is halogen,
 10 and, (i) if desired, converting a compound of the formula (I) wherein R⁵ is cyano or protected tetrazolyl,
 and R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, into a compound of the formula (I)
 wherein R⁵ is tetrazolyl and R¹, R², R⁴, R⁵, A, W and n have the above-defined meanings, (ii) if desired,
 converting a compound of the formula (I) wherein -R³ is lower (C₁₋₄) alkoxy carbonyl or halogenocar-
 bonyl, and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, into a compound of the
 15 formula (I) wherein R³ is carboxyl, or optionally substituted carbamoyl and R¹, R², R⁴, R⁵, R⁶, A and n
 have the above-defined meanings, or (iii) if desired, converting a compound of the formula (I) wherein
 -R³ is carboxyl, and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined meanings, into a compound of
 the formula (I) wherein R³ is halogenocarbonyl and R¹, R², R⁴, R⁵, R⁶, A and n have the above-defined
 20 meanings, and, if desired, converting a compound of the formula (I) into a pharmaceutically acceptable
 salt thereof.

25

30

35

40

45

50

55



EUROPEAN SEARCH
REPORT

EP 91 10 2513

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A,D	JOURNAL OF MEDICINAL CHEMISTRY, vol. 31, 1988, pages 1786 - 1793; R.K. RUSSELL et al.: "Thiophene Systems. 9. Thienopyrimidinedione Derivatives as Potential Antihypertensive Agents." * page 1788, table III *	1,3,23	C 07 D 495/04 A 61 K 31/435 // (C 07 D 495/04 C 07 D C 07 D 333:00 C 07 D 221:00)
A	US-A-4 670 560 (J.B. PRESS ET AL.) * column 8, lines 6 - 37; claim 1 ** examples 47, 48 *	1,3,22,23	(C 07 D 495/04 C 07 D C 07 D 333:00 C 07 D 239:00)
A	US-A-4 835 157 (J.B. PRESS ET AL.) * claims 1, 19, 24, 29 *	1,3,22,23	
A	CHEMICAL ABSTRACTS, vol. 99, no. 3, 18 July 1983 Columbus, Ohio, USA R. BOEHM et al.: "Thieno compounds. Part 1. Phase transfer-catalyzed alkylation of thieno[2,3-d]pyrimidin-4[3H]-ones or -2,4-diones" page 616; ref. no. 22419Q & Pharmazie 1983, 38[2], 135-6 * abstract *	1,3,24	
A	US-A-4 880 804 (D.J. CARINI ET AL.) * claims 1, 9 *	1,22,23	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
A	EP-A-0 323 841 (E.I. DU PONT DE NEMOURS AND CO.) * page 2, lines 23 - 31; claims 1, 10, 14 *	1,22-24	C 07 D 495/00
A,P	EP-A-0 400 835 (MERCK AND CO., INC.) * page 12, reaction scheme 1; page 25, lines 4-7; abstract *	1,22-24	
A,D	HYPERTENSION, vol. 13, 1989, Dallas, Tex., US, pages 489 - 497; P.C. WONG et al.: "Nonpeptide Angiotensin II Receptor Antagonists. IV. EXP6155 and EXP6803" * -- * * -- * * -- *	22,23 -/-	

The present search report has been drawn up for all claims

Place of search	Date of completion of search	Examiner
Berlin	05 June 91	HASS C V F
CATEGORY OF CITED DOCUMENTS		
X: particularly relevant if taken alone	E: earlier patent document, but published on, or after the filing date	
Y: particularly relevant if combined with another document of the same category	D: document cited in the application	
A: technological background	L: document cited for other reasons	
O: non-written disclosure		
P: Intermediate document		
T: theory or principle underlying the invention	&: member of the same patent family, corresponding document	

EUROPEAN SEARCH
REPORT

Application Number

EP 91 10 2513

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)		
A,D	<p>JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 247, no. 1, October 1988, pages 1 - 7; P.C. WONG et al.: "Nonpeptide Angiotensin II Receptor Antagonists. I. Pharmacological Characterization of 2-n-Butyl-4-chloro-1-[2-chlorobenzyl]..."</p> <p>-----</p>	22,23			

The present search report has been drawn up for all claims					
Place of search	Date of completion of search	Examiner			
Berlin	05 June 91	HASS C V F			
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention					
E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document					